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Abstract
The Pip gene encodes two proteins (proteolipid protein and DM20), by alternative 
splicing of the primary transcript, that between them account for greater than 50% 
of total myelin protein in the central nervous system. Though the proteolipid 
protein is thought to have a structural role in the compaction of the myelin sheath 
the role of the DM20 protein isoform remains uncertain but is speculated to involve 
oligodendrocyte development. The Pip gene has been strongly conserved during 
evolution, and across species, and it is well recognised that its mutation is involved 
with dysmyelination. It has become increasingly clear that as well as mutations 
altering the nucleotide sequence being associated with disease that duplications of 
the gene locus, without nucleotide changes, are also significant in disease 
aetiopathogenesis in man. This project describes the phenotypic consequences of 
extra copies of the Pip gene on two lines of transgenic mice (#66 and #72) in 
relation to myelin gene expression.
Mice homozygous for the two transgenic cassettes dysmyelinate, though they are 
affected to different degrees. The level of Pip gene transcription is o f a similar 
order to wild type litter mates suggesting that this is not a consequence of 
insufficient gene transcription. There is an increase in the total glial cell density 
during development suggesting a change in the dynamics of the glial cell 
population. Oligodendrocytes in these mice appear to be compromised in their 
ability to elaborate a myelin sheath. The myelin sheath that is formed is normally 
compacted.
Myelination in mice hemizygous for the two transgenic cassettes is 
indistinguishable from their wild type litter mates, though there is evidence for an 
increase in the total glial cell density during development. However, as hemizygous 
mice age they develop tract specific neurodegeneration which exhibits a specific 
temporal progression. This process is characterised by the development of 
abnormal myelin loops and an axonopathy. Eventually there is extensive 
demyelination but it primarily affects tracts with narrower fibres. Close 
examination of the homozygous mice demonstrated that they also develop 
demyelination, superimposed on the dysmyelinated background, which contributes 
to the characteristics of their phenotype.
As an incidental observation these transgenes were shown to lead to the 
incorporation of the PLP isoform in compact myelin o f the peripheral nervous 
system. Further evaluation of this phenomenon indicated that Schwann cells from 
these transgenic mice are capable of differential targeting of the PLP and DM20
i
protein isoforms. This has potential implications for the trafficking of these 
protein isoforms in oligodendrocytes.
To
Pam ela and Robert who have been faced with far greater challenges in
life than I
and
my parents for not asking why
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1. Introduction
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1.1 Background
Diseases involving the perturbation of myelin are responsible for a significant 
degree of morbidity and mortality in the human and animal populations and 
furthering their understanding is an important feature o f biomedical research. The 
use o f animal models has featured strongly in advancing understanding and the 
investigation of a new neurological phenotype potentially offers to yield further 
information. Through the understanding of the abnormalities associated with gene 
dysfunction that result in abnormal myelination not only can inferences be made 
about probable gene function but experimental models o f disease can be developed.
The stimulation for the work presented in this thesis, a study of perturbed 
myelination related to increased gene dosage of the Pip gene, stems from the 
unexpected development of a neurological phenotype in transgenic mice harbouring 
extra copies o f the Pip gene. These mice were created as part o f a larger experiment 
to address the rescue of the PlpJP phenotype, using an approach similar to that 
which had been successful with the shiverer (Mbps^ )  mouse. This 
hypomyelinating mutant has a deletion of the myelin basic protein (MBP) gene, 
encoding for the second most abundant family of proteins in CNS myelin, and was 
phenotypically rescued by transgenic complementation.
Two lines o f transgenic mice complemented with extra copies o f the wild type Pip 
gene were generated by Readhead et aV s original experiments, with line #66 
carrying a greater number o f gene copies than #72 and it was the homozygous #66 
mice that exhibited neurological abnormalities. The initial study of the homozygous 
#66 mice confirmed that they were dysmyelinated which contrasted with the initial 
data on homozygous #72 which described these mice as minimally dysmyelinated, 
implying a gradation in phenotypic severity apparently related to gene dosage. 
These observations justified further study to explore the development of the two 
phenotypes in relation to the progress of myelination and Pip gene expression. As 
these studies proceeded continuing behavioural studies on the mice revealed a late 
onset neurological phenotype in homozygous #72 mice and in both hemizygous #66 
and #72 mice. These observations broadened the study to include characterising the 
late onset phenotype, in which demyelination and an axonopathy were prominent 
features.
Though point mutations resulting in qualitative changes in the Pip gene were well 
recognised in causing perturbations o f myelination the development o f an abnormal
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phenotype following the introduction of extra copies of a wild type gene (a 
quantitative change) was hardly recognised. This observation suggested that 
abnormalities of myelination could stem from causes other than the presence of an 
abnormal myelin protein.
The unexpected observation of the incorporation of the PLP/DM20 protein isoforms 
into the myelin of the peripheral nervous system (PNS) became the basis of a 
separate study into the behaviour of Pip transgenes in the PNS. This was further 
expanded by introducing Pip and Dm20 minigenes to assess the contribution of the 
two isoform messages and products to this phenomenon.
Though at the time of creation of the #66 and #72 mice Pip gene dosage was only 
suspected as being involved in the aetiopathogenesis of disease this picture was to 
change as the project developed and gene dosage is now recognised to be a major 
factor in the development of Pelizaeus-Merzbacher disease (PMD), the human 
clinical syndrome for which the Pip mutants are good animal models. As the 
genetic analysis o f pedigrees affected by PMD has developed it has become clearer 
that there is a wide spectrum of disease associated with a large and expanding group 
o f mutations o f the Pip gene locus.
The purpose of the introduction is to put the #66 and ##72 transgenic mice in the 
context of current thoughts on myelin biology and the consequences of mutation of 
the Pip gene.
1.2 Myelination
1.2.1 The composition and structure of myelin
The following description of myelin refers in the main to that found in the 
mammalian central nervous system (CNS), with references to PNS myelin to 
highlight the similarities and differences. Myelin, however, is a specialised feature 
of vertebrates and there are significant differences in protein composition between 
phyla, some of these differences and their possible significance is explored in
1.2.2.1.1 Phylogenetic evolution of the Pip gene (page 13).
1.2.1.1 The myelin sheath
The myelin sheath is a specialised development of the cell membrane elaborated and 
maintained by specialised, tissue specific cells. In the CNS these are 
oligodendrocytes and in the PNS the myelin forming Schwann cells (MFSC).
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The myelin sheath surrounds axons in a multi -layer lamellar structure. Examination 
by electronmicroscopy (EM) demonstrates that the structure has a regular 
periodicity, made up o f the major dense line (MDL) representing the apposition of 
the cytoplasmic surfaces and intra-period (IPL) which represents the apposition of 
the extracellular surfaces (Raine, 1984).
The presence of the myelin sheath allows the saltatory conduction o f impulses thus 
facilitating transmission (both in terms of speed and energy consumption) and 
reducing the volume of axon required for fast conduction. The emergence of this 
structure during evolution was necessary for the development of the integrated 
function of the vertebrate nervous system (Rogers et al, 1997).
Abnormalities of this structure due to either abnormal development 
(dysmyelination) or loss (demyelination) almost invariably have a profound effect 
on the function o f the nervous system and the viability o f the organism (see 1.3.1 
Dysmyelination and demyelination in the CNS, page 24).
1.2.1.2 Comparison of CNS and PNS myelin
The myelin o f the two divisions of the nervous system share many similarities, 
though several notable differences exist as they are products o f different cell types 
in different nervous tissue environments. One o f the most notable differences is the 
relationship between these two myelinating cells and the number of axons they 
ensheath. Oligodendrocytes are capable of myelinating segments o f multiple axons 
and up to 60 may be supported by one cell, though the relationship between axon 
diameter and number of sheaths supported is complex (Szuchet, 1995). Conversely 
the Schwann cell myelinates only one axonal intemode (Bunge and Femandez- 
Valle, 1995). Occasionally oligodendrocytes with a Schwann cell like relationship 
to an individual axon are found in the developing spinal cord (Remahl & 
Hildebrand, 1990).
The nature of the lamellar structure is similar but the periodicity is different (CNS 
10.5-11.5nm c.f. PNS 11.5-12.7nm) and CNS sheaths are thinner compared to those 
of the PNS for a given axonal diameter (Fraher, 1992). Schwann cells, unlike 
oligodendrocytes, have a basal lamina and the myelin sheath is formed from the 
soma of the cell whilst oligodendrocytes are not as tightly apposed to the axon 
(Bunge and Fernandez-Valle, 1995; Szuchet, 1995).
Compaction of the myelin sheath excludes the majority o f the cytoplasm from the 
final structure although cytoplasmic domains do remain in both the CNS and PNS 
and they from a continuous cytoplasmic network that completely surrounds the
4
compacted regions These are the paranodes and the Schmidt-Lanterman incisures 
(SLI) in the PNS (Colman et a l, 1996) and the lateral loops and longitudinal 
incisure in the CNS (Raine, 1984).
The protein composition of CNS and PNS myelin differs. Some proteins are 
common to both CNS and PNS myelin (for example MBP, myelin-associated 
glycoprotein (MAG) and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP)). 
However, the proportions may differ e.g. the amount of MBP is in lower in the PNS 
as compared to the CNS (5-15% c.f. 30% (Lees and Brostoff, 1984)). Myelin - 
associated oligodendrocyte basic protein (MOBP), myelin oligodendrocyte protein 
(MOG), oligodendrocyte-myelin glycoprotein (Ompg) are specific to the 
oligodendrocyte and thus the CNS (Holz et a l, 1996). Po is Schwann cell specific 
and detected only in the PNS (Suter, 1997). PMP22, previously thought to be 
exclusive to the PNS, has been localised to CNS motor neurones, though it has not 
been shown to be a constituent of CNS myelin (Parmantier et a l, 1995). The 
putative structure of PMP22 shares similarities with those proposed for PLP (see 
Figure 1, pages 8-9 and Figure 2, page 10) and it has been speculated that they have 
similar functions (Suter & Snipes, 1995).
1.2.1.3 The composition of central nervous system myelin
Myelin is a heterogeneous combination of proteins and lipids. A small number o f 
constituents make up the bulk of myelin, with many o f the proteins being myelin 
specific.
1.2.1.3.1 Lipids
Lipids make up the 70% of the dry weight o f myelin (Norton and Cammer, 1984). 
No lipids are specific to myelin but the high proportions of galactosphingolipids, 
cerebroside (galactosylceramide) and sulphatide are a characteristic of myelin. 
Cerebroside is the most myelin specific of these lipids and is an oligodendrocyte 
specific marker in the CNS (Raff et a l, 1978).
1.2.1.3.2 Proteins
1.2.1.3.2.1 The myelin proteolipid proteins (PLP/DM20)
Proteolipids are not specific to myelin and are a general feature o f the cell 
membranes of plants and animals and are characterised by their solubility in organic 
solvents, particularly chloroform/methanol mixtures (Folch & Lees, 1951). Myelin 
has two specific proteolipids, termed proteolipid protein (PLP) and DM20. PLP is
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the major CNS myelin protein representing approximately 50% of myelin protein 
(Lees and Brostoff, 1984). PLP has no specific activity that can be measured to 
quantify its presence and is thus detected immunologically. It has been important to 
demonstrate that with such techniques there is no cross reactivity with non-neural 
proteolipids or other myelin proteins, such as MBP (Macklin et a l, 1982).
The PLP and DM20 protein isoforms are alternative splice products o f the Pip gene 
and are size separated on a sodium dodecyl sulphate (SDS) polyacrylamide gels. 
PLP has an apparent molecular mass of ~24KDa and DM20 is so called because of 
its apparent molecular mass of ~20KDa. The actual masses are greater: PLP 
~30kda; DM20 ~26.5KDa (Nave et a l, 1987; Stoffel et a l, 1983).
PLP consists o f 276 amino acid residues and is highly hydrophobic, with the amino 
acid residues that confer this behaviour grouped into four domains, which are 
separated by hydrophilic domains (Lees and Brostoff, 1984). In vivo the 
hydrophobic nature of the protein is increased by acetylation with long chain fatty 
acids at four o f the cysteine residues in PLP but only two in DM20 (Weimbs & 
Stoffel, 1992). Acylation is a dynamic process that occurs in myelin and is possibly 
related to maintenance (Bizzozero & Good, 1991). DM20 is generated from an 
alternate 5' splice site in exon 3 which results in a protein 35 amino acids shorter 
(amino acids 116-150) but otherwise identical to PLP (Nave et a l, 1987). The PLP- 
specific region of the protein is highly charged and hydrophilic.
The orientation of the PLP/DM20 protein isoforms within the lipid bilayer has yet to 
be elucidated partially because of technical difficulties due its integral position 
within this structure. Models have been inferred based on considerations of 
available evidence, some of which is contradictory, and the similarity to other 
known structural proteins. These models are summarised in Figure 1 (pages 8-9). 
A common feature of these models is a number of transmembrane domains, with the 
major differences between models being the positions o f the N and C terminals and 
the PLP specific region. For comparison a schematic representations o f some of the 
other major myelin proteins are presented in Figure 2 (page 10).
The most recent studies place both terminals on the cytoplasmic surface, though 
only the C-terminus has been specifically located (Konola et a l, 1992). The 
extracellular nature o f domains proposed by Laursen (1984), Popot et al (Popot ei 
al, 1991) and Wiembs and Stoffel (1992) are supported by the work of Greer et al 
(1996) and Gow et al (1997). The residues 103-116, which are adjacent to the PLP 
specific region, have been shown to be at the MDL (Sobel et a l, 1994) suggesting
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that the PLP specific region is probably also on the cytoplasmic surface. DM20 has 
been proposed to share the topology of PLP (Gow et al, 1997).
The contribution of PLP to the IPL of compact myelin is documented where it is 
postulated to be an adhesive strut (Duncan et al., 1987). This concept is supported 
by the perturbations of the IPL in myelin mutants (see 1.3.2.1 Animal models, page 
26) and knockout mice (Klugmann et al., 1997). It has been suggested that PLP 
may also be involved in the generation of the MDL (Kitagawa et a l, 1993; Duncan 
etal., 1987).
A full evaluation of the functions of PLP and DM20 has yet to be completed. The 
high degree o f conservation of the amino acid sequences across diverse species and 
through evolution (see 1.2.2.1.1 Phylogenetic evolution o f the Pip gene, page 13) is 
suggestive of a fundamental and crucial role for the protein-protein interactions of 
these products o f the Pip gene locus. Analysis of the evolution of this gene suggests 
the hydrophobic transmembrane domains exhibit the strongest conservation, 
suggesting the arrangement of these regions within the membrane are critical and 
very sensitive to disruption. PLP forms hexamers under certain conditions (Smith et 
al., 1984) and such an assembly could be sensitive to disruptive changes. 
Examination of the DM-like family of proteins shows similarity with channel 
forming regions of the nicotinic acetylcholine receptor and glutamate receptor 
macromolecular complexes (Kitagawa et al, 1993) (also see 1.2.2.1.1 Phylogenetic 
evolution of the Pip gene, page 13). The proposed structure of the PLP/DM20 
protein isoforms places them in a heterogeneous group of membrane bound ‘four 
helix bundle’ proteins (Nave, 1996). There are several other myelin proteins 
(PMP22, OSP and the connexins) with a similar topology (Gow et al., 1997) (also 
see Figure 2, page 10). Whether the PLP/DM20 proteins are members o f the group 
of proteins, described by Wright and Tomlinson (1994), with four-transmembrane 
regions and having ion-channel properties is yet to be resolved. Other authors have 
presented evidence that PLP may form pores and be involved in ion transport 
(Knapp, 1996). There is also a considerable body of data suggesting roles other 
than that o f structural proteins for the products o f the Pip gene, pointing in particular 
for a role for DM20 in oligodendrocyte development (Montague and Griffiths, 
1997).
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Figure 1. Proposed models for the orientation of PLP/DM20 within the myelin 
lipid bilayer. The proposed hydrophobic transmembranous domains are shaded 
(brown). The PLP specific segment is in red. (a) Stoffel et al (1984); (b)
Laursen et al (1984); (c) Hudson et al (1989).
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Figure 1 (continued). Proposed models for the orientation of PLP/DM20 within 
the myelin lipid bilayer, (d) Popot et al (1991); (e) Weimbs and Stoffel (1992); 
(f) Gow et al (1997). The blue line represents a region of the C-D loop that the 
authors postulate may be significant in PLP-PLP interactions and also part of 
the epitope recognised by B cells.
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Figure 2. Schematic diagram illustrating the arrangem ent of some of the other 
major myelin proteins in CNS and PNS myelin (hydrophobic regions thought to 
be transmembranous domains are represented by an orange filled box). P0 and 
MAG are both monotopic proteins whilst PMP22 and connexin 32 (Cx32) are 
polytopic, with four transmembranous domains (Snipes & Suter, 1995). MBP 
does not cross the lipid bilayer and appears to lie on its intracellular surface 
(Smith, 1992), where it is proposed to interact with the negative charge of the 
phosphate groups on the lipid bilayer's inner surface.
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1.2.1.3.2.2 Myelin basic protein (MBP)
MBP is the other major CNS protein representing ~ 30% of total myelin. 
Differential gene splicing produces a family of related proteins which in rodents 
consists o f four isoforms (Campagnoni, 1988). MBP is associated with the MDL of 
compact myelin (Nave, 1996) but its isoforms have different developmental profiles 
including expression during embryogeny, suggesting a role distinct to that of a 
structural component of myelin (Nakajima et a l, 1993). Recently a regulatory role 
has been suggested for one of the MBP isoforms, MBPexII, as it is preferentially 
targeted to the nucleus (Pedraza et al, 1997).
1.2.1.3.2.3 Myelin associated glycoprotein (MAG)
MAG is predominantly found in the periaxonal regions o f the CNS myelin sheath 
and very little is found in compact myelin (Trapp, 1990). It is specific to 
myelinating cells and member of the Ig superfamily and thus probably has adhesive 
properties (Nave, 1996). Two message isoforms are produced which show 
developmental regulation (Kirchhoff et a l, 1997). There are two protein isoforms 
designated L-MAG (large) and S-MAG (small) (Quarles et a l, 1992). These 
isoforms have different patterns of expression in the CNS, with L-MAG being 
associated with active myelination and S-MAG associated with mature myelin 
(Minuk & Braun, 1996). In the PNS S-MAG is the major isoform expressed during 
development (Nave, 1996). These different patterns o f regulation o f the two 
isoforms implies a functional difference between the isoforms but though a number 
are postulated none has been specifically attributed to either isoform (Minuk & 
Braun, 1996).
1.2.1.3.2.4 2',3-cyclic nucleotide 3'-phosphodiesterase (CNP)
The enzyme CNP is expressed by developing oligodendrocytes (Scherer et al, 
1994). It is localised beneath the oligodendrocyte surface membrane and within 
cytoplasmic domains of the myelin sheath (De Angelis & Braun, 1996) rather than 
in compact myelin. It exists as two isoforms of 44 and 48kD (Campagnoni, 1988) 
which are differentially expressed during development (Scherer et a l, 1994). The 
specific substrate and action are uncertain but the evidence suggests roles in 
maintenance of the myelin sheath and oligodendrocyte differentiation (Gravel et al, 
1996; Trapp, 1990).
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1.2.1.3.2.5 Myelin-oligodendrocyte basic protein (MOBP)
The MOBPs are a recently identified family of myelin proteins and are currently 
being actively characterised. MOBP message is the third most abundant mRNA 
species, after PLP and MBP (Yamamoto et a l, 1994). A number o f isoforms are 
produced, one of which (MOBP81) is associated with development (Holz et al., 
1996). The MOBP family are small basic proteins of between 69 and 99 amino 
acids in length, which are identical from residues 1 to 68 and thus vary at the C- 
terminal. The expression of one abundant isoform occurs in conjunction with 
myelin compaction suggesting a late role in myelination and a possible role in 
myelin compaction (Montague et al, 1997).
1.2.1.3.2.6 other minor protein constituents o f CNS myelin
CNS myelin contains small amounts of other myelin specific proteins which are 
currently of uncertain significance. These include: myelin/oligodendrocyte 
glycoprotein (MOG); oligodendrocyte-myelin glycoprotein (OMpg); myelin- 
oligodendrocyte specific protein (MOSP) (Montague and Griffiths, 1997). Recently 
a new oligodendrocyte protein oligodendrocyte-specific protein (OSP) has been 
described (Bronstein et al, 1996). The small amounts of these proteins present in 
myelin is not necessarily a reflection of their functional significance, which will 
become clearer as they are further characterised. As the recent identification of 
MOBP and OSP illustrates there are likely to be other proteins as yet 
uncharacterised.
1.2.2 The Pip gene locus
1.2.2.1 The organisation of the Pip gene
The single Pip gene locus is located on the X-chromosome (at Xq21.33-22 in man) 
(Mattei et a l, 1986; Willard & Riordan, 1985). It is a complex transcriptional unit 
encoding for at least two protein isoforms. The molecular architecture is 
summarised in Figure 3, page 14. It is greater than 17Kb in size and is considered to 
comprise seven exons and six introns, though an eighth exon has been proposed by 
Kamholz et al (1992). In rodents two transcription initiation sites have been 
described, at nucleotides -130 and -160, but there is heterogeneity around the major 
initiation point between these sites (Macklin et a l, 1987; Bradley & Jenkison, 
1973). The Pip gene has three polyadenylation sites resulting in heterogeneous 
population of mRNAs, with three major transcripts observed: 1.5-1.6Kb; 2.4-2.6Kb 
and 3.0-3.4Kb. The proportions of these transcripts varies between species and on 
northern hybridisation the following patterns are observed: the rat has a major band
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at 3.2Kb and minor band of 1.6Kb (Bradley & Jenkison, 1973); the mouse has major 
bands of 3.0-3.4Kb and 2.4-2.6Kb with a minor band of 1.6Kb (Sorg et a l, 1987; 
Gardinier et a l, 1986); man has a major band of 3.2Kb and a minor band of 2.2Kb 
with a very small amount of the 1.6Kb transcript (Kronquist et a l, 1987). However, 
all transcripts have an open reading frame of 831 nucleotides and are translated to 
either protein isoform (Milner et al, 1985). The significance of the multiple 
transcripts is unknown but a possible benefit is greater tolerance to mutations within 
the important post-transcriptional processing sites.
1.2.2.1.1 Phylogenetic evolution of the Pip gene
Myelin is a specialised macromolecular feature of all vertebrates (with the exception 
of those with no jaw). In non-tetrapods Pq is the major integral membrane protein 
of both the CNS and PNS whilst in tetrapods Pq is not present in the CNS and has 
been replaced by the products of the Pip gene. All tetrapods, with the exception of 
anurans (Schliess & Stoffel, 1991), express both the PLP and DM20 protein 
isoforms (Colman et al, 1996) and there is striking intra-species conservation of the 
sequence of the Pip gene locus and its products. This is particularly marked in the 
coding regions, for example, out of the 831 nucleotides that code for the protein 
sequence there are only 11 degenerate differences between rat and mouse (Milner et 
al, 1985) and 25 between human and mouse (Diehl et a l, 1986). The redundancy 
of the genetic code results in a high degree of conservation of the amino acid 
sequence with complete conservation between man and rodents (Diehl et a l, 1986) 
and >98% including dog and cow. Moreover, this conservation extends into the 5’ 
non-coding sequence and is particularly strong within the first 250bps upstream of 
the initiation codon (see 1.2.3.1.1.2 Transcription o f the Pip gene, page 17). Other 
genes that exhibit such strong conservation include the oestrogen receptor and actin, 
whose products have specific and extensive interactions with a range o f other 
molecules (Hudson andNadon, 1992).
The discovery of novel DM20-like proteins (DMa, p and y (Kitagawa et a l, 1993), 
in Elasmobranch cartilaginous fishes Squalus acanthias (shark) and Torpedo 
californica (electric ray) and homologues in the mouse (M6a and b (Yan et a l,
1993)) has led to the concept of a DM-like family of proteins. DM a has the greatest 
similarity to mammalian DM20 (62.7% identity and 80.5% similarity). The DM 
family proteins do not have the same degree of conservation across species as seen 
with the Pip gene. For example, M6a of the mouse shares 85% amino acid identity 
with DMp but D M a does not appear to have a vertebrate homologue (Colman et al, 
1996).
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PLP-like proteins appear to have developed about 400 million years ago, before the 
evolution of tetrapods, in the CNS myelin of Sarcopterygli fish (lung fish) and the 
Coelacanth (Waehneldt & Malotka, 1989; Waehneldt et a l , 1986). However, 
DM20 appears to be a relatively recent development as fish (Colman et a l, 1996) 
and amphibia (Schliess & Stoffel, 1991) do not express a DM20 protein and a Dm20 
message cannot be detected in Xenopus (Nave et a l, 1993). Neither the DM-like or 
M6 genes contain the PLP-specific segment. These observations support the idea 
that the present vertebrate Pip gene has developed from a duplication of one of the 
DM-like genes and the acquisition of the PLP-specific segment (Colman et al, 
1996) Other postulations for the generation of DM20 are a de novo mutation 
creating a splice site in exon 3 of a Pip like gene in post-amphibian tetrapods 
(Schliess & Stoffel, 1991), or alternatively the loss of the splice site in amphibia.
Expression of the DM-like gene family appears to have a greater diversity o f tissue 
expression than the Pip gene. Though M6b is expressed in developing glia (Yan et 
al, 1996) it is also expressed in neurones whilst M6a is expressed in developing 
neurones, renal tubules, olfactory epithelium and choroid plexus (Yan et a l, 1993). 
DM a and y are expressed in shark white matter tracts whilst DMp is expressed in 
neurones, kidney and choroid plexus but not white matter (Kitagawa et a l, 1993). 
The early appearance of the M6 message in mouse CNS suggests a role in the 
development of a number of neural cell types (Yan et a l, 1996).
The question as to why PLP, a tetraspan protein, appears to have replaced Po, a 
monotopic protein, in myelin compaction remains unresolved and intriguing.
1.2.2.2 Developmental expression of the Pip gene in the CNS
This data has been accrued from a range of species, various areas o f the CNS and 
using a range of experimental techniques with varying sensitivities. Data also vary 
between descriptions of gene activity describing the presence of transcript, product 
or both. However, general patterns of gene transcription and translation can be 
deduced.
Plp/Dm20 transcripts have been documented in embryonic nervous tissue including 
brain (Ikenaka e ta l,  1992), spinal cord (Timsit et a l, 1995; Timsit et a l, 1992), and 
PNS (Yu et a l, 1994; Timsit et al, 1995; Timsit et a l, 1992) (also see 1.2.3.3 
Expression of the Pip gene in the PNS, page 23). The first myelin sheaths are seen 
at E l8 in the mouse and thus such transcripts are in tissues in which the 
oligodendroglia are immature and non-myelinating. The Dm20 transcript is the 
sole/predominant transcript at this stage. Expression in non-neural tissue types has 
been shown to be predominately Dm20, with both transcript and protein being
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described in some organs (Pribyl et a l, 1996). Likewise, in the PNS transcripts are 
also predominantly Dm20. The significance of these Dm20 transcripts has not been 
established but in consideration with other observations lends credence to the idea 
o f a developmental role for the gene products and in particular for Dm20.
There is controversy over the cell types responsible for the Pip gene transcripts in 
embryonic CNS tissue and progenitors of other cell types have been proposed as 
expressing these transcripts (Dickinson et al., 1996; Richardson et a l, 1997; Timsit 
et a l, 1995; Yu et a l, 1994). This arises from difficulties in confident identification 
o f the immature cells shown by in situ hybridisation to express Plp/Dm20. There is 
a lack of a robust marker for early committed oligodendroblasts and there is the 
possibility that expressing cells may be pluripotential (Williams et a l, 1991). 
However, some of these Dm20 positive cells have been identified as being of the 
02-A  lineage and thus destined to ultimately differentiate into oligodendrocytes 
(Dickinson et al, 1996).
In mice the Plp/Dm20 message isoform population is Dm20 dominant from E 12- 
E l 6, equivalent from E17-P1 and is characterised by a Pip dominance (3:1) during 
myelination and myelin maintenance (Figure 4, page 20). After myelination starts 
and during myelin maintenance the Pip isoform is the dominant message and PLP 
protein is the dominant isoform.
1.2.3 Regulation of Pip gene expression and co-ordinate expression 
of the myelin genes
1.2.3.1 Regulation of Pip gene expression
Proteins are the effectors of eukaryotic cell activity and the genes that encode for 
them and are transcribed by the RNA polymerase II (PolII) transcriptional 
machinery. The co-ordinated flow of information from DNA to protein requires a 
complex regulatory circuit to achieve the appropriate spatial and temporal 
expression in co-ordination with other genes and their products. The product of 
transcription, termed nascent or pre-mRNA, is subject to further processing, 
including splicing, that influences the final mRNA population. The Pip gene is one 
of the spectrum of cellular and viral genes that are transcribed by the PolII 
transcriptional machinery for which the major step determining the level o f mRNA 
is the control o f initiation and thus the amounts of nascent product produced.
The current paradigm of the basic mechanisms in the control of transcription of 
PolII genes involves regions of gDNA sequence, termed c/s-elements, that are 
recognised by a heterogeneous group of molecules termed trans-factors. The final
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levels of protein may be influenced at other stages in the process including 
alternative splicing of the nascent RNA, changes RNA half life, control of 
translation and post-translational influences on cellular trafficking. It is important to 
note that message levels cannot be used as a measure of protein levels.
1.2.3.1.1.1 Transcription of the Pip gene
As described in 1.2.2.2 Developmental expression of the Pip gene in the CNS (page 
15) the absolute amounts and ratios o f the Pip and Dm20 messages are 
developmentally regulated. The regulatory circuit responsible for the co-ordination 
of these events is complex. Pip gene regulation has been demonstrated (or inferred) 
to be effected at the levels o f transcription, translation and post-translation 
(Montague and Griffiths, 1997). Many of these experimental regimes have studied 
elements o f the Pip gene in isolation and the interpretation of such studies must be 
cautious as in such circumstances the behaviour o f such isolated elements may be 
unregulated. Further problems arise from the diversity o f techniques that have been 
employed and the use in vitro tissue cultures systems, particularly the use o f stable 
cell lines the existence of which implies changes from in vivo gene regulation.
There are three broad areas of interest in the regulation of the Pip gene: the 
developmental changes in message ratios; the transcriptional burst o f activity 
associated with myelination; the co-ordination of Pip gene expression in relation to 
other myelin genes.
Nuclear run-off assays (Cook et al., 1992) demonstrated that the Pip gene is 
regulated principally at the level of transcription. This is in common with other 
myelin genes such as MBP (Cook et al., 1992), and typical of genes transcribed by 
the PolII transcriptional machinery.
There has been intense activity directed towards identifying the potential cis- 
elements of the gene locus related to transcriptional control. Sequence analysis of 
the 1.5Kb upstream of the translation start codon (+1) demonstrates areas of 
remarkable conservation between mouse, rat and man (Janz & Stoffel, 1993). This 
is about 95% between -250 and +100, falling to about 50% further upstream and 
suggests evolutionary conservation of a region and the presence of putative cis- 
elements. Physical techniques (footprint and gel shift) and functional analysis 
(transfection studies and the creation of transgenic mice) have been used to confirm 
putative c/s-elements and identify the associated ^raws-factors Positive (Bemdt et 
al, 1992)and negative cw-regulatory elements (Nave & Lemke, 1991) have been 
identified in the 5' non-coding region and possibly in intron 1 (Wight et a l, 1993).
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Tissue specific expression for genes from other systems has also been associated 
with enhancers in both 5' regions and introns (Lefebvre et a l, 1996).
In this upstream region there are two copies of the sequence AAGGGGAGGAGA, 
which is conserved between mouse, rat and man (-63 to -75) and has 
complimentarity to sequences found in the 5' regions of other myelin genes (see
1.2.3.2 Co-ordinate expression of the CNS myelin genes, page 21), (Hudson et a l, 
1996)). This sequence lies within a purine rich element of 44 purines residing on 
one strand (Bemdt et al, 1992). This element is in a region of the Pip gene 
promoter that confers maximal expression of the Pip gene in a variety of transfected 
cells and its function is sensitive to mutation (Hudson et a l, 1996). It is recognised 
by factors that are ubiquitous (Spl) and others that are tissue specific (a brain 
enriched 66Kda protein with similarities to an ETS domain) (Janz & Stoffel, 1993). 
The ETS domain is important in glial cell development in invertebrates (Hudson et 
a l, 1996) but is also seen in neural precursors (Charron et al., 1995). Another 
putative glial specific elements has been identified at -118 which is also found in 
other myelin genes (Bemdt et al, 1992).
A range of factors have been shown to increase Pip gene transcription. These 
include thyroid hormones, steroids, retinoic acid, PDGF (Grinspan et a l, 1993) and 
cAMP (Nave & Lemke, 1991). The thyroid hormone response element is present in 
both the 5' region and exon 1 presenting the possibility o f both transcriptional and 
post-transcriptional control (Gao et al, 1997) (also see 1.2.3.2 Co-ordinate 
expression of the CNS myelin genes, page 21). Steroids have conflicting effects in 
vivo (negative (Tsuneishi et al, 1991)) and in vitro (positive (Zhu et a l, 1994)). 
Retinoic acid has been demonstrated to increase message half life (Zhu et a l, 1994) 
and also has a role in early differentiation of oligodendrocytes (Fraichard et a l, 
1995; Barres et a l, 1994). Expression of the Pip gene is also modulated by signals 
from other components of nervous tissue for example axons (Scherer et a l, 1992; 
Kidd et a l, 1990) (see 1.2.4 The relationship between axons and glia in 
development of the myelin sheath, page 23).
Genes responsible for trans-factors that are required for glial differentiation have 
been identified in Drosophilla and there are also genes for trans-factors that are 
important for glial development after cells are committed to the glial lineage 
(Hudson et a l, 1996). 7><ms-factors that have been described include myelin
transcription factor 1 (MyTl), which is a zinc finger transcription factor, the 
expression of which is strongly associated with oligodendrocyte development and 
which binds to a site in the Pip gene promoter (Armstrong et a l, 1995) and other
18
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myelin genes (Hudson et al, 1996). Currently the control o f these early steps in the 
regulation of vertebrate Pip gene expression are poorly understood.
1.2.3.1.1.2 Post-transcriptional regulation
The varying ratios in the Pip and Dm20 message isoforms observed during 
development is achieved by varying the use of the two potential splice sites in exon 
3, one of which is internal and the other is at the 3' exon/intron boundary (Figure 3, 
page 14). Both sites show a similar degree of complimentarity with U1 small 
nuclear ribonucleoproteins (snRNP), which form an RNA duplex with the 5' splice 
site, an early regulatory event in the formation of the spliceosome (Montague and 
Griffiths, 1997). It has been suggested that the selection of the distal site is the 
default pathway for spliceosome assembly (Montague and Griffiths, 1997). 
Selection of a particular site is also related to the relative and absolute amounts of 
SR proteins which vary between tissues (Zahler & Roth, 1995), a mechanism by 
which both temporal and cell specificity may be enhanced. Hudson et al ( 1996) 
suggest that the embryonic expression of Dm20 message may represent loose 
transcriptional control at this early stage of development, as a consequence of the 
requirements of regulation at later stages, and imply that the message observed does 
not necessarily have physiological significance.
1.2.3.1.2 Post-translational events
The Pip and Dm20 mRNAs are translated on the rough endoplasmic reticulum 
(RER) and the proteins follow the secretory pathway passing through the Golgi 
apparatus en route to the cell membrane (Gow et a l, 1994). In vitro studies suggest 
that in developing oligodendrocytes these proteins are stored for a period before 
assembly into myelin (Dubois-Dalcq et al, 1986), however, in vivo studies show 
that translocation can take as little as 30 minutes (Colman et al., 1982). Transport to 
the cell membrane is in association with the micro-tubular apparatus possibly in 
association with other myelin components (Brown et al., 1993; Trapp, 1990). 
Membrane proteins are recycled and enter the endocytic pathway for eventual 
degradation. It is likely that interactions with other cell types are important in 
modulating any differences in trafficking between the two isoforms (Montague and 
Griffiths, 1997).
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Mouse spinal cord: semi-quantitative RT-PCR
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Figure 4. Semi-quantitative RT-PCR analysis o f PIp:Dm20 ratios in spinal cord. a) 
densiometric analysis o f RT-PCR products illustrates marked up-regulation o f  the Pip gene 
coinciding with the change to predominance o f the Pip message isoform around PI; b) 
Increasing predominance o f the Pip isoform in post-natal life is seen in the Plp:Dnt20  transcript 
ratios rising from greater than 1 to 3.5 by P20. Gestation length was approximately 20 days in 
the strain o f mice studied and approximate point o f birth is marked on the graphs (*). From 
Dickinson, 1995, Figure 20, page 99 (with permission).
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The PLP and DM20 protein isoforms undergo two post-translational modifications 
which are loosing the N-residue (Milner et al., 1985) and becoming acylated. The
lack of an amino terminal leader sequence, a feature of some but not all 
transmembranous proteins, suggests that targeting is by an internal signal. The first 
13 amino acids may contain a topogenic signal sufficient for membrane 
incorporation (Wight et al., 1993) (also see 6.5 Discussion, page 177). However, 
Gow et al (1994) demonstrated that transfected COS-7 cells are able to translocate 
PLP and DM20 through their secretory pathways suggesting that glial specific 
elements are not essential for correct folding and transport.
The complex topography of the oligodendrocyte with multiple processes supplying 
intemodes of different sizes with potentially differing requirements suggests a 
sophisticated system for ensuring appropriate delivery. These mechanisms in 
relation to the PLP/DM20 protein isoforms are unknown. The local translation of 
Mbp mRNA at the periphery of the cell, which may be regulated by local 
requirements for myelin components, has been suggested to be a potential regulator 
of PLP/DM20 transport (Hudson et al., 1996). Some transfection studies have
suggested that both PLP and DM20 must be present for incorporation to occur 
(Sinoway et al., 1994) but other studies, using different cell types do not support this
(Montague, unpublished observations). The experiments of Sinoway et al (1994) 
suggest that the two proteins form a complex reminiscent of adhesive proteins such 
as P0 and cadherin, concentrated at regions of cell-cell contact.
1.2.3.2 Co-ordinate expression of the CNS myelin genes
The ability of oligodendrocyte to both elaborate and maintain a myelin sheath 
requires the co-ordinated activity of many genes encoding both structural proteins 
and those involved in the mechanisms of intracellular transport. The mechanisms 
behind this achievement are only just being answered.
No “master” gene has been identified that orchestrates the expression o f the CNS 
myelin genes, as for example the Pax-6 gene is thought to have a pivotal role in lens 
formation (Schedl et al., 1996). Co-ordination is not achieved by a unique trans- 
factor that regulates each individual gene but through a complex, and potentially 
more flexible system, involving the interaction of a cohort of specific and ubiquitous 
factors. A cis-structure (see above) has been identified to be common to the Mbp, 
Mag and Omg genes and the glial specific JC virus (Hudson et a l, 1996). There are 
also homologues of c/s-elements found in the Pip gene in other myelin genes. The 
thyroid response element illustrates how common c/s-elements may be involved in 
co-ordinate but temporally specific expression of myelin genes. Both the Mbp and
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Pip genes are modulated by thyroid hormone and have the similar hormone 
response elements in their promoters. However, the two genes have different 
co-transcription factors binding to the element and it is the developmental profile of 
these co-factors that mirrors specific gene activity (Hudson et a l, 1996). The Pip 
gene also shares a co-factor with another group of genes modulated by thyroid 
hormone that are related to the production of liposomes, an organelle important in 
lipid metabolism (Hudson et al., 1996).
1.2.3.3 Expression of the Pip gene in the PNS
Initially the Pip gene was thought to be expressed exclusively in the CNS. It is now 
well established that it is transcribed in a number of other tissues including cells of 
the PNS (Griffiths et al, 1995). In all PNS cell types Dm20 message isoform and 
DM20 protein are predominant. Transcription occurs in both non-myelin forming 
Schwann cell (NMFSC) and MFSC and the product is localised to cytoplasmic 
domains and is not generally detected in PNS myelin (see 6 Expression of Pip 
transgenes in the peripheral nervous system, page 171). The DM20 protein isoform 
is also detectable in the perineuronal satellite cells o f the spinal cord, cranial and 
autonomic ganglia and in the ensheathing cells of the olfactory nerve layer of the 
olfactory bulb (Dickinson et al, 1997).
The functional significance if any of Pip gene expression in the PNS is unknown. It 
is notable that it is expressed in cells that do not produce myelin. Developmental 
studies show that regulation of the Pip gene is not related to PNS myelination 
(Griffiths et a l, 1995; Kamholz et al, 1992; Stahl et a l, 1990). Dm20 is strongly 
expressed in the embryo at a point when Schwann cell precursors are actively 
mitotic and motile and not expressing myelin protein genes (Griffiths et a l, 1995). 
Observations by Kamholz and others (1992) concur with the Pip gene not being part 
of co-ordinate myelin gene expression in the PNS. For example, in sciatic nerves 
undergoing Wallerian degeneration PNS myelin proteins are markedly 
downregulated whilst Pip gene transcription is minimally affected (Kamholz et al, 
1992).
The reasons for these differences in Pip gene expression between the PNS and CNS 
are not known. Different transcription start sites are used in Schwann cells 
compared with oligodendrocytes and may thus represent different promoter sites in 
these cell types implying a response to different combinations o f trans-factors 
(Kamholz et al, 1992). PNS myelin has a different composition from CNS myelin 
and it has been proposed that the physical association of these proteins excludes 
PLP from participating in myelin assembly (Kamholz et a l, 1992) (see 6 Expression
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of Pip transgenes in the peripheral nervous system, page 171). The converse 
relationship between the two isoforms in the PNS, as compared to the CNS, may 
result in conditions that are stoichemetrically unfavourable for insertion (see
1.2.3.1.2 Post-translational events, page 19). The purported lack o f acylation of the 
PLP/DM20 isoproteins in Schwann cells (Agrawal & Agrawal, 1991), refuted by 
Tetzloff and Bissozero (1993), has been suggested as being significant, though 
acylation probably develops within myelin.
These observations, though not providing a mechanistic reason for Pip gene 
expression in the PNS, support the growing consensus that DM20 has a separate, but 
as yet undefined, role in development and that this may not be confined to the 
oligodendrocyte.
1.2.4 The relationship between axons and glia in development of the 
myelin sheath
The development and maintenance of the organs o f eukaryotic organisms is 
dependent on the interaction of disparate groups of cell types. In the CNS the 
oligodendrocyte should be considered in relation to the cell it ensheathes - the 
neurone and its axon- and the other glia, in particular the astrocyte.
A number o f features of the formation of the myelin sheath demonstrate the 
importance o f the influence of the axon over whether it is ensheathed and the 
properties o f any myelin sheath that does form (reviewed by Doyle and Colman 
(1993), Waxman and Black ( 1995)). The formation of the sheath in relation to 
thickness (the number of myelin turns) and the length of the intemode is a function 
o f the axon diameter and as the majority of oligodendrocytes ensheath multiple 
intemodes of axons of varying diameters this is very suggestive of local factors 
influencing the properties of distal regions of oligodendrocyte processes. Though 
the precise mechanism by which oligodendrocyte processes are attracted to axons 
and stimulated to ensheath them remains unclear it is evident that a sequential 
cascade o f gene expression encompassing a variety of gene groups, including 
adhesion and structural genes, is essential for the formation of a functional myelin 
sheath. Oligodendrocytes that fail to ensheath an axon undergo apoptosis 
illustrating the importance of this relationship in their continued survival and 
development (Trapp et al, 1997).
This establishment of the close association between oligodendrocyte and axon 
influences the ultrastructure of axons and glial cells. In the axon there are 
influences on both membrane structures (e.g. ion channels) and axoplasmal contents
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(e.g. packing of neurofilaments). The loss o f myelin results in the loss of this 
axonal organisation (Rosenbluth, 1995).
1.3 Abnormal development and loss of myelin
1.3.1 Dysmyelination and demyelination in the CNS
Myelin is both elaborated and maintained by oligodendrocytes and perturbations of 
cell development, metabolism or death are likely lead to myelin abnormalities.
The inability to elaborate a compact myelin sheath is referred to as dysmyelination 
and consequently is a feature of abnormal development. The essential features are 
hypomyelination due to failure of myelin production, often with concomitant 
abnormalities of any myelin elaborated (see 1.3.2 Naturally occurring mutants, page 
26). Myelin debris is not usually a feature. Though dysmyelination has been 
associated with mutations of the myelin genes the mechanisms underlie the failure 
of the system are poorly understood. Dysmyelination also may be associated with 
mutations in genes encoding for proteins other than the specific myelin genes. For 
example, the quaking (qk) mouse has is a deletion in chromosome 17 affecting a 
signal transduction and activator of RNA protein (STAR protein), which is proposed 
to affect the alternative splicing of myelin specific protein(s) (Ebersole et al., 1996).
Demyelination, the loss of formed myelin with relative preservation of the axon, is 
the final common pathway of multiple aetiologies including the effects of toxic 
chemicals, trauma, viruses, etc. and the end-stage of a considerable number of 
inflammatory and non-inflammatory diseases. The initiation of breakdown is poorly 
understood and is the potential key to a number of significant conditions, for 
example multiple sclerosis (MS). Both the oligodendrocyte and the myelin sheath 
are potential targets. Myelin potentially may be lost due to a failure of the 
oligodendrocyte to maintain the sheath or the sheath may be attacked directly. 
Oligodendrocyte metabolism can be affected by exogenous chemicals (Blakemore, 
1984) and factors produced by cells (cytokines, reactive oxygen species (ROS), 
nitric oxide (NO) )(Cuzner & Norton, 1996; Sun et al., 1995; Rodriguez et al., 
1994). Demyelination is often associated with a change, often inflammatory in 
character, in the local cell population. Cells may be exogenous to the CNS arriving 
in the circulation but there also may be local proliferation of microglia and 
astrocytes. Cytokines released from activated cells, for example TNFa, are also 
significant in modulating other local events that may contribute to the process. In 
viral infections the virus itself may damage the oligodendrocyte or possibly render it 
susceptible to attack by CD+ T cells (Rodriguez et al., 1994). It is the macrophage
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lineage cells that are currently thought to be the pivotal cells in inflammatory 
disease, though their role may vary (Rodriguez et a l, 1994; Sun et a l, 1995; Cuzner 
& Norton, 1996; Dijkstra et al, 1992). The myelin sheath may be attacked directly 
by macrophages in experimental allergic encephalomyelitis (EAE) and MS (Dijkstra 
et a l, 1992). Opsonisation increases the susceptibility o f myelin to attack by 
stimulated macrophages. There also exists the possibility of myelin damage by 
enzymes released during “frustrated” phagocytosis by macrophages unable to 
internalise intact myelin (Cuzner & Norton, 1996).
Predictably the first manifestation of dysfunction resulting in an inability to 
maintain the myelin sheath would be an abnormality o f the inner tongue, this being 
the most distal part of the oligodendrocyte cytoplasm. This phenomenon of a 
“dying back oligodendrogliopathy” is observed in some intoxications (Blakemore, 
1984), in the demyelinating form o f Theiler's virus infection and more 
controversially in early cases of MS (Allen and Kirk, 1997; Rodriguez et a l, 1994). 
Histologically the first stages of demyelination are vesiculation and swelling of the 
myelin sheath, with splitting of the IPL and potentially the development of vacuoles 
(Blakemore, 1984). Myelin changes following administration of toxic chemicals, 
such as hexachlorophene or triethyl tin, may be limited to vacuolation which is 
reversible, implying that exposure of myelin constituents does not necessarily result 
in demyelination (Ludwin, 1995). However, in many circumstances once myelin 
breakdown is initiated there appears to be a common pathway of destruction. The 
exposed myelin proteins and lipids are exposed to endogenous enzymes, which may 
derive from inflammatory cells or from the circulation through an incompetent 
blood-brain-barrier. In the CNS microglia/macrophages may be an important source 
of such enzymes. The final removal o f myelin debris is by phagocytic cells, 
predominantly macrophages and microglia, though myelin debris can be observed in 
astrocytes (Cuzner & Norton, 1996).
1.3.1.1 Demyelination in mice due to viral infection
Demyelination is a recognised sequela to a range of viral infections in mice. Viruses 
from a range of unrelated groups are implicated. These infections must be 
considered when animals are not maintained in a specific pathogen free 
environments. In stable populations such infections can be enzootic.
1.3.1.1.1 Mouse hepatitis virus (MHV)
The possible consequences of infection with this corona virus are reviewed by 
Fujiwara ( 1994). It is extremely contagious and can be transmitted in tissue grafts. 
Infection is the norm in multipurpose breeding facilities and in most
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immunocompetent mice the effects are sub-clinical (Lindsey et a l, 1991). 
Potentially the virus may cause enteric, hepatic, respiratory and neurological 
disease. Susceptibility varies with viral tropism and between mouse strains. 
Demyelinating disease results from the infection of oligodendrocytes, which can be 
persistent and latent. MHV is well recognised as having effects on experimental 
responses and the potential effects are wide ranging but those pertinent to 
neurological disease include activating natural killer cells and affecting phagocytic 
responses.
1.3.1.1.2 Toga virus
Toga virus infection is usually a meningitis with severe mononuclear cell infiltration 
and perivascular cuffing. A late demyelinating condition of white matter can arise 
as the result of the infection of oligodendrocytes (Lindsey et a l, 1991).
1.3.1.1.3 Picomavirus (Theiler's murine encephalomyelitis virus-TMEV)
The possible consequences of infection with this picomavirus are reviewed by 
(Lipton et a l, 1994). Usually infection is innocuous causing an asymptomatic gut 
infection but occasionally will enter the CNS resulting in flaccid paralysis (Theiler's 
disease). Some strains, if given by intra-cranial injection, produce an acute myelitis 
followed by a chronic, inflammatory demyelinating condition in which the vims is 
thought to persist in the oligodendrocytes and other glia. This manifestation is 
characterised by weight loss, abnormal gait, tremor, ataxia, poor righting reflex, 
urine staining, priapism and death. There is a variation in susceptibility between 
mouse strains.
1.3.2 Naturally occurring mutants with abnormal myelination
1.3.2.1 Animal models
The inherent advantages of animal models as research tools for investigating the 
function of the Pip gene has resulted in intense activity to both characterise naturally 
occurring examples and with the recent advantages in recombinant DNA 
technology, create specific types of mutant (see 1.4.2 Methods of creating 
transgenic animals, page 35).
Mutants have been characterised in a number of species and these are summarised in 
Table 1 (page 33). The mutations are all point mutations and with the exception of 
PipIP have a single amino acid substitution in a variety of exons. They result in 
primarily non-conservative amino acid substitutions but surprisingly there is a 
conservative substitution (PlpjP~msd) (Hudson and Nadon, 1992) (there is also an
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example of a conservative amino acid substitution in Pelizaeus-Merzbacher 
disease). In PipiP there is mutation at the 3' acceptor site o f intron 4 which results 
in the deletion of exon 5 from the mRNA, a frame shift and a truncated product with 
an altered carboxy-terminus (Nave et a l , 1987).
The general phenotype of the animal Pip gene mutants is neurological dysfunction 
related to hypomyelination, with the severity o f disease varying between mutants. 
Hypomyelination in these mutants is a function o f abnormal development and thus it 
is considered to be dysmyelination (see 1.3.1 Dysmyelination and demyelination, 
page 24). The primary features of the phenotypes are an early onset o f generalised 
tremor and ataxia. The more severely affected mutants (.PlpJP, PlpiP^, md rat) 
seizure and die prior to adulthood. The less severely affected phenotypes {PlpJP~ 
rsh, sh-pup and Pt rabbit) do not seizure, attain maturity and can reproduce. In 
PlpjP~rsh the tremor ameliorates with age and becomes confined to the hind limbs 
during ambulation.
The degree of hypomyelination varies between mutants and is most severe in the 
mutants with the most profound disease. Occasional thin, poorly compacted myelin 
sheaths are found in the severe mutants, which fail to immunostain for PLP (Schwab 
& Bartholdi, 1996). In md rat and PipiP there are abnormalities o f the intraperiod 
line (IP) (Duncan et a l, 1989; Duncan et a l, 1987). The less severe mutants have 
thicker myelin sheaths (negative for PLP immunostaining) and in Pt rabbit they 
increase with age, suggesting a delay in the process of myelination as well as a 
reduction in the amount of myelin formed (Tosic et a l, 1993).
Numbers of mature oligodendrocyte are profoundly reduced in the severely affected 
mutants. However, numbers are approximately normal during myelination in PipIP 
(Ghandour & Skoff, 1988). However, the population distribution is skewed to the 
more immature phenotype, which undergo an increased rate of apoptosis reducing 
the number of potential myelinating cells (Skoff, 1995). Increased mitotic rates of 
immature glia have been observed (Skoff, 1982) and there is an increase in 
transcription of glycerol phosphate dehydrogenase, an early marker of 
oligodendrocytes (Macklin et al, 1991). In sh pup  there is a reduction in mature 
oligodendrocytes but this is apparently not due to cell death (Nadon & Duncan, 
1996). Reduced oligodendrocyte numbers are not a feature of PlpJP~rs^  and Pt 
rabbit (Tosic et al, 1993; Schneider et a l, 1992). These two mutants show normal 
(increased in Plp/P-"rsh) numbers of cells, though there is delayed maturation (Tosic 
et a l, 1993). The oligodendrocytes of these two mutants do not undergo an 
increased rate of apoptosis (Schneider et a l, 1992; Tosic et a l, 1994). A moderate
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to severe astrocytosis is a feature of the myelin mutants and abnormalities in 
astrocyte cell cycle and metabolism have been described (Knapp & Skoff, 1993).
Mutations of the Pip gene are associated with perturbations not only its transcription 
and translation but also of other genes expressed by oligodendrocytes, with the Mbp 
gene being the most studied example. In the PlpJP mouse brain, Pip transcripts are 
similar to wild type at 3 days but there is no upregulation, as seen in wild type 
during myelination, and by 20 days levels are about 5% of normal. Mbp message 
levels also fails to show a developmental increase in PlpiP and at 20 days are about 
6% o f wild type (Macklin et al, 1991; Gardinier et a l, 1986). In sh pup  the 
transcription of myelin specific genes is reduced but there is a delayed peak 
mirroring wild type in the spinal cord (Nadon & Duncan, 1996). Assessment of 
Mbp gene expression shows that there is a relative increase in the isoforms 
associated with immature oligodendrocytes, a reduction in those associated with 
maturity (Kemer & Carson, 1984) and the cellular distribution of protein also 
suggests cell immaturity (Shiota et a l, 1991). The Cnp and Mag genes also have an 
altered pattern of expression (Yanagisawa & Quarles, 1986).
In PlpJP~rsh, Pt rabbit and sh pup the changes in Pip gene transcripts levels and 
ratios differ from those of mutants such as PlpiP. Though there is also a reduction 
in the amount of Pip message and product, this is not as uniform across the two 
isoforms. There is a significant change in the ratio o f DM20/PLP protein isoforms 
and the PLP dominance is lost (Tosic et a l, 1994; Mitchell et a l, 1992). In Pt 
rabbit the DM20/PLP ratio is increased from 0.70 to 1.14 at 8 weeks (Tosic et al, 
1994). In PlpJP-tsh the amount of DM20 synthesised in some tissues is similar to 
wild type (Mitchell et al, 1992). An increase in the DM20/PLP ratio is also 
observed in sh pup  and PlpJP~msd, which are intermediate in severity between PlpJP 
and PlpjP~rsh (Yanagisawa et al, 1987). It is this relative maintenance of the levels 
of the DM20 protein isoform in these mutants that is postulated to ameliorate the 
phenotype and suggests a role other than as structural protein for DM20 (Schneider 
et a l, 1992).
The levels of myelin gene mRNA and protein observed in CNS tissues of severely 
affected mutants, such as PipIP and Pipjp~msdf may jn part reflect the preponderance 
of immature cells in the population of the oligodendrocytes. As discussed above in 
PipIP mouse there is skew in maturity of the oligodendrocyte population and the 
majority of oligodendrocytes die about 2-3 days before they might be expected to 
elaborate significant amounts of myelin (Vermeesch et a l, 1990). In Plp//7"1"^ 
oligodendrocytes persistently express markers associated with an immature 
phenotype and the elaboration of myelin is delayed. Whether the few PlpJP
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oligodendrocytes that reach maturity elaborate Pip gene derived proteins in vivo is 
controversial. That such oligodendrocytes can elaborate myelin, albeit abnormal, 
can be observed in Pip//7 spinal cord where a proportion of axons have some myelin 
(Duncan et al., 1989). Generally there is no positive immunostaining for wild type 
PLP as many of these antibodies recognise epitopes that would be absent in the 
truncated PlpiP protein. A number of authors have reported failed attempts to purify 
a PlpiP PLP protein from brain (Benjamins et al, 1994; Sorg et al., 1986). One 
group report a single band (~23kDa) on Western analysis, which is recognised by 
PLP antibodies and not by antibodies to the C-terminal, a region which is predicted 
to be altered in PipIP (1994). Recently Knapp et al (1996) have demonstrated the 
production of a protein recognised by antibodies that recognise an epitope specific 
to the truncated PlpJP protein. This protein was also recognised by antibodies that 
recognise epitopes that should be common to the wild type and PlpiP PLP protein 
isoform.
1.3.2.2 The consequences of m utant Pip alleles for carrier females
X-linked diseases predominantly affect males, with in many diseases apparently 
unaffected females carrying the affected allele and passing it onto the next 
generation. In normal females there is inactivation of one of the pair o f X 
chromosomes in each somatic cell and theoretically the mean overall contribution of 
each X-chromosome is 50%, though ratios o f 60:40 and greater are common 
(Willard, 1995). Quantification of oligodendrocyte numbers in females 
heterozygous for the PlpiP allele suggests that there is a reduction in 
oligodendrocytes (Skoff & Ghandour, 1995) that progresses with time (Griffiths, 
unpublished data). Phenotypic signs do not develop which may be due to 
compensation with unaffected oligodendrocytes elaborating more myelin (Skoff & 
Ghandour, 1995). Females of the less severe mutants (for example sh pup  and 
Plpjp-rsh ) can show mild phenotypic changes implying improved survivability of 
mutant oligodendrocytes. Abnormalities have also been noted in some females 
from human pedigrees with muscular dystrophy (Belmont, 1996) and PMD (see 
below). Control of X-inactivation may be influenced by other genes and may 
explain why individual carrier females occasionally have phenotypic signs in 
contrast to the majority (Belmont, 1996).
1.3.2.3 Hum an diseases associated with the Pip gene
1.3.2.3.1 Pelizaeus-Merzbacher disease / X-linked spastic paraplegia 
Pelizaeus-Merzbacher disease is a rare disorder characterised by profound 
hypomyelination, due to dysmyelination, the consequences of which are severe
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neurological disease, with early mortality in the majority o f patients. There is both 
inter and intra-family heterogeneity in the clinical course of the disease and until 
recently this caused difficulty in the classification o f some candidate cases. Clinical 
classification is related to the severity of disease and is of some value in assessing 
the impact o f the underlying genetic abnormalities. The classification system of 
Seitelberger is often referred to but this has now been shown to include diseases not 
associated with the Pip gene locus (Hodes et al., 1993).
This condition is considered to be X-linked (indeed this is a requirement of some 
classification systems), however, PMD like disease does occur in females associated 
with Pip mutations (Hodes et al, 1995) and late onset neurological disease has been 
observed in female carriers (Nance et a l, 1993). For further discussion see 1.3.2.3.2 
PMD-like disease in females, page 32. De novo cases also arise where X-linkage 
cannot be determined.
PMD was first described at the turn of this century but it was not until the late 1980s 
that linkage with the Pip locus was established (Trofatter et a l, 1989; Hudson et a l, 
1989). Pip polymorphisms are rare (Mimault et a l, 1995; Boespflug-Tanguy et al, 
1994) and the first linkage of PMD to the Pip gene was established by specifically 
screening the Pip gene of an affected family for point mutations (Hudson et al, 
1989). An expanding range of principally exonic mutations is described with only 
two families sharing a specific mutation (Pratt et a l, 1995; Otterbach et a l, 1993) 
(see Table 1, page 33). Initially the significance of Pip mutation in the aetiology of 
PMD was uncertain, though extensive analysis o f PMD pedigrees had revealed a 
spectrum of mutations affecting the exonic regions, these represented only about 
one in four or five pedigrees (Hodes & Dlouhy, 1996). However, tight linkage of 
PMD in families without demonstrable exonic mutations to the Pip gene locus has 
been confirmed by Boespflug-Tanguy and others (1994). The potential involvement 
o f duplication of the Pip gene in the aetiopathogenesis o f PMD, initially reported by 
Cremers and others (1987) and reinforced by Ellis and Malcolm (1994), was an 
important step in refining the molecular basis of PMD pedigrees.
Techniques that identify changes in the coding sequence, for example single strand 
conformational polymorphism analysis (SSCP), will not identify duplications and 
thus there has been an expansion in the techniques used to investigate pedigrees. 
Initially this involved blotting techniques (Ellis & Malcolm, 1994) but a PCR based 
technology is now described (Inoue et a l, 1996). The proportion of PMD cases 
demonstrating duplication is increasing as more pedigrees are suitably investigated 
(Hodes & Dlouhy, 1996). It is likely that duplication will represent the largest 
group o f mutations associated with PMD.
30
Introduction
PMD is a disease of development. However, in the early literature there is one 
pedigree (Camp & Lowenberg, 1941; Lowenberg & Hill, 1933) and a number of 
rare de novo cases where PMD-like disease has been described in adults (Bruyn et 
al., 1985). This association is on clinicopathological grounds as these cases predate 
mutational analysis of the Pip gene. They differ on features of pathology and affect 
both males and females. Some cases share similarities with SPG2 (see below). The 
inclusion of these cases in the description of PMD has been controversial but new 
instances of such disease can now be assessed to see whether they have Pip 
mutations. Two pedigrees with known Pip mutations contain individual carrier 
females who have exhibited late-onset neurodegenerative disorders. One family had 
a deletion (Raskind et al, 1991) and one a point mutation in (Nance et al., 1993).
The X-linked hereditary spastic paraplegias (HSP) are rare diseases that form a sub­
group of a heterogeneous clinical classification, many of unknown aetiology, termed 
the hereditary ataxias and paraplegias (Harding, 1983). They are characterised by 
spastic paraplegia, but latterly the arms may be affected, and are sub-classified 
according to whether individuals exhibit other neurological signs The so called 
complicated form). They were assigned to potential genes and linkage analysis 
undertaken: spastic paraplegia gene 1 (SPG1) for the complicated form and SPG2 
for the uncomplicated form. Cases of SPG2 are rarer than those SPG1 (Cambi et 
al., 1996). Linkage analysis showed that SPG2 was allelic to the Pip gene (Cambi 
et al., 1996). SPG1 was mapped to both the Pip and L I cam (at Xq28) gene loci 
(Bonneau et al., 1993). Further examination of the clinical manifestation of cases 
SPG1 linked to the Pip gene suggest they lack features seen in diseases associate 
with Lcaml. The product of the Lcaml gene locus is a neural cell adhesion 
molecule (Jouet et al., 1994). In SPG1 the associated neurological disease may 
develop concurrently with the spastic paraplegia, or may develop at a later, variable 
date (Saugier-Veber et al., 1994). Though SPG1 has not been specifically linked to 
Pip gene duplication it is suspected (Cambi et a l, 1996). Other dominant spastic 
paraplegias have been demonstrated to be linked to other chromosomes (Kobayashi 
e ta l,  1996).
The pathology of these diseases is poorly described as they are rare and most 
patients have a reasonably normal lifespan. As the association with the Pip gene is 
only recently described its status in many of the cases described is unknown. The 
pathology is likely to involve demyelination, as the onset is after myelination should 
be well advanced or complete.
The nosology of PMD/X-SPG has changed, moving from clinical criteria to a 
genetic basis by linkage with the Pip gene, which has linked these two previously
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separate clinical entities. This has expanded the clinical definition of PMD and 
clinicians are looking at a broader group of patients for Pip gene mutations (Hodes 
& Dlouhy, 1996). These two diseases confirm the heterogeneity o f phenotype 
caused by mutation of the Pip locus also observed in the animal models. Indeed, as 
can be seen from the above, the clinical classification of some pedigrees has been 
difficult due to the similarity o f the clinical findings in “mild” PMD and SPG2 
(Hodes et al., 1993).
1.3.2.3.2 PMD-like disease in females
Since the first description of a PMD pedigree by Merzbacher in 1910 there have 
been occasional cases of affected females described. Affected individuals have 
been members of large pedigrees, with typical or atypical PMD, and de novo cases. 
These cases, and the de novo cases in particular, have posed problems of 
classification as their inclusion challenged the proposed X-linked status of PMD 
(though there are precedents for disease in carrier females in other X-linked diseases 
- see below). Though some cases of PMD-like disease in females may be due to 
other aetiologies resulting in a similar phenotype, demonstration o f Pip gene 
mutations in affected females has confirmed the involvement of the Pip gene in this 
group of patients (Hodes et al, 1995; Hodes et a l, 1993).
There are two phenotypes seen in females associated with Pip gene mutation. The 
early onset disease that parallels that seen in male children and a late-onset 
condition which presumably represents demyelination.
Early onset disease is likely to be due to predominant expression of the mutant 
allele. There are at least four recognised explanations for phenotypic expression of 
X-linked disease in females (Willard, 1995): Turner’s syndrome which has a 45 XO 
karyotype and a female phenotype; a female with two mutated genes, a very 
unlikely situation, in human pedigrees; skewing of X-chromosome inactivation 
(extreme lyonisation) favouring the survival of cells carrying the mutant allele; 
uniparental disomy.
Late-onset disease suggests that cells with an active mutant allele are present and 
that the product of this allele perturbs the maintenance of the myelin sheath It has 
also been proposed that the myelin elaborated is in some way abnormal and 
ultimately is lost (Ellis & Malcolm, 1994). It is also possible that the mutant allele 
is expressed by cells other than oligodendrocytes, explaining their longevity, and 
that the activity of the mutant gene leads to late-onset perturbations in other cell 
types.
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Species Allele designation Nature of m utation
rabbit
rat
dog
man
Plpl'P
P lpiP-m sd
pipjp-rsh
PlpiP~4j
Pt
m d
sh-pup
PMD
mouse J  missense at splice site 3 ’ exon 4,
frameshift, truncated C-terminal
missense, exon 6
missense, exon4
missense, exon 2
missense, exon 2
missense, exon 2
missense, exon 2
missense, exons 2, 3, 4, 5, 6
nonsense, exon 3B
deletions (partial exon 1, 3, 4, and 
total)
frameshifts, 
duplications 
silent, exon 3, 4
insertion exon 7 and 3 ’ untranslated
others (no exonic mutations, may have 
duplications)
SPG 2 missense, exon 3B
missense, exon 4 (equivalent to 
Plpjp-rsh)
Table 1. Sum m ary of naturally occurring Pip m utant animals and m utations 
found in man. (sh-pup and p t rabbit have a m utation affecting the same base 
pair but have a different substitution).
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1.3.2.4 Hereditary motor and sensory neuropathies (HMSN) of the PNS
As discussed above PM22 is a probable homologue of PLP in the PNS (1.2.1.2 
Comparison of CNS and PNS myelin, page 4). Thus the consequences of mutation 
in this gene are of interest in the study of Pip gene mutations.
Charcot-Marie-Tooth disease 1A (CMT1A), a sub-group o f the HMSN, and the 
associated syndromes hereditary neuropathy with liability to pressure palsies 
(HNPP) and Dejerine-Sottas disease (DSD) are due to mutations o f the PMP22 gene 
(chromosome 17) (Thomas et al, 1996). They all exhibit demyelination (with or 
without remyelination) o f the peripheral nerves though they are clinically and 
pathologically distinct. DSD has the most severe phenotype and HNPP the mildest.
In general the association of mutation with phenotype is quite strong with 
duplication of PMP22 resulting in CMT1A and deletion in HNPP, with DSD due to 
point mutations. The picture is slightly complicated by rare cases o f point mutations 
with phenotypes of both HNPP or CMT1A. It also must be remembered that these 
are clinical groupings and thus diseases with similar phenotypes may be due to 
mutations affecting other genes (Thomas et a l, 1996).
1.4 Experimental strategies for the manipulation of 
myelination
As described above a wide variety of natural mutant animals with mutations of the 
Pip gene have been identified and have proved to be invaluable research tools. 
However, to address questions about specific mutations recombinant DNA 
technology techniques have been utilised to dissect aspects o f Pip gene function.
1.4.1 Expression of cloned genes
A natural development of the evolution of recombinant DNA techniques was the 
wish to study the properties of cloned genetic material in living systems. Methods 
for introducing eukaryotic genes into prokaryotic cells (transformation), though 
successful in achieving high levels of transcription, are o f limited value because of 
the lack of post-translational modification, problems with folding and secretion 
(Harvey et a l, 1992).
The introduction of foreign genes into mammalian cells in culture (transfection) is a 
widely used, flexible approach that has been extensively used in the study of the Pip
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gene. Exogenous DNA constructs can be expressed either transiently or 
incorporated into the endogenous DNA to give stable transfectants. The use of cell 
lines allows the expression of genes in controlled conditions. The availability of a 
wide range of cell lines allows the behaviour o f cloned genes to be studied within 
and without their normal cellular environments. Cell culture transfection results 
must be interpreted with care because of the abnormal cellular environment and 
should be examined in the context of in-vivo studies.
1.4.2 Methods of creating transgenic animals
To study the properties of a gene in relation to the development and maintenance of 
a tissue within an organism requires the stable manipulation of the genome of an 
appropriate animal.
The creation of transgenic organisms is now a important tool in many fields of 
biology and their uses and applications are wide and varied. There are broadly two 
approaches to the stable integration of exogenous DNA into the genome: 
pro-nuclear injection and gene targeting by homologous recombination in 
embryonic stem (ES) cells. The selection of technique is reflected by the ambition 
of the experiment. In general pro-nuclear injection is used to complement the 
genome with extra gene copies and homologous recombination to target a gene with 
specific mutations.
1.4.2.1 Pro-nuclear injection
The purified DNA construct is injected directly into the pro-nucleus of donor eggs. 
Currently there is no control over the number of integration events, the number of 
gene copies involved per integration event (constructs tend to be integrated as 
variable chains of head-to-tail concatomers) and position within the genome. The 
efficiency of the technique in the number of transgenic animals bom is relatively 
low, even in laboratories experienced in the technique (Kollias and Grosveld, 1992). 
Transgenic animals are identified by Southern blotting or PCR. Occasionally 
integration occurs after the first division and the resulting animal is a mosaic thus 
transgenic animals are test mated to establish whether there has been integration into 
germ cells.
The behaviour o f transgenes should be interpreted in the light of a the limitations of 
the technique. The behaviour of a specific construct is potentially be influenced by 
a number of factors including number of copies in the integrated cassette, 
chromosomal location (position effect) and possible influences of modifying loci 
(Wilkins, 1990; Clark et al, 1994). These influences can be ameliorated by careful
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construct design and it is possible to produce transgenic animals with transgenes 
having copy number dependent activity apparently free of position effects (Clark et 
al, 1994). The production of a number of different lines from the same original 
experiment, thus almost certainly with different areas of integration, can be useful in 
assessing a transgenic cassette in relation to these concerns. The nature o f transgene 
integration means there is the potential for random disruption of genes with the 
possibility o f an unexpected phenotype related to insertional mutagenesis. This can 
give rise to a phenotype characterised by neurological abnormalities (Orian et a l,
1994).
1.4.2.2 Homologous recombination in embryonic stem (ES) cells
The basis of this approach is the phenomenon of homologous recombination of 
exogenous DNA with homologous chromosomal sequences. This allows the 
targeting of specific sequences and thus the ability to engineer changes in a gene 
locus by introducing sequences with specific mutations.
This technique has been pioneered in mice where the ES cells are derived from the 
inner cell mass of mouse blastocyst. Though they are at a later stage of 
development than the cell type used in pro-nuclear injection they are pluripotent and 
have the potential to contribute to all cell types o f the chimera that develops after 
their introduction into blastocyts. ES cells represent a convenient cell type in which 
to introduce targeting vectors as they can be maintained in their pluripotent state in 
tissue culture. The exogenous DNA can be introduced by a number of techniques 
including nuclear injection and electroporation. Homologous recombination events 
are relatively rare and random integration is possible, thus the design o f selection 
markers to allow the identification of successful clones is an important part of vector 
design.
ES technology has been used extensively to engineer null alleles o f selected genes 
(the so called “knockout”). This technology is routinely available and many 
facilities offer a custom service to the scientific community (P. Montague, personal 
communication).
1.4.2.3 Application of transgenic animals to the investigation of Pip gene 
function
Transgenic animals models have been created that address a number of aspects of 
Pip gene regulation and function. These include: transgenes with increased copy 
number of the wild type gene (see below); gene knockouts (Klugmann et a l, 1997; 
Boison & Stoffel, 1994); minigenes that code for individual Pip and Dm.20 protein
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isoforms (Johnson et a l , 1995; Mastronardi et a l, 1993); a Lac-z fusion gene 
(Wight et a l, 1993); and as tool for tracking transplanted glial cells (Gout et 
a l, 1991). The Pip gene is X-linked and all the Pip gene transgenics produced by 
pro-nuclear injection have autosomal integration sites and thus the transgenes 
exhibit a simple Mendelian autosomal pattern of inheritance.
The main thrust behind the creation of the Pip gene derived transgenic mice 
currently described has been as part of larger experimental programmes directed 
towards the “rescue” of PlpJP mice by gene complementation. These experiments 
were stimulated by the success of rescuing the hypomyelinating phenotype of the 
MBP mutant sh mouse by transgenic complementation of the sh genome with extra 
copies o f the wildtype MBP gene (Readhead et a l, 1987). The experimental 
strategies for PlpJP mice differ in that the initial complementation with extra copies 
if  the gene was of wild type mice and attempting the rescue of PlpiP offspring by 
mating (Kagawa et al, 1994; Readhead et a l, 1994). However, the Dm20 minigene 
mice described in the literature have been developed expressly to explore the role of 
DM20 protein isoform (Johnson et al, 1995).
1.4.2.3.1 Pip transgenic mice with extra copies of the wild type Pip gene 
There are currently two groups of mice with transgenic cassettes conferring extra 
copies o f the wild type murine Pip gene: #66 and #72, in which the pro-nuclear 
injection using the same construct has resulted in two different integration events 
representing 7 (#66) and 3 (#72) copies per haploid genome (Readhead et a l, 1994); 
4e in which there are two copies per haploid genome (Inoue et a l, 1996; Kagawa et 
a l, 1994). It was thus in independent experiments that mice with a neurological 
phenotype was observed. In both instances this involved the breeding of founder 
mice (#66 and 4e) to produce homozygous individuals. In both lines affected 
individuals were noticeable from the time of ambulation as being affected by a 
tremor, developed seizures and died prematurely. In both lines Southern 
hybridisation analysis linked the mutant phenotype to homozygosity for the 
transgene.
The transgenic cassettes used to produce these two groups of mice were developed 
independently from different clones of the Pip gene, and though both contain the 7 
exons and 6 introns of the wild type gene they differ significantly in the amount of 
flanking sequence information they incorporate. The constructs differ primarily in 
the amount o f 5’ sequence, with 4e containing a considerably larger region (4e 
20Kb c.f. #66/72 3.5Kb), with a relatively small difference at the 3 ’ end (4e 4Kb c.f. 
#66/72 ~6Kb).
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Both groups confirmed the sequence of the their transgenes was unaltered. The 
transgenes ability to produce the wild type PLP/DM20 protein isoforms was 
confirmed by expressing the transgenes on a male PlpJP background on which 
positive immunostaining with antibodies to the C-terminal region confirms the 
presence o f wild type protein isoforms.
1.4.2.4 Evidence that increased Pip gene dosage affects myelination
The nature o f the pathology underlying the phenotype in both these homozygous 
mice was confirmed to be dysmyelination. The existence of two independent 
examples o f increased wild type Pip gene dosage leading to perturbation of 
myelination provides useful corroboration that the dysmyelinating phenotype is an 
effect of the increase in Pip gene dosage, as opposed to a feature of the transgenic 
cassette or a function of the site of integration. Though they are conceptually are 
very similar there are a number of similarities and differences.
The constructs are both based on the wild type Pip gene, though cloned from 
different DNA libraries and into different backgrounds. Both constructs contain the 
7 exons and associated introns but differ markedly in the amount of flanking 
sequences, particularly in the 5’ region, which contains many putative regulatory 
regions (see 1.2.3.1 Regulation of Pip gene expression, page 16).
The phenotypic abnormalities of 4e mice are apparently more severe than those of 
the homozygous #66 and #72 mice. Other changes seem more pronounced e.g. 
oligodendrocytes in 4e mice show more dramatic ultrastructural abnormalities than 
homozygous #66 mice. Most interestingly, regarding the work presented in this 
thesis hemizygous 4e mice relatively quickly develop demyelination a process 
which was not recognised in the #66 and #72 lines at the inception of this project.
In contrast the effect on myelination of the Pip related minigenes that have been 
created is variable. The only Pip cDNA construct results in no detectable 
phenotypic abnormalities (Nadon et al., 1994), even after extended periods of 
observation o f 18-24 months (personal observation). There are two groups of 
DM20 minigene, one based on the construct described by Nadon et al (1994) and 
the other based on a construct described by Mastronardi et al (1993), both have 
which have been used to produce a range of transgenic mice with different numbers 
of intergrates. O f these only one, ND4 carrying ~70 copies o f the transgene 
(Johnson et al., 1995; Mastronardi et a l, 1993), is related to a phenotype in which 
there is late onset CNS demyelination. This is associated with an increase in DM20 
and a reduction in PLP with the total amount of proteolipid proteins much reduced. 
These changes are detected before demyelination is observed. A transgene with the
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same construct, but containing fewer copies (ND3), induces similar abnormalities in 
the relative amounts of the PLP and DM20 protein isoforms but does not associated 
with demyelination in homozygous mice (Johnson et a l, 1995).
All the Pip minigene constructs have 5’ sequence derived from human clones and 
have between 2.9Kb (Johnson et al, 1995; Mastronardi et a l, 1993) to 4.2Kb 
(Nadon et a l, 1994) but do not include any Pip gene intronic sequence. The lac-z 
fusion gene transgenic construct includes 2.4Kb human 5’ sequence and the Pip 
gene intron 1 (Wight et a l, 1993). The lack of dysmyelination associated with these 
constructs implies that extra copies of these transcriptionally important sites is not 
related to dysmyelination.
Considering this spectrum of Pip gene related transgenic mice suggests that there is 
a role for increased Pip gene dosage to influence myelination.
1.4.3 Other genetically engineered myelin mutants
The transgenic approach is a popular and versatile one and has been used to address 
the aspects of gene regulation and function for a number o f other myelin genes. 
Transgenic animals with extra copies of wild type genes have been created for Cnp 
(Gravel et a l, 1996) and Pmp22 (Huxley et a l, 1996; Sereda et a l, 1996) and extra 
copies of anti-sense constructs in Mbp (Ikenaka & Kagawa, 1995), Mog (Jaquet et 
al, 1996) and Pmp22 (Maycox et al, 1997). The creation of null alleles has been 
examined for Cgt (UDP-galactose:ceramide galactosyl-transferase (CGT), resulting 
in failure GalC synthesis) (Coetzee et al, 1996) and Pq (Giese et a l, 1992).
1.5 Aims of thesis
The observation that increased Pip gene dosage was related to a dysmyelinating 
phenotype was an unexpected and exciting finding. The development of a 
phenotype associated with increased gene dosage is a relatively unusual occurrence 
and in this case there were strong links to the emerging story of the importance of 
gene dosage in Pelizaeus-Merzbacher disease in man.
The availability o f the two lines of Pip gene transgenic mice (#66 and #72) afforded 
the opportunity to compare and contrast the development of CNS myelination. At 
the time of the projects inception it was unclear whether mice homozygous for the 
#72 transgene developed significant neurological dysfunction, though subtle 
abnormalities o f myelin sheaths were documented. When it became clear that a 
delayed phenotype did develop in honmzygous #72 mice this delayed onset implied
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other aetiopathological features other than the recognised mild dysmyelination. 
Likewise it was unclear whether mice hemizygous for the #66 and #72 transgenes 
would develop a neurological abnormalities as they were phenotypically 
unremarkable in early adulthood.
Techniques for the identification of the lines of transgenic mice studied in this 
project were described but not established in the Applied Neurobiology Group. The 
first task was to establish these techniques within the laboratory so that mice bred 
could be reliably identified.
The initial aim was to document the development of dysmyelination in homozygous 
#66 and #72. Techniques that had previously developed in the Applied 
Neurobiology Group for the study of other dysmyelinating mutants were applicable 
to this task. This included studying the nature of the developing glial cell 
population, combining total white matter glial cell counts from a representative area 
of CNS white matter with in-situ hybridisation to assess the adequacy 
oligodendrocyte population. The presence of myelin proteins was documented by 
immunocytochemistry using a panel o f appropriate antibodies the validity of which 
had been well established by work in this group and elsewhere. The quality and 
quantity of myelin was assessed for the same region in which the glial cell 
population was quantified. Steady state levels of mRNA for the Pip and other 
myelin genes were assessed by northern hybridisation to put the observed 
dysmyelination in the context of myelin gene activity. Examination of early 
quantitative data suggested that generation of sufficient data points for rigorous 
statistical assessment was outwith the technical resources of this project and data 
collection was made with the goal of identifying trends that may be present.
The observation of a late onset neurological phenotype in mice hemizygous for 
these two transgenic cassettes was approached by initially detailing early 
development and comparing this to wild type littermates to assess whether there was 
evidence of dysmyelination. This involved collection of similar classes o f data 
during myelination and early adulthood to that outlined above for homozygous 
mice. The variable age of onset of phenotypic abnormalities with the lack of a 
quantitative measure of phenotypic progression made the collection o f data from 
animals of equivalent phenotypic status difficult. Consequently, in this initial study 
of this late onset neurodegenerative phenotype the aim was to confirm that this was 
indeed a late onset phenomenon and illustrate qualitatively the features o f the 
neurodegeneration.
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A separate aspect of this project developed from the incidental observation of 
PLP/DM20 immunostaining in PNS myelin in mice homozygous for the #72 
transgene. Though the Pip gene is known to be translated in Schwann cells it is 
generally accepted that it is not incorporated into myelin. The distribution of 
PLP/DM20 was examined in relation to the major myelin protein Pq using confocal 
microscopy. To study the transcription of the Pip gene and the distribution of the 
two protein isoforms in the PNS the transgenes were introduced onto a male PlpJP 
background on which there was the potential to differentiate the wild type product 
o f the transgenes from the PlpJP message and product. The availability o f Pip and 
Dm20 minigenes extended this work by allowing the assessment of the distribution 
of the two protein isoforms in this model.
In summary the overall aims of this project were to establish the nature of the 
phenotypes associated with increased dosage of the Pip gene and put these in 
context of phenotypic consequences already described for Pip gene mutations.
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2. Materials and Methods - General 
Techniques
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The details of the preparation of all fixatives, stains, buffers, bacterial media, etc. 
are given in the 8 Appendix (page 200). The specific page number is given in the 
text.
Solutions were sterilised as appropriate. Bulk solutions were autoclaved. Small 
volumes, and fluids that could not be autoclaved were filter sterilised using a 
Flowpore 0.45pm filter (Biomedicals Ltd.).
2.1 Tissue fixation and processing
2.1.1 Fixatives
2.1.1.1 Buffered neutral formaldehyde, 4% (BNF)
This fixative was used for the preservation of tissues destined for in situ 
hybridisation, immunocytochemistry and routine haematoxylin and eosin (H and E) 
staining. See page 201.
2.1.1.2 Karnovsky's modified fixative (paraformaldehyde/glutaraldehyde 
4%/5%)
This fixative was used for the preservation of tissues destined for light and electron 
microscopy as well as immunocytochemistry using resin sections. See page 201.
2.1.1.3 Periodate-lysine-paraformaldehyde
This fixative was used for the preservation of tissues destined for staining with the 
microglia marker and T cell markers. See page 202.
2.1.2 Fixation techniques
2.1.2.1 Immersion
Teased sciatic nerve preparations were immersion fixed prior to immunofluorescent 
staining (see 2.9.2 Teased fibres, page72).
2.1.2.2 Cardiac perfusion
All perfusions were undertaken in a fume cupboard. Each mouse was handled with 
a separate pair of latex gloves. All mice over 10 days of age were killed in a carbon 
dioxide chamber. Mice under this age were killed in a halothane (Fluothane, 
Mallinkrodt Veterinary) chamber.
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Immediately following death the carcass was sexed, weighed and pinned out on a 
cork board in dorsal recumbency. Tails were isolated from the board by a fresh 
piece o f aluminium foil. The root of the tail was clamped with haemostats and the 
tail severed with a new scalpel blade. The tail sample was stored at -20^C until 
required.
The skin o f the thorax was removed and the contents exposed by dividing the 
diaphragm, incising through the ribs on either side and reflecting the ribs and 
sternum. The right atrium was nicked and the perfusion carried out by instilling 
solutions into the left ventricle via either a 21 or 25 gauge hypodermic needle, 
depending on body size.
The blood was flushed from the circulation with 0.85% saline. This was followed 
by the fixative. All solutions were injected from a syringe by another operator. The 
volumes used were dependent on the size of the carcass and varied between 
~20-60ml.
2.2 Processing
2.2.1 Paraffin wax processing
Tissues for paraffin wax embedding was processed using a Shandon Elliot 
automatic tissue processor (Histokinette). For processing protocol see page 202.
Tissues were blocked out in paraffin wax at 60^C.
2.2.2 Resin processing
Samples were processed for araldite resin embedding using a Lynx el microscopy 
tissue processor (Leica). For processing protocol see page 203.
2.2.3 Cryo-preservation
Cryo-preservation was used for tissues destined for immunofluorescent 
immunocytochemistry and in-situ hybridisation.
Nervous tissue was dissected from the freshly killed carcass and immediately 
immersed in “Tissue-Tek” OCT compound (Miles Inc.) in foil boats. The foil boats 
were immersed in isopentane which was cooled with liquid nitrogen. Once frozen 
the foil was removed and the block double wrapped (to limit dehydration) in 
“Sealon film” (Fuji) and stored at -20^C. Muscles were maintained in tension, 
covered in talcum powder to reduce ice artefact, and snap frozen in liquid nitrogen.
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Tissues from animals perfused with periodate-lysine-paraformaldehyde were also 
cryo-preserved. Immediately following perfusion tissues were removed and further 
immersion fixed in the buffer for 4-6 hours at 4^C. They were cryo-protected by 
immersing overnight in 20% sucrose before being frozen in OCT as above.
2.2.4 Preparation of sections
2.2.4.1 Paraffin-embedded tissue
Paraffin-embedded tissue sections were cut on a Biocut 2035 microtome (Leica) at 
6pm for ISH and routine stains and left overnight at 60^C.
2.2.4.2 Cryo-preserved tissue
OCT-embedded cryo-sections were cut on an OTF cryostat (Bright Instrument 
Company) at 15pm for ISH and immunocytochemistry and stored at -20^C.
2.2.4.3 Resin sections
Sections for light microscopy were cut at 1 pm on a Ultracut E ultratome (Reichert- 
Jung) and mounted on plain sulphuric acid-treated slides.
2.2.4.4 Ultra-thin sections for electronmicroscopy
Sections for electronmicroscopy were cut at ~70nm (ultratome see above) and 
mounted on 200 mesh-3.06mm diameter copper grids.
2.2.4.5 Teased sciatic nerves
Whole nerves were taken immediately after death and teased in PBS, on poly-L- 
lysine coated slides, to separate the fibres. Prepared fibres were air dried and 
processed promptly.
2.3 Staining techniques
2.3.1 Light microscopy
2.3.1.1 Haematoxylin and eosin (H and E)
Sections from paraffin blocks were routinely stained with H and E to assess tissue 
quality. For details of technique see page 204. Sections were mounted in DPX 
(BDH).
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2.3.1.2 Haematoxylin
ISH sections were counterstained with haematoxylin following autoradiography. 
For details o f technique see page 204. Sections were dehydrated and mounted as for 
H and E staining.
2.3.1.3 Methylene blue/azur II
Resin sections were routinely stained with methylene blue/azur II (page 207). 
Slides were heated on a hot plate to 60^C and flooded with stain for 10-30 secs 
followed by rinsing in running tap water. Slides were dried overnight on the hot 
plate and mounted in DPX (BDH).
2.3.2 Electron microscopy
Ultra thin sections o f araldite embedded tissue were mounted on copper grids and 
stained with uranyl acetate and lead citrate for electron microscopy. Details see 
page 205.
2.4 Microbiological manipulations
2.4.1 Bacterial media
2.4.1.1 Luria-Bertani (LB) medium
This nutrient broth was used for culturing bacteria. For details see page 210.
2.4.1.2 SOC medium
This enriched broth was used for the growth of transformed competent cells. For 
details see page 210.
2.4.1.3 Ampicillin LB agar plates
LB agar plates were prepared at a concentration of 1.2% by the addition of 12g agar 
(Agar bacteriological, Oxoid) per litre of LB medium prior to autoclaving. The mix 
was cooled to ~ 50^C before ampicillin was added (lOOpg ml“l). Approximately 
30ml LB agar was poured into each 90mm plate. Plates were stored at 4^C. Plates 
were dried before use in the 37^C incubator for 2 hrs to reduce “sweating” and 
smearing, which interfere with plating and reduce colony separation.
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2.4.2 Competent cell preparation
Competent cells were prepared from JM101 Esherichia coli bacteria (supE, thi, 
V(/ac-proAB), [F \ traD36, proAB, /acI9ZVMI5]) (Pharmacia Biotech) maintained 
on M9 thiamine agarose plates as single colony cultures. Cultures were replated 
every 6-8 weeks to maintain the population as a single clone with the required 
properties.
To ensure that the culture consisted of a single clone a single colony was inoculated 
into a 10ml LB broth and cultured overnight at 37^C at 200rpm in an orbital 
incubator (Gallenkamp). One ml o f the overnight culture was inoculated into 100ml 
LB broth and incubated under the same conditions for 1.5-2 hrs, until the optical 
density at 600nm was between 0.2-0.3, thus ensuring that the cell density did not 
exceed 10^ cells ml"l. At this concentration the bacterial population will be in the 
exponential part o f its growth phase and thus consist mostly o f viable cells. For 
operational reasons the bacteria were precipitated by centrifuging the broth as 3 -  
33ml aliquots in 40ml sterile, chilled, polypropylene tubes (Becton Dickinson) 
followed by and incubation on ice for 20 mins. Bacteria were recovered by 
centrifugation at 5000rpm (JA-20 rotor) for 10 mins at 4^C and followed by 
removal of the supernatant to leave the pelleted cells. The pelleted cells were gently 
reconstituted in 50ml of chilled sterile lOOmM magnesium chloride and recovered 
as in the previous step. After reconstitution as before the pelleted cells were 
incubated on ice with occasional agitation for 1 hr. The cell were recover cells as 
above and reconstitute in 10ml ice cold sterile lOOmM calcium chloride with 15% 
(V/V) glycerol. Aliquots were placed into 1.5ml eppendorf vials and snap frozen in 
liquid nitrogen and stored at -70^C. Aliquots were stored for a minimum of 24 hrs 
prior to use.
2.4.3 Transformations
All cultures were performed in the presence of ampicillin.
Transformations were performed in sterile 40ml polypropylene tubes pre-chilled on 
ice. To allow for variations in preparations acquired from other laboratories two 
transformations were performed at nominal 0.1 fig and lfig of DNA, made up to 
100fil with TE buffer (page 209). An aliquot of competent cells was slowly thawed. 
A 100fil aliquot of cells was added to each DNA sample, swirled gently to mix and 
incubated on ice for 30 mins. The cells were heat shocked at 42^C for 45 secs and 
rapidly transferred to ice for a further 2 mins, after which 800|il o f SOC medium 
was added. Cultures were incubated in an orbital incubator at lOOrpm for 60 mins
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at 37^C, after which 200 j l l 1 aliquots were plated out on LB agar plates and incubated 
overnight at 37^C.
2.4.4 Plasmid preparations
Plasmid DNA was isolated from the host bacteria using QIAfilter midi kit (Qiagen). 
This protocol is based on the alkaline lysis procedure (Bimboim & Doly, 1979) with 
lysis o f the bacterial cell wall using the detergent SDS and sodium hydroxide. The 
lysis time is optimised to release the maximal amount of plasmid DNA with the 
minimal amount of degradation. In the neutralisation conditions the plasmid DNA 
preferentially renatures whilst the longer chromosomal DNA is precipitated, with 
the denatured proteins and cell debris. Plasmid DNA is further purified by 
preferential binding to a column followed by elution in TE buffer.
All cultures were performed in the presence of ampicillin. Cultures were made of 
single colonies of the appropriate transformed bacteria grown on LB plates. 
Bacteria were initially cultured in seeder broths of 5ml LB broth, in 50ml tubes 
(Becton Dickinson) to allow adequate aeration, at 37^C in an orbital incubator for 
~2 hours. Aliquots of the seeder broth (250jal) were added to 12.5ml LB broth in a 
50ml tube and cultured overnight at 37^C in an orbital shaker at 220rpm. Cultures 
were placed on ice, to keep the bacterial population within the log phase o f growth, 
until extraction was undertaken. A 25ml culture yielded ~80-100pg o f plasmid 
DNA.
2.5 Isolation and manipulation of nucleic acids
2.5.1 Isolation of nucleic acids from tissues
2.5.1.1 Extraction of genomic DNA from mouse tails
2.5.1.1.1 Tail tipping
Tissue from live animals was collected under anaesthesia. Mice were anaesthetised 
in a chamber using halothane (Fluothane, Mallinkrodt Veterinary), the tail tip 
removed with a scalpel and the wound cauterised. Tissue was stored at -20^C. 
Tissue could be stored at this temperature in excess of one year and yield good 
quality gDNA (see Figure 8, page 83).
2.5.1.1.2 Preparation of genomic DNA 
See 3.2 genomic DNA extraction page 77
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2.5.1.1.3 Preparation of RibonucleaseA (RNaseA)
Lyophilised bovine pancreatic enzyme (NBL Gene Sciences Limited) was 
resuspended in lOmM Tris pH 7.5, 15mM sodium chloride at 20mg/ml. Remaining 
DNase activity was removed by heating the solution in a water bath at lOO^C for 15 
mins. The solution was cooled slowly to room temperature, aliquoted and stored at
-200c.
2.5.1.1.4 Preparation of proteinase K
Proteinase K was supplied lyophilised with the QuiAMP kit. It was reconstituted in 
SDW at 20mg/ml and stored at -20^C in small aliquots. Any remaining after 
defrosting was discarded.
2.5.1.2 The isolation and storage of RNA
2.5.1.2.1 Tissue storage
Tissues were removed immediately after death, placed in freezer tubes (Nucleon) 
and snap frozen in liquid nitrogen. The majority of tissues were stored in liquid 
nitrogen freezers, with a small number being stored at -70^C.
2.5.1.2.2 Isolation of RNA
RNA was isolated from fresh frozen tissues using RNAzol B (Biotech Laboratories 
Inc.) following the manufacturer’s instructions. This is a modification o f the one 
step method described by Chomczynski and Sacchi (1987). RNAzolB contains 
guanidinium and phenol/chloroform in a monphasic solution. This technique is 
based on RNA forming complexes with guanidinium and water, keeping it in the 
aqueous phase, whilst DNA in this environment loses its hydrophilic properties and 
is sequestered in the phenol/chloroform phase with the protein.
All plastic-ware and apparatus were treated with 0.1% di-ethyl pyrocarbonate 
(DEPC). Apparatus was soaked in the solution overnight. Pipette tips and 
eppendorf vials were soaked overnight, oven dried and autoclaved. Distilled water 
prepared with DEPC was autoclaved to remove remaining DEPC, as this may 
interfere with downstream applications.
All nervous tissue samples were homogenised by tituration through sterile 
hypodermic needles of decreasing sizes (21-27 gauge) in the presence of the 
appropriate amount of RNAzol B. Organs were crushed initially in a sterile pestle 
and mortar in the presence of liquid nitrogen. This was homogenised in a Dounce 
homogeniser in the presence of the appropriate amount of RNAzol B.
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A one tenth volume of ice cold chloroform was added to the homogenate and this 
was vortexed for 15secs and allowed to sit on ice for 15 minutes. The sample was 
centrifuged for 15 minutes at 12,000g at 4^C and the upper aqueous phase was 
removed and retained.
The RNA was precipitated by adding an equal volume of isopropanol to the aqueous 
phase. In situations where > lp g  was anticipated this was left on ice for 15 mins. 
Samples with expected yields of < lpg  were precipitated at -20^C overnight. The 
RNA was pelleted by centrifuging for 15 minutes at 12,000g at 4^C.
An alternative technique for the precipitation of small amounts o f RNA the Paint 
Pellet (Novagen) system was used. Paint Pellet is a fluorescent-dye labelled carrier 
that encourages precipitation of nucleic acids and labels the resulting pellet allowing 
easy visualisation with UV light. RNA was precipitated in the presence of sodium 
acetate and 2 volumes of ethanol with 2pl Paint pellet. The sample was vortexed 
briefly and incubated at room temperature for 2 minutes. Samples were recovered 
at 12,000g at room temperature for 5 mins to pull down the RNA.
Pellets were washed with 800pl 75% ethanol/DEPC-treated sterile distilled water 
(SDW). After further centrifugation the pellet was air dried for 5 minutes and 
reconstituted in an appropriate volume of DEPC-treated SDW. The RNA 
concentration was measured as described below. Samples were stored at -70^C.
2.5.1.3 Quantification of nucleic acid
Nucleic acid samples, with the exception of the small amounts extracted from sciatic 
nerves and fragments extracted from gels, were quantified using a GeneQuant 
RNA/DNA calculator (Pharmacia Biotech). A spectrophotometer cell with a 
minimum volume of 70pi ensured that the minimal amount o f nucleic acid was 
discarded during quantification. Working concentrations were a mean of two 
readings, o f different dilutions, that were within 10% of each other.
The concentration of small quantities of nucleic acid was estimated by gel analysis 
against varying aliquots of an appropriate sample of known concentration. 
Alternatively, in the absence of an appropriate sample for quantifying small 
amounts o f DNA samples were run out against aliquots of a low DNA mass ladder 
(Life Sciences, Paisley).
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2.5.1.4 Nucleic acid electrophoresis
2.5.1.4.1 Agarose gels
Routine analysis of both DNA and RNA was performed on 0.7-2% agarose gels in a 
Tris acetate EDTA (TAE buffer). 0.7% agarose was used for the analysis o f gDNA; 
1% for the analysis of RNA; 1.3% for the separation of digested plasmids; 2% for 
the analysis of PCR products. Samples of RNA were examined on a denaturing gel 
if there was doubt about their integrity.
Gels were cast from ultra pure electrophoresis grade agarose (Life Sciences, 
Paisley). The agarose was melted in the presence of TAE buffer (see page 208). 
Ethidium bromide (from a stock at lOmg ml_l) was added to the cooled gel to give a 
final concentration of ~4pg ml"l. Samples were loaded with a 6x gel loading buffer 
(page 210). Gels were run in TAE buffer.
Gels were viewed with a “Fotoprep I” ultraviolet (UV) transilluminator (Fotodyne 
Inc.) and photographed using a Polaroid MP4 land camera (Polaroid) on Polaroid 
667 (ASA 3000) film through a Wratten 22A filter (Kodak). Alternatively 
analytical gels were recorded using the ImageDoc Gel Documentation system 
(Scotlab) consisting of a high performance CDC video camera (COHU), UVT-28M 
UV transilluminator (Herotech) and a UP890CE video graphic thermal printer 
(Sony).
2.5.1.4.2 Denaturing agarose gels
Denaturing gels were used for gel separation of RNA populations prior to northern 
transfer. The addition of formaldehyde prevents the formation of secondary 
structures that would interfere with the migration of RNA species. One percent 
agarose gels (ultra pure electrophoresis grade agarose (Life Sciences, Paisley) were 
made in a formaldehyde/MOPS environment (see 8.5.2.2 MOPS xlO , page 209). 
The buffering capacity of the MOPS buffer comes from both the sodium acetate and 
the 3-(N-morpholno) propanesulphonic acid (MOPS) (which is used in preference to 
Tris as it does not react with the formaldehyde).
Gels were cast by melting the agarose in MOPS buffer and allowing it to cool to 
~60^C before adding 40% formaldehyde, to give a final formaldehyde concentration 
of 6.4% (w/v).
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2.5.2 Polymerase chain reaction (PCR)
The same basic protocol was used for all primer pairs, with specific variations of 
magnesium chloride concentration and cycle number depending on individual 
primer pairs and the ambition of the experiment.
Primers were obtained as pairs and sourced from the same manufacturer (Cruachem, 
Glasgow).
2.5.2.1 PCR core programme
Samples were initially denatured at 94^C for 90 secs. The step cycle consisted of an 
annealing period o f 45 secs at 55^C, an extension period of 60 secs at 72^C and a 
denaturation period of 45 secs at 94 ®C. The step cycle was varied according to the 
requirements o f specific primer pairs (details with specific primer pairs). The final 
cycle consisted o f an extended annealing period of 60 secs at 55^C and an extended 
extension period of 5 mins at 72^C. The extended extension period was shown to 
significantly increase the product yield. PCR products were harvested by careful 
pipetting from beneath the oil layer.
2.5.2.2 Genomic PCR
Amplifications for genotyping were performed either on the Perkin Elmer DNA 
thermal cycler or a PHC-3 (Techne). Reactions were carried out in 50pl volumes, in 
0.5ml eppendorfs, and overlaid with 50pl of molecular biology grade mineral oil 
(Sigma) to prevent evaporation. Reactions contained lOOng target, 0.2mM dNTPs, 
0.3 pM of the forward and reverse primers (see 3.3 PCR genotyping, page 79), the 
specific concentration of magnesium chloride and were performed in the presence of 
2.5U Taq polymerase (Bioline) with the manufacturers ammonium buffer. The 
addition o f ammonium sulphate decreases the incidence of non-specific primer 
annealing by destabilising weak hydrogen bonding. Thirty cycles were used for all 
primer pairs with the exception of the primer pair used to identify the Pip and Dm20 
minigene mice, which required 39 cycles to produce a robust Dm20 signal.
2.5.3 Southern transfer
2.5.3.1 Gel preparation
A mid-gel system (Model H3-SET, Anachem) giving a gel 15x13cm, approximately 
100ml in volume, was used to provide wells of a suitable size within a gel of 
appropriate thickness for Southern transfer. The digested gDNA samples were run 
on 0.7% agarose gels (see 2.5.1.4 Nucleic acid electrophoresis, page 51) in
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conjunction with suitable size markers. A photographic record was kept to aid 
interpretation of the autoradiograph (Figure 5, page 54).
The size separated gDNA fragments were denatured by soaking the gel in 0.5M 
sodium hydroxide/1.5M sodium chloride for 30 mins on a slowly shaking platform. 
The gel was neutralised in 1.5M sodium chloride/0.5M Tris pH7.4 to enhance 
binding of the nucleic acids to the transfer filter, which is reduced in environments 
>pH9.0.
2.5.3.2 Transfer
Transfer was achieved using a vacuum blotter (model 785, Bio-Rad) in a high salt 
environment (lOxSSC, see page 209) onto a nylon filter (Hybond-N, Amersham). 
Transfer was for 90 minutes with a vacuum equivalent to 5 inches o f mercury. 
After transfer filters were washed in 2xSSC to remove gel fragments and blotted 
dry. Nucleic acids were immobilised by UV cross-linking using an XL-100 
(Spectronics Corporation).
2.5.3.3 Hybridisation
Pre-hybridisation and hybridisation were undertaken in a hybridisation oven with 
rotisserie (Micro-4, Hybaid) using Rapid-hyb buffer (Amersham). Volume of 
hybridisation buffer depended on size of the hybridisation bottle and the number of 
filters hybridised. Oven, bottles and hybridisation buffer were preheated to 65^C. 
Pre-hybridisation was for a minimum of 3 hrs. Probe was added to the hybridisation 
buffer and hybridisation was carried out over night at 65^C.
2.5.3.4 Stringency washing
Filters were washed to remove non-specifically bound probe. All stringency washes 
were in conducted at 65^C and 0.1% SDS in a sealed container in a shaking 
waterbath. The first two washes were in 2xSSC for 30 minutes. The second two 
washes were of increased in stringency, being in O.lxSSC, with the first wash being 
for 30 mins. At this point filters were monitored and on the basis o f the level of 
activity the final wash was conducted for between 30 mins and overnight. A final 
wash in 0.1%xSSC was conducted briefly at room temperature to remove the SDS.
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Figure 5. Example of gDNA digested with B am \\\ run out on a 0.7% agarose
gel immediately prior to Southern transfer. Arrows indicate the position of 
satellite bands, an indication of satisfactory gDNA digestion. M arker (m) X 
H indlll.
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2.5.3.5 Development
Hybridised filters were blotted dry (but not allowed to completely dry to prevent 
irreversible probe binding) and sealed in plastic bags. Autoradiography was 
performed using Cronex 10S film (DuPont) at -70^C. Films were developed using a 
Cronex-130 (DuPont) automatic processor.
2.5.4 Analysis of transcripts
2.5.4.1 Reverse transcription polymerase chain reaction (RT-PCR).
2.5.4.1.1 Design o f novel PCR primers
This was undertaken using the Genetics Computing Group Wisconsin Package 
(Version 8)1. Sequences were obtained from GenBank and EMBL. PCR primers 
were designed using the Extension program m es^. The particular programme used 
for PCR primers was “PRIMA”.
2.5.4.1.2 cDNA preparation
First strand cDNAs were synthesised from 2(ig of total RNA, given availability. 
RNA was initially denatured at 65^C for 5 mins and quenched on ice. Reactions 
proceeded in the presence of 3pg random primers (Life Sciences, Paisley), 0.5mM 
dNTPs, lOmM dithiothrietol and 20U RNasin (Promega) for 30 mins at 37^C 
followed by 60 mins at 42^C using 400U Moloney murine leukaemia virus (M- 
MLV) reverse transcriptase (Life Sciences, Paisley) in the manufacturer’s buffer. 
Reactions were terminated with the addition of 500mM ETDA to give a 
concentration o f 12.5mM. The product was ethanol precipitated in the presence of 
0.3M sodium acetate pH5.2 by adding 2 volumes of cold ethanol and incubating for 
1 hr at -20^C. The product was pelleted by centrifugation at 12,000g for 30 mins. 
Excess salt was removed with a 70% ethanol wash and the pellet air dried for 5 
mins. The product was reconstituted in SDW at 25ng pl"l. For cDNA preparations
1 Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 
Science Drive, Madison, Wisconsin, USA 53711
2 Program Manual for the EGCG Package, Peter Rice, The Sanger Centre, Hinxton Hall, Cambridge, CB10 
IRQ, England
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from RNAs extracted from sciatic nerve the Paint Pellet technique was used to 
maximise the yield (see 2.5.1.2.2 Isolation of RNA page 49).
2.5.4.1.3 RT-PCR
These experiments were carried out exclusively on the DNA thermal cycler (Perkin 
Elmer) to reduce variability in results. This semi-quantitative procedure is based on 
the generation of a product from a constitutively expressed gene that acts as an 
internal control for invariant temporal expression. Cyclophilin (Danielson et al., 
1988) primers were used for parallel experiments to control for target and gel 
loading.
Reactions were performed in 25pl volumes in 0.5ml eppendorf vials overlaid with 
50 j l i 1 molecular biology grade mineral oil (Sigma). The target was 12.5ng of cDNA 
and this was amplified with 1.25U Taq DNA polymerase (Bioline) in the 
manufacturer’s ammonium buffer in the presence o f 0.2mM dNTPs and 0.3pM each 
of the forward and reverse primers. The concentration of magnesium chloride was 
optimised for each primer pair. Cycle assays were performed and a cycle number 
within the linear range used for subsequent experiments. The core PCR cycle is 
described in 2.5.2.1 PCR core programme (page 52). The primer pairs used for 
transcipt analysis are described in Table 2 (page 58).
2.5.4.2 Northern blotting
This technique was used to compare the steady state levels o f specific mRNA 
populations within the general mRNA pool of various tissues. RNA was extracted 
and quantified as in 2.5.1.2.2 Isolation of RNA (page 49).
2.5.4.2.1 Equipment preparation
All plastics were prepared as above. The mid-gel rig was soaked overnight in 0.5% 
DEPC water and dried without being rinsed.
2.5.4.2.2 Sample preparation
RNA samples were defrosted and kept on ice. Aliquots o f 5pg were made up to a 
total volume of lOpl with DEPC treated water to which 31. 12pl of denaturing buffer 
(page 209) was added. Samples were denatured by heating to 65^C for 5 minutes 
and 5 pi o f northern loading buffer (page 210) was added.
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2.5.4.2.3 Gel conditions
A 100 ml 1% agarose denaturing gel was prepared as described in 2.5.1.4.2 
Denaturing agarose gels (page 51). The MOPS buffer was changed once during the 
run as the heat generated during electrophoresis leads to buffer denaturation. The 
gel was washed 3x for 5 mins in DW to remove formaldehyde and equilibrated with 
transfer buffer by soaking for between 10 and 45 minutes.
2.5.4.2.4 Transfer
Transfer was as for Southern blots (see 2.5.3.2 Transfer page 53). Filters were 
stored between sheets o f filter paper.
2.5.4.2.5 Methylene blue staining
To assesses integrity and equality of transfer of RNA filters were stained with 
methylene blue. Filters were bathed in 5% acetic acid for 15 mins in a shaking 
water bath and stained by soaking in methylene blue for 10 mins. Staining was 
highlighted by removing the background staining by washing the filter in DW 
followed by air drying. The filter was photographed (see 2.5.1.4.1 Agarose gels 
page 51) using a green filter (Figure 6, page 59). Methylene blue readily identifies 
the ribosomal RNA species 28S and 18S, which migrate at approximately 5.1Kb 
and 1.9Kb respectively (Nyberg-Hansen, 1964). The position of these was marked 
by creating pinpricks, these can be identified on an autoradiograph due to non­
specific binding, thus allowing estimation of the size of hybridised species.
2.5.4.2.6 Hybridisation
See 2.5.3.3 Hybridisation, page 53.
2.5.4.2.7 Stringency washing
See 2.5.3.4 Stringency washing, page 53.
2.5.4.2.8 Development
See 2.5.3.5 Development, page 55.
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Figure 6. Methylene blue stained northern Fdter. The 18S and 28S bands can 
be seen clearly. They have been marked with pinpricks to aid subsequent 
analysis of the autoradiograph and represent -  1.9Kb and 5.1Kb respectively.
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2.6 Analysis of proteins
2.6.1 Isolation of protein from tissue
Protein was isolated from whole mouse brains by homogenisation in 0.1M Tris 
(pH6.8) and lmM Na-p- tosy 1-1-lysine chloro-methyl ketone (TLCK) to which 2% 
SDS was added and the samples boiled for 5 minutes. The samples were 
centrifuged at 13,000g for 5 minutes in a Heraeus Biofuge at 4^C, the supernatant 
retained and stored at -20^C. Total protein concentration was measured using the 
BCA Assay (Pierce). DTT was added to give a final concentration o f 40mM.
2.6.2 Western blotting
Aliquots (lOOpg) were resolved on a 5-17.5% gradient SDS-polyacrylamide gel 
with a 2.5% stacking gel. Electrophoteric transfer o f the separated proteins onto 
Hybond ECL nitrocellulose membrane (Amersham Life Sciences) was performed at 
200mA for 4 hours at 4^C in a transblot cell (Bio-Rad).
Immunodetection was accomplished using enhanced chemiluminescence (ECL). 
Non-specific binding was blocked by overnight treatment in Tris buffered saline 
(pH7.6) containing 5% dried milk, 0.2% gelatin and 0.1% Tween 20. The ECL 
nitrocellulose membrane was treated with the primary antibody, anti-PLP C- 
terminus (PLP226X at 5000 for 60 minutes at room temperature, followed by 
extensive washing in the blocking buffer. The membrane was incubated in the 
secondary antibody, goat anti-rabbit IgG conjugated with peroxidase (Sigma), at 
1:5000 for 60 minutes at room temperature, followed by extensive washing with the 
blocking buffer and a final rinse in Tris buffered saline (pH7.6). The ECL 
nitrocellulose membrane was incubated in equal volumes of luminol enhancer 
solution and stable peroxide solution (Pierce Chemical Co.) for five minutes at room 
temperature. The membrane was wrapped in Saran wrap and exposed to X-omat 
imaging film (Kodak) in a radiography cassette for 30 seconds. The film was 
developed using an automatic processor (DuPont Cronex CX-130).
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2.7 Preparation of radiolabelled probes
2.7.1 Isolation of DNA fragments from agarose gels
The digested plasmid DNA was run out on a 1.3% agarose gel (see 2.5.1.4.1 
Agarose gels page 51) to separate the fragment o f interest from associated plasmid 
DNA. The region of interest was excised and the DNA fragment extracted from the 
gel slice using the QIAEX II Gel Extraction kit (Qiagen). This is a spin column 
system and is based on the QIAEX II silica particles that absorb DNA in a high salt 
environment from which it can be subsequently eluted in low salt conditions.
The gel slice was incubated in 3x its volume in buffer QX1 at 50^C in the presence 
of lOpl of QuiexII silica beads for 10 mins, with frequent vortexing. In these 
conditions the agarose melts and the nucleic acids are selectively absorbed onto the 
QuiexII beads. The beads were pelleted and the supernatant removed. The beads 
were resuspended by vortexing for 30 secs in a further 500pl o f QX1, this wash 
removing further traces o f agarose. Two similar washes in 500pl buffer PE, a high 
salt/ethanol buffer, removes final traces of salts. Traces of ethanol were allowed to 
evaporate as the pellet was air dried for 10 mins. The final step was to elute the 
DNA which was achieved by vortexing for 30 secs in SDW. Eluted DNA fragments 
were stored at -20®C.
2.7.2 Radiolabelling
DNA fragments were radiolabelled using High Prime (Boehringer-Mannheim) an 
optimised mixture of random oligonucleotide primers, dNTPs, Klenow enzyme in 
5x buffer and glycerol. This kit is optimised for the use of radioactive dCTP. The 
use of random primers produces a mixed population of labelled fragments 
complementary to the 3 '-5 ' strand.
The DNA fragment, usually lOOng, was made up to 11 pi in SDW, denatured for 10 
mins at lOO^C and quenched on ice. To this was added 4pl High Prime and 5 pi 
a32p dCTP (Amersham) and the mixture thoroughly mixed. The labelling reaction 
was performed at 37^C for 10 mins at which time it was quenched by the addition 
of 0.2M EDTA to give a final concentration of lOmM EDTA. Labelled mixtures 
were stored at 4^C until the removal of unincorporated nucleotides (see below).
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2.7.2.1 Removal of unincorporated nucleotides
Unincorporated nucleotides were removed by passing the labelled mixture through a 
Nick column (Pharmacia Biotech) containing Sephadex® G-50 beads. The eluted 
labelled DNA fragment was stored at -20^C until use.
2.8 In situ hybridisation (ISH)
2.8.1 35S riboprobes
A 35s riboprobe was generated which was complementary to a sequence common 
to both Pip and Dm20 mRNA, using the SP6/T7 Transcription kit (Boehringer- 
Mannheim). This probe, termed PLP-1, was generated from a 0.8kb cDNA 
containing mainly the coding region cloned into pGEM 4 (Promega) (Milner et al., 
1985) (see Figure 7, page 67). The plasmid was linearised using BamHl (Life 
Sciences, Paisley), the digestion being confirmed by analytical gel analysis, ethanol 
precipitated and reconstituted at a final concentration of 500ng pH. The choice of 
restriction enzyme was influenced by the need to generate a 5' overhang as 3' 
overhangs may cause aberrant transcript generation.
A 20pl labelling reaction contained the following: l-2pg linearised plasmid DNA, 
l.Opl each of the nucleotides (ATP, GTP, UTP (lOmM in Tris buffer), 5.0pl 
(50pCi) 35s aCTP (specific activity 37Tbq mM~l;<1000Ci mM"l; Amersham), 
2.0pl lOx transcription buffer, l.Opl RNase inhibitor (20U p H )  in a final volume of 
20pl in DEPC SDW. The mixture was incubated at 37^C for 30 mins after the 
addition of l.Opl of T7 RNA polymerase (20U pH). An additional l.Opl enzyme 
was added and the incubation extended for a further 30 mins. Template was 
digested by the addition of 2.0pl DNase (10U pH, RNase free) and incubated for a 
further 15 mins. The product was phenol-chloroform extracted and a further 
extraction made after the addition of a further 22pl DEPC SDW. The RNA was 
precipitated with 7.5M ammonium acetate, a 5.0pl aliquot was set aside (A) and the 
product pelleted by centrifugation and a 5.0pl of the supernatant set aside (B). The 
RNA pellet was reconstituted in lOOpl DEPC SDW and 5.0pl was set aside (C). 
The riboprobe was reprecipitated overnight in ethanol. The aliquots A, B and C 
were placed in 5ml Ecoscint (National Diagnostics).
The Ecoscint vials were counted on a LS 1801 scintillation counter (Beckman). 
Vial A represents total isotope; B represents unincorporated isotope; C represents 
incorporated isotope. Percentage incorporation was calculated from the ratio of 
B/A. Isotope incorporated into RNA in the form of the riboprobe, was calculated
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from a standard formula and it was reconstituted in 0.01 M DTT at a concentration 
of 1 .Ong |al_l kb"l. Probe was stored at -20^C and used within 6-8 weeks.
Probes were prepared by Dr P. Dickinson.
2.8.2 ISH protocol
The basic procedure was as described by Cox et al (Cox et al., 1984) and modified 
by Wilkinson et al (Wilkinson et al., 1987). Pre-treatment involves several steps 
which maximise the accessibility of the target to the probe whilst maintaining the 
tissue morphology. Proteinase K treatment removes protein bound to the target 
whilst acetylation decreases non-specific binding due to electrostatic interactions 
between basic proteins and the probe (Hayashi, 1978). Hybridisation is undertaken 
in low stringency conditions to favour hybrid formation with the unbound probe 
removed by the higher stringency washes. An RNase step is included to remove 
single stranded RNA.
2.8.2.1 Preparation of apparatus
2.8.2.1.1 RNase treatment of glassware
To minimise RNase activity all glassware and slides were soaked in 6.0% sulphuric 
acid/6% potassium dichromate overnight, rinsed in tap water for 2-4 hrs, rinsed in 
DW, immersed in 0.01% DEPC SDW overnight, oven dried at 60^C and baked at 
180^C for 4 hrs loosely wrapped in foil. Eppendorf vials and pipette tips were 
treated as described in 2.5.4.2.1 Equipment preparation (page 56).
2.8.2.1.2 Preparation of coverslips
The coverslips used to cover sections during hybridisation were soaked in 1M 
hydrochloric acid for 30 mins, rinsed 3x in DW and air dried. Cleaned coverslips 
were immersed in Repelcoat (BDH) for 20 mins, rinsed 2x in DW and baked at 
130^C for 90 mins. The siliconisation with Repelcoat was included to reduce probe 
binding.
2.8.2.1.3 Preparation of APES coated slides
Cleaned slides were coated with 3-aminopropyltriethoxy-silane (APES) (Sigma). 
Slides were washed in the detergent Decon 90 (5%) (Decon Lab Ltd) to remove 
grease overnight, washed well in DW and oven dried wrapped in foil. In a 
fumehood slides were soaked in 0.25% APES in methylated spirit for 2 mins
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followed by 0.01% DEPC SDW for 2 mins prior to oven drying wrapped in foil. 
Slides were stored at room temperature.
2.8.2.2 Preparation of tissue
In situ hybridisation was performed on 6pm tissue sections from BNF perfused / 
paraffin wax embedded tissue (see 2.2.4.1 Paraffin-embedded tissue page 45) on 
APES slides and 15pm unfixed cryo-preserved tissue (see 2.2.3 Cryo-preservation 
page 44) also on APES slides.
2.8.2.3 Pre-treatment
Slides were passed through the following solutions:
1) xylene 10 mins paraffin embedded sections only
2) absolute alcohol 5 mins paraffin embedded sections only
3) methylated spirit 5 mins paraffin embedded sections only
4) 0.85% saline 5 mins
5) PBS 5 mins
6) 4% paraformaldehyde 
(in PBS)
20 mins
7) PBS rinse 5 mins (x”)
8) proteinase K* 7.5 mins paraffin embedded sections only
9) 4% paraformaldehyde 
(in PBS)
5 mins only proteinase K treated sections
10) 0.1M triethanolamine 
+625 pi acetic 
anhydride
5 mins performed in fumehood using 
magnetic stirrer
11) add further 625 pi acetic 
anhydride
further 5 
mins
12) PBS rinse 5 mins
13) 0.85% saline 5 mins
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14) methylated spirits 5 mins
15) absolute alcohol 5 mins (x2)
16) air dry 1 hr
2.8.2.4 Hybridisation
The total volume of probe required was calculated depending on the number and 
area o f sections (brain ~ 6 pi, spinal cord ~ 3 pi) and the working dilution of the 
probe which was generally 1:10. The probe was diluted in the hybridisation buffer. 
Hybridisation buffer was stored at -20^C with 1% 1M DTT (diluted in DEPC SDW) 
added to the final probe/hybridisation buffer mixture. Probe was denatured at 80^C 
for 2 mins, quenched on ice and aliquoted onto the sections and covered with a 
siliconised cover slip (see 2.8.2.1.2 Preparation of coverslips page 63). Slides were 
placed horizontally in a slide box containing tissue soaked in 50% 
formamide/5xSSC. The box was sealed with tape, placed inside 3 vacuum sealed 
bags and immersed in a 50^C waterbath for overnight hybridisation.
2.8.2.5 Washing and mounting
Post-hybridisation treatment consisted of:
1)
2)
3)
5)
6) 
7)
wash 1 5xSSC/0.01M DTT
wash 2 2xSSC in 50%
formamide/0.1M DTT
wash 3 0.5M sodium
chloride/0.005M 
EDTA/0.01M Tris-HCL 
(pH7.5)
4) wash 3 0.02mg ml-1 RNaseA
wash3
wash 2
wash 4 2xSSC
8) wash 5 O.lxSSC 
followed by dehydration and mounting:
50°C
650C
370c
37°C
37°C
650c
30 mins 
20 mins
10 mins (x3)
30 mins 
30 mins 
20mins
room temperature 15 mins 
room temperature 15 mins
65
Materials and Methods
1) 75ml ethanol, 162.5ml DW, 12.5ml 30 secs
6M ammonium acetate
2) 150ml ethanol, 87.5ml DW, 12.5ml 30 secs
6M ammonium acetate
3) 200ml ethanol, 37.5ml DW, 12.5ml 30 secs
6M ammonium acetate
4) 237.5ml ethanol, 12.5ml 6M 30secs
ammonium acetate
Slides were rinsed in absolute alcohol for 2 mins, air dried.
2.8.2.6 A utoradiography
Slides were exposed to Cronex (DuPont) autoradiography film in a radiography 
cassette overnight at room temperature. The intensity of the image determined the 
subsequent exposure to photographic emulsion. Slides were dipped in a solution of 
Ilford K5 emulsion in a 1:1 ratio with DW containing 1.0% glycerol at 42®C. Slides 
were air dried for 4-6 hrs and stored at 4®C in light tight boxes, containing a sachet 
o f silica gel, for a period of 1-2 days. The slides were developed by immersion in 
D19 developer (Kodak) at 18^C for 3-5 mins. This was stopped by immersion in 
1% acetic acid/1% glycerol. Slides were fixed in 30% sodium thiosulphate for 8 
mins and washed in water for 20-30 mins in the dark before air drying.
Sections were counterstained with haematoxylin (see 2.3.1.2 Haematoxylin, page 
46) dehydrated and mounted.
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T7 PLP-1 836 bp SP6
Hind ill Pst I Bam HI bco Rl
ANTISENSE SENSE ^
875 bp ^ SENSE TRANSCRIPT
ANTISENSE TRANSCRIPT
^  880 bp
Figure 7. Generation of the PLP-1 probe for in-situ hybridisation. The use of 
the T7 promotor produces an a-sense sequence which will hybridise with mRNA 
in the tissue. The fragment recognises both the Pip and Dm20 message 
isoforms.
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2.9 Immunocytochemistry
2.9.1 Tissue sections
All incubations with antibodies and links where sections were bathed in small 
volumes o f fluid were performed in a humidifying chamber. Control sections were 
included where the primary antibody was omitted and replaced with PBS. Tissue 
sections were cut as described in 2.2.4 Preparation of sections (page 45).
2.9.1.1 Peroxidase anti-peroxidase (PAP)
The primary antibodies, sources, dilutions and links used for PAP immunostaining 
are summarised in Table 3 (page 70) with the exception of the antibodies used for 
the demonstration of microglia and T cell sub types, which are summarised in 4.3.4 
Immunocytochemistry (page 91).
2.9.1.1.1 Paraffin wax embedded tissue 
Sections were hydrated:
1) xylene 2 min
2) absolute alcohol 2 min
3) methylated spirit 2 min
4) water 2 min
5) Lugols iodine 1 min
6) water 1 min
7) 5% sodium thiosulphate 
(hypo)
1 min
8) water
Endogenous peroxidase activity was quenched by immersing slides in 3% hydrogen 
peroxidase (in absolute alcohol) for 30 minutes followed by a wash in running water 
for 30 mins. Non-specific binding was blocked by incubating in 10% normal goat
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serum (NGS) in PBS for 2 hr at room temperature. Sections were incubated in the 
primary antibody in 1% NGS in PBS overnight at 4^C.
Sections were adjusted to room temperature and washed for 30 mins in PBS (six 
changes) followed by the link antibody in 1% NGS at room temperature for 1 hr. 
Excess antibody was removed by washing in PBS for 30 mins (6 changes) and the 
sections incubated in the PAP complex for 30 mins at room temperature. Excess 
was removed by washing in PBS for 30 minutes (6 changes). The chromogen was 
developed in filtered 0.1M phosphate buffer (pH7.3) containing 0.5mg/ml 3,4,4',4',- 
tetraminobiphenyl hydrochloride (DAB) and 0.003% hydrogen peroxide until the 
required colour intensity had been achieved (30s-5 mins). Sections were washed in 
running water, dehydrated and mounted in DPX (BDH).
2.9.1.1.2 Resin embedded tissue
Resin was removed by immersing slides in sodium ethoxide (50% ripened sodium 
ethoxide in 50% absolute alcohol) for 30 mins after which they were examined by 
microscopy to ensure that this had been achieved. Sections were washed in absolute 
alcohol for 30 mins (six changes) and running water for 30 mins. Endogenous 
peroxidase activity was quenched with 3% hydrogen peroxide in water. Further 
steps were as above. After development of the DAB reaction, sections were 
osmicated in 1 % osmium, to intensify the colour product, for 1 min before washing, 
dehydrating and mounting in DPX.
2.9.1.2 Immunofluorescence
The antibodies, their source, dilutions and links used in fluorescent immunostaining 
are summarised in Table 4 page 71. Secondary antibodies labelled with fluorescein 
isothiocyanate (FITC) and Texas red (TXR) were used and sections examined by 
epifluorescence. FITC absorbs light with a wavelength 495nm and emits it at 
525nm which can be visualised as green light using a blue filter. The TXR labelled 
conjugate absorbs light at 596nm and emits it at 620nm which can be visualised as 
red light using a green filter.
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Materials and Methods
2.9.1.2.1 Cryo-sections
Sections were allowed to warm to room temperature, dry and washed in PBS for 10 
mins, to remove the embedding medium. Sections were fixed in 4% 
paraformaldehyde at room temperature for 20 mins, rinsed in PBS, followed by 
methanol at -20^C for 10 mins and 2x 5 minute washes in PBS. Incubation in the 
primary antibody, in 1% NGS, was for 1 hr at room temperature or overnight at 
4^C. Sections were washed 6x 5 mins in PBS and the secondary antibody applied 
for 30 mins at room temperature. After a final thorough wash with 3x 5 mins in 
PBS followed by 5 mins in running water sections were mounted in Citifluor (UCK 
Chem Lab), to prevent fading, and stored in the dark at 4^C.
2.9.1.2.2 Paraffin wax embedded sections
Sections were hydrated as in 2.9.1.1.1 Paraffin wax embedded tissue (page 68). The 
sections were not further fixed and immunostaining and mounting was as described 
above.
2.9.2 Teased fibres
2.9.2.1 Immunofluorescence
Prepared fibres were fixed in fresh 4% paraformaldehyde for 20 mins at 4^C, rinsed 
briefly in PBS, followed by 10 mins in methanol at -20^C. Sections were incubated 
in primary antibody in 1% NGS for 1 hr at room temperature. Excess antibody was 
removed by washing in PBS for 20 minutes. Sections were incubated in secondary 
antibody for 30 minutes, rinsed in water and mounted as above.
2.10 Morphometry
2.10.1 Glial cell quantification
All cell counting was performed on 1pm resin-embedded sections of cervical cord at 
the level o f approximately C2, stained with methylene blue/azur II. Counting was 
performed with a 6.3x eyepiece in combination with a lOOx oil immersion lens with 
a 100 square graticule (Graticules Ltd.). The area selected was the ventral columns 
immediately adjacent to the ventro-median fissure and its continuation onto the 
ventral surface of the cord. Only cells in which the nucleus was sectioned were 
counted. Between 400-600 cells were counted, depending on the animals age, with
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a minimum of 12pm between sections to prevent individual nuclei being counted 
more than once. Counts were made of all glial cells and precursors with 
categorisation made on morphological characteristics. Endothelial cells were not 
counted. Longitudinal sections taken from the cord immediately caudal to the 
counting area were used to estimate the mean and maximum nuclear lengths. Areas 
o f sections were calculated from Polaroid light microscopy images using Sigma 
Scan/Image measurement software (Jandel Scientific Software) and SummaSketch 
III graphics tablet (Summagraphics). Corrected total cell glial counts and glial 
densities were calculated using Abercrombie's formula as discussed by Sturrock 
(1983). Three animals were counted for each age and transgenic status. The results 
were plotted using Graphpad Prism software (Graphpad Software Inc.).
2.10.1.1.1 Dead cell density
The dead cell density was estimated by counting pyknotic nuclei distributed 
throughout the white matter of the cord section. For each mouse two sections, 
separated by 12pm, were counted and the mean calculated. Though the type of cell 
cannot be ascertained it is well recognised that during development of the CNS a 
large proportion of such dead cells represent glial cells of which the majority are 
oligodendrocytes (Vela et a l, 1996).
2.10.2 Myelin thickness
Araldite blocks used for cell counting were trimmed and ultra-thin sections prepared 
for electron microscopy (2.2.4.4 Ultra-thin sections page 45 and 2.3.2 Electron 
microscopy page 46). Random fields from the ventral columns were photographed 
at approximately 5000x and printed at 2x magnification. Calibration was achieved 
by photographing a diffraction grating of known size for each set o f prints.
Myelin and axons were outlined using a graphics pad to generate the total area of 
axon and myelin and axon area (software/hardware as above). A total of 150-180 
myelinated axons were measured for each mouse. This data was used to derive 
(Excel 5, Microsoft) diameters of circles with equivalent areas and thus the notional 
myelin thickness. The derived myelin thickness and equivalent axonal diameter 
allowed the derivation of the g value (g is defined as the ratio of axon diameter to 
that o f the axon plus sheath).
To examine the relationship between axon diameter and g  value the data for mice of 
the same age and zygosity was pooled.
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2.10.3 Myelin density
These measurements were performed by point counting of the electron-micrographs 
using a method described by Williams ( 1977). Squares of 2cm^ were used giving a 
total o f 64 possible intercepts per electron-micrograph with 10-12 photographs 
being counted per animal. The myelin to axon ratio was calculated from the 
contacts made with myelin sheath or axon.
2.11 Statistical methods
In general, the results for experimental groups were summarised graphically by 
three data points. In most instances the small group sizes limited the applicability of 
complex statistical analysis, but by presenting all the data points comments on 
general trends can be made. Comparisons were made referring to the median. The 
median was selected as it is less susceptible to distortion by out lying values. In 
populations with a normal distribution the median and mean have the same value. 
Occasionally only two data points were available for a group and interpretation was 
limited to commenting on any apparent trend. Experimental groups with sufficient 
data were compared using the non-parameteric two tailed Mann-Whitney test. This 
test ranks the data and makes a statement on the significance of the mixing of the 
distributions o f ranked values from the two groups. Throughout this thesis, 
statistical significance was set at the 5 percent level (i.e.P<0.05).
2.12 Image recording
2.12.1 Photomicrographs
Photographs o f histological sections were taken on a Olympus Vanox-S. Dark field 
images of ISH sections were captured on a stage illuminated by a Fibre-Lite Series 
180 (Doran Jenner Industries, Inc.).
2.12.2 Immunofluorescent photography
Photographs were taken using a Reichart-Jung Diastar photomicroscope with 
epifluorescence (Model 2090).
2.12.3 Confocal microscopy
The confocal system was a MRC600 (BioRad). This data output from this system is 
in the form computer graphic files and the images presented are from these original 
data files.
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2.12.4 Electronmicroscopy
The electronmicroscope was an AEIEM6B.
2.12.5 Image presentation
Suitable images were scanned from transparencies using a Coolscan II (Nikon) and 
the images printed on a Epson Stylus Color 800. Images o f epifluorescence are not 
suitable for this process and have been printed from transparencies.
2.13 Growth of mice
Mice were weighed immediately after being killed.
Body weight as a measure of development is a parameter that is straightforward to 
obtain. The information must be considered in the light o f the variables that have 
been demonstrated to affect weight gain, many of which are pertinent to this study. 
The following general features have been identified as having significant effects on 
weight gain (Cunliffe-Beamer and Les, 1987): age of dam; age o f sire; parity of 
dam; size o f litter; availability of food; etc.
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3.1 Introduction
The transgenic status of the mice described in the following chapters was confirmed 
using a combination of data including: phenotype, observations on pathological 
features, PCR data and Southern blotting.
3.2 genomic DNA extraction (gDNA)
The selection o f a procedure to be adopted for routine gDNA extraction was 
influenced by the potential downstream ambition of semi-quantitative Southern 
analysis, and its requirements for reproducibility and high quality. Another criterion 
in the selection of a technique for gDNA extraction was its suitability for 
simultaneous handling of multiple extractions.
As a base line, the traditional technique of cell lysis and deproteinisation by phenol- 
chloroform extraction was assessed. Tissues were incubated at 55^C in buffers 
based on SDS (to lyse cell membranes) and proteinase K to denature proteins 
(including DNases) and EDTA (which also inhibits DNases). This was followed by 
protein extraction using phenol-chloroform and an alcohol precipitation of nucleic 
acids. A number o f extraction buffers, varying in SDS and EDTA content, were 
assessed. Though high molecular weight gDNA with good digestibility and 
consistent quantification could be obtained using this system it proved time 
consuming and less reliable when used with large numbers o f samples. There are 
also inherent problems associated with working with and disposing of phenol.
Three commercial kits were assessed. Such kits are marketed primarily as offering 
high quality gDNA from procedures with reduced manipulations (giving time 
savings) and increased safety by removing the requirement for phenol-chloroform 
extraction. The three kits selected were based on different principles, though all 
initially utilised a cell lysis step including a cell lysis buffer and proteinase K.
Contaminating RNA was removed with RNaseA treatment (see 2.5.1.1.3 
Preparation of RibonucleaseA (RNaseA), page 49) the specifics o f which varied 
between protocols.
Nucleon (Scotlab) is based on a patented resin that in combination with sodium 
perchlorate and chloroform removes protein and cellular debris. Though the quality 
o f the gDNA was acceptable, physical limitations on the amount o f tissue that could
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be handled resulted in relatively small yields which would have been insufficient for 
the downstream requirements without multiple preparations from each tail.
Puregene (Flowgen) is based on a protein precipitation buffer, which produces an 
insoluble pellet of protein and cell debris from which the DNA is separated by 
removing the supernatant in which it is dissolved. This system proved to be 
inconsistent in the quality of the gDNA produced.
The QIAamp Tissue kit (Qiagen) is based on a patented spin column system in 
which gDNA is first absorbed onto the membrane allowing the removal o f proteins 
in the flow-through followed by a change in buffering that results in the elution of 
gDNA from the membrane. This system proved to give consistently high yields of 
undegraded, easily digestible gDNA with a high molecular weight (Figure 8, page 
83) and was selected for routine preparations.
3.2.1 QuiAMP gDNA extraction
Frozen mouse tail samples of approximately 0.5cm were finely chopped and added 
to 1 80 j l x 1 of buffer ATL and 20pl of proteinase K (see 2.5.1.1.4 Preparation of 
proteinase K, page 49) in a sterile 1.5ml eppendorf and vortexed. Tail samples were 
incubated at 55^C with brief vortexing every -20  mins until well digested. This 
period varied with the age of the mouse between approximately 1 and 5 hrs. 
Digested samples were spun at 12,000g for 15 minutes to sediment the tissue 
debris, after which 180pl of supernatant was removed to a fresh sterile eppendorf. 
To the supernatant 20pl of 20mg pl~l RNaseA was added followed by a brief vortex 
and 2 mins incubation at room temperature. A mixture of 200pi buffer AL with 
210pl alcohol was added to each sample and the whole volume spun through a 
column to bind the gDNA to the membrane and extract the protein. This was 
followed by two washes in buffer AW to remove final traces of protein from the 
membrane. The gDNA was eluted in buffer AE at 70^C. Pre-heated buffer (200pl) 
was added to the column and the assembly incubated at 70^C for 5 minutes before 
the buffer was spun through the column. The importance of this incubation as 
compared with centrifugation immediately following the addition o f the warmed 
buffer was assessed and found to significantly increase the final yield. This step 
was repeated to give a final volume of 400pl. Yields varied with the age of the 
mouse but were between ~60-140pg with an OD260/280 ° f  -7 (see 2.5.1.3 
Quantification of nucleic acid, page 50). Samples were stored at -20^C.
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3.3 PCR genotyping
All the transgenes could be identified specifically by PCR with the appropriate 
primer pairs (see below). This system, however, did not differentiate between 
hemizygous and homozygous individuals. Gene dosage or zygosity was assessed by 
Southern blot analysis.
The core PCR protocol is described in 2.5.2.1 PCR core programme (page 52). The 
positions o f the primer pairs for the specific transgenes is illustrated in Figure 9 
(page 84). The sequence of the specific primers pairs and their PCR conditions are 
in Table 5 (page 85). Though all primer pairs have been described previously their 
behaviour was reassessed for this laboratory with regards to quantity of target, 
magnesium concentration and cycle assay to give conditions in which the presence 
o f the transgene could be recognised reliably.
3.3.1 #66 and #72 mice
The only transgene specific sequence in the construct was a portion of the T7 
promoter at the 3' end (see Figure 9, page 84). A T7 specific primer in conjunction 
with a primer from the 3' end of the murine PLP gene produces a PCR product of 
250bp with both transgenes and was described by Readhead and others (1994). It 
was noted in preliminary experiments that the system was relatively easily 
overloaded with target. Therefore as the potential for false negatives existed, 
accurate quantification of the gDNA target for was important
To ensure consistent results all PCR runs included target from a wild type other than 
the transgenic background, a known transgene positive, a known transgene negative 
and a no target as controls. The PCR product is illustrated Figure 10 (page 86).
3.3.2 PlpTagl and Dm20Tag2 mice
The transgenic status o f the P//?tagl and Dm20tag2 mini gene mice were assessed 
using primers described by Nadon et al (1994). The two transgenes generate 
products o f different sizes (P/ptagl 412bp; Dm20ta.gl 307bp) confirming the nature 
o f the transgene in an individual mouse. Controls similar to those used for #66 and 
#72 mice were used. The PCR products obtained for each of the two transgenes is 
illustrated in Figure 10 (page 86).
3.3.3 PlpJP carrier females
The Pip gene mutation underlying the PlpJP phenotype results in the abolition of a 
DdeI restriction site at the 5' end o f exon 5 (see Figure 11, page 87). This was used
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to identify female carriers o f the Plpip allele by PCR using primers that span this 
region, followed by DdeI digestion of the product. The primers used were those 
described by Ikenaka et al (1988). The product of this primer pair is a discrete 
population thus lOpl aliquot of the PCR product was digested in a 12pi reaction 
with 6u Ddel (Life Technologies, Paisley) for 1 hr at 37°C and run out on a 2% 
agarose gel with a lOpl aliquot of undigested product. The resulting restriction 
profile is illustrated in Figure 11 (page 87).
3.4 Southern blot assessment of #66 and #72 
transgene zygosity
Southern blotting was used both to confirm suspected zygosity (as assessed from a 
combination o f phenotypic and pathological findings in conjunction with PCR) and 
in situations where there was no other information, other than PCR identification.
3.4.1 gDNA digestion
The goal o f Southern analysis was to assess relative hybridisation signal intensities. 
To enhance such differences the quantity of gDNA digested was at the lower end of 
the detection range in this system (see 3.6 Discussion, page 82).
The fragment used for labelling was a BamHl digest and hence the gDNA was 
subjected to the same digest. Digests of 5pg were performed in 35pi volumes using 
BamHl (Life Technologies, Paisley) for 3 hrs at 37°C, at which point representative 
0.5pg aliquots were gel-checked to assess the completeness of the digestion. A 
further indication of the complete digestion was the presence of satellite bands after 
gel electrophoresis of the digests (see Figure 5 page 54). Completed digests were 
stored at-20°C.
Southern blots were designed to include wild type and homozygous/hemizygous 
controls. All gDNA samples were processed as duplicates.
3.4.2 Southern transfer
See 2.5.3 Southern transfer, page 52
3.4.3 Hybridisation probes
A 2.5Kb BamHl fragment (termed B6), a sub-clone of COS901, was radiolabelled. 
The fragment used for hybridisation recognised a sequence including exon 1 of the
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endogenous Pip gene and the transgenes (Figure 3, page 14) as described previously 
(Readhead et al., 1994).
Probe preparation is described in 2.7.2 Radiolabelling (page 61). Probes were 
prepared with an activity in excess of 10^ cpm (ig~l. Final probe concentration in 
the hybridisation buffer was 10pg m l'l for probes 10^ cpm pg"l and 2|ig ml"l for 
probes >10^ cpm pg- ! (Greenberg and Bender, 1997).
3.4.3.1 Interpretation
Comparisons o f signal intensity between controls and unknowns was made to assess 
zygosity taking into account the relative gDNA loading as determined from the gel 
photograph. An example o f the relative intensities of the various zygosities is 
shown in Figure 12 (page 88).
3.5 Breeding of transgenic mice and Plpip crosses
Mice were bred primarily in the animal house of the Veterinary Research Facility, 
University o f Glasgow Veterinary School and also at the animal breeding facilities 
GMBH, Heidelberg. The particular animal house used in Glasgow is known to have 
evidence of MHV and picoma virus infection both of which have been associated 
with neurological disease in mice (see 1.3.1.1 Demyelination in mice due to viral 
infection, page 25), however, there has been no evidence of clinical disease during 
the period of the project. Mice bred at GMBH are specific pathogen free and had 
not been exposed to these viruses. There were no apparent differences in phenotype 
or pathology in the mice bred at the two facilities nor were there abnormalities in 
the wild type mice bred at Glasgow, suggesting that these viruses were not 
significant in the development of the phenotypes described below.
The four lines of transgenic mice were maintained by creating harems of transgenic 
positive animals that were genotyped by PCR as described above. In harems of #72, 
Plptgl and Dm20tg2 occasional pairings included a breeding adult that was 
transgene negative to ensure that both hemizygous and homozygous offspring were 
bred. However, for #66 the early death meant that only hemizygous animals were 
suitable for breeding.
To produce offspring with the PlpdP phenotype and carrying one of the transgenes 
harems o f PlpJP carrier females and transgene positive males were set up. Offspring 
were tail tipped at P10 and assessed for their transgenic status by PCR. This
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breeding strategy could only result in transgene positive mice being hemizygous and 
samples were not assessed by Southern blot.
3.6 Discussion
The initial description of #66 and #72 mice by Readhead and others (1994) 
established the relationship between zygosity and the mutant phenotypes. With 
aspects o f the pathology already outlined such details as phenotype and pathological 
findings could be used, in conjunction with PCR data, as internal controls to 
Southern blotting. Their experiments had also estimated the copy number 
associated with the #66 and #72 transgenic cassettes.
In this project the ambition for the Southern analysis was the determination of 
zygosity and thus experiments were not required for quantitative hybridisation 
analysis. It was considered unnecessary to achieve a quantitative analysis as the 
experimental design is more complex and is not easily achieved using 
autoradiography - the technology available (Darling and Brickell, 1994). Using a 
suitably labelled probe (lO M o^ dpm pg“l) approximately 0.5pg of target DNA can 
be detected which for a single copy of a 500bp sequence, in the human genome, is 
equivalent to 3.3pg of DNA (Brown, 1997). Consequently to emphasise 
hybridisation differences Southern analyses were performed at the lower limits of 
detection (5pg) at which over saturation of the autoradiograph was less likely. This 
resulted in weak signals from wild type mice which was not considered significant 
as the status of these mice was identified by PCR. The ability to assess confidently 
differences in hybridisation were an important aspect o f this project and of 
particular significance in assessing the zygosity o f #72. Here the difference 
between hemizygous and homozygous is only 3 copies, and at the limits of 
resolution for this approach and as a consequence samples from mice in which 
identification was not clear cut were rejected for further study.
The technical requirements for accurate estimation of transgene copy number could 
not be fulfilled and this was not undertaken. There, however, exists the possibility 
for changes to occur to the transgenes. This includes changes in copy number and 
the present study does not address this specifically, other than by not observing 
changes in the established phenotypes. The late onset phenotype, which had not 
been noted previously, was observed in litters of mice in which the phenotype of 
homozygous mice was as expected.
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*  w MM
Figure 8. Assessment of the quality of gDNA extracted from fresh (lanes 1-3) 
and frozen (lanes 4-6) mouse tails with the QIAamp Tissue kit. Lanes: 1 and 4 
gDNA incubated at room tem perature; 2 and 5 incubated at 37°C in the 
presence of buffer and the absence of enzyme; 3 and 6 B am \\\ digest at 37°C; 7 
X Hin d ill  m arker showing undigested gDNA as a tight population of molecular 
weight 23Kb. The frozen tail sample had been stored for 14 months at -20°C.
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3'UTR T7 #66 and #72 c a sse tte s
3'UTR .-------------------- ^  endogenous Pip gene
a)
3ATT 3B P/ptag1
3A Dm20tag2
3A 3B intron 3
b)
endogenous 
Pip gene
Figure 9. The position of primers (red sense, blue a  sense) to produce a 
transgene specific product from genomic DNA to identify mice carrying the #66 
/ #72 transgene and PlpTagl and Z>/w20Tag2 transgenes.
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Figure 10. Products of PCR reactions used for identification of #66/#72, 
/VpTagl and Z)/w20Tag2 transgenes. Lane 1 wild type, lane 2 #66 (400bp), lane 
3 #72 (400bp), lane 4 P/pTagl (412bp), lane 5 Dm20Tag2 (307bp), lane 6 wild 
type. PCR in lanes 1-3 was performed with the Plp-Tl prim er pair and PCR in 
lanes 4-6 with the P/p:Dm20 primer pair (see Table 5, Page 85). M arker lOObp 
ladder.
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The PlpiP mutation results in the loss o f  a DdeI restriction site at the intron 4/exon 5 
boundary due to an a—»g substitution. Dde I recognises the sequence C T N A G
wild type sequence accttag/GT (lower case denotes intronic sequence)
PlpJP sequence atcttgg/GT (mutation in bold)
PCR product with Dde I sites (— ! — ) and restriction product sizes (bold)
159 JP 75 24
0 159 234 258
The mutated Dde I site is marked {JP).
a)
- 6 0 0  bp 
—100bp
b)
Figure 11. Identification of PlpJP carrier females by PCR of gDNA and 
subsequent Dde I digest, a) explanation of how the loss of a Dde I restriction site 
can be used to identify the PlpiP allele; b) gel showing: lane 1 undigested 
product, lane 2 wild female (both alleles digested), lane 3 PlpJP heterozygote 
female with PlpiP (undigested*) and wild type Pip alleles (digested), lane 4 PlpJP 
male with one PlpJP allele (undigested*) and lane 5 lOObp ladder. *a 24bp 
fragm ent is produced
-  1 2 3 4  5
1
S
87
Genotyping and breeding of transgenic mice
c)
Figure 12. Examples of autoradiographs of Southern blots using probe B6. All 
samples are run as pairs and lanes are numbered in pairs, a) #72 mice: lane 1 
homozygous, lane 2 homozygous, lane 3 wild type and lane 4 hemizygous; b) 
#66 mice: lane 1 homozygous, lane 2 wild type, lane 3 wild type, lane 4 
hemizygous and lane 5 hemizygous. Lanes 1 and 4 are relatively overloaded as 
can be seen in c) the gel photograph. The strong hybridisation signal to the left 
of lane 1 represents non-specific binding to the lOObp ladder.
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4. Late onset neurodegeneration in 
mice hem izygous for the #66 and #72 
transgenes
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4.1 Background
At the inception of this project there was limited information concerning the effects 
o f increased Pip gene dosage on mice hemizygous for the #66 and #72 transgenes. 
Specifically they had not been recognised as having an abnormal phenotype, in 
contrast to their homozygous littermates, though they were thought to be mildly 
dysmyelinated and have Pip mRNA levels greater than both homozygous and wild 
type mice in adulthood (Readhead et al, 1994). Late onset disease had, however, 
been observed in Dm20 minigene transgenic mice (Mastronardi et al., 1993). A 
demyelinating phenotype was also observed in hemizygous 4e mice (Inoue et al., 
1996; Kagawa et al., 1994). Thus it was considered that hemizygous #66 and #72 
mice were potential candidates for developing neurological abnormalities.
Litters of hemizygous mice and their wild type littermates were allowed to age and 
observed for the development of phenotypic abnormalities. Neurological 
abnormalities developed in mice over about 12 months of age.
4.2 Aims
The aims of this work were to describe myelination in hemizygous mice, confirm 
the late-onset nature of the development of the neurological abnormalities and 
examine transcription of Pip and other selected genes in relation to the development 
of phenotypic abnormalities. Mice were sampled around the peak of myelination 
and time points representing early and late adulthood. Older mice with and without 
clinical signs were examined to assess the abnormalities associated with the 
development of neurological signs and in particular how the glial population were 
affected. The development of the neurological phenotype is associated with 
increased cellularity of the affected tissues. Though morphologically many of these 
cells appear to be microglia it has been speculated that in 4e mice (Inoue et al., 
1996) there may be an immune component, accordingly studies were undertaken to 
assess whether there is an associated T cell response.
4.3 Methods
The developmental studies were performed at P20 (peak of myelination) and P60 
(early adulthood). Tissues were procured for glial cell quantification; myelin 
morphometry; assessment of the transcriptional output of the combined endogenous
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and exogenous Pip genes and other myelin genes; assessment of the distribution of 
myelin proteins and other proteins; description of the extent of pathological change. 
Tissues from older transgenic mice with neurological signs and their non-transgenic 
(wild type) littermates were collected.
Glial cell counts were also undertaken in younger animals to characterise further the 
development of the glial cell population.
ISH for Pip gene transcripts was used to examine the oligodendrocyte population 
both during development and assess qualitatively the effects of the pathology on 
population numbers and Pip gene transcription.
As an indication of myelin gene transcription the steady state mRNA levels o f the 
Pip, Mobp and Mbp genes were assessed by northern hybridisation in addition to 
RT-PCR determination of Plp:Dm20 ratios.
4.3.1 Mouse breeding
The breeding and identification of #66 and #72 transgenic and wild type mice for 
these experiments is described in 3 Genotyping and breeding of transgenic mice, 
page 76.
4.3.2 Preparation of tissue
The preparation of tissues for resin and paraffin wax embedding, frozen sections 
and electronmicroscopy is described in 2.1 Tissue fixation and processing (page 43). 
The extraction of RNA is described in 2.5.1.2 The isolation and storage of RNA 
(page 49).
4.3.3 Histopathology
A survey of the nervous system was undertaken on 1 pm resin sections stained with 
methylene blue/azur and on paraffin sections stained with H&E. The resin sections 
give excellent visualisation of myelin and cell morphology.
4.3.4 Immunocytochemistry
4.3.4.1 Immunostaining for myelin proteins
Immunostaining for myelin proteins (PLP/DM20, MBP, MAG) and GFAP was 
performed on both resin, paraffin embedded sections and frozen sections. The 
protocols are summarised in 2.9 Immunocytochemistry (page 68) and the details of 
the antibodies, link antibodies/fluorescent conjugates and their sources are presented
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for the PAP technique in Table 3 (page 70) and Table 4 (page 71) for fluorescent 
techniques.
Protocols for microglial and T cell immunostaining are described below.
4.3.4.2 Immunostaining for microglia
Sections for immunostaining for microglia were prepared from mice perfused with 
periodate-lysine-paraformaldehyde fixative (2.1.1.3 Periodate-lysine-
paraformaldehyde, page 43) and the tissues cryo-preserved with sucrose (2.2.3 
Cryo-preservation, page 44). Details o f the antibody, secondary antibodies and their 
sources are given in Table 6 (page 107).
Slides were thawed and allowed to dry. All incubations were carried out at room 
temperature. Endogenous peroxidase activity was quenched by immersing the 
sections in 0.3% hydrogen peroxidase for 20 mins. Sections were washed in PBS 
for 30 mins to remove embedding medium. Non-specific binding was blocked by 
incubating in 1% rabbit serum for 30 mins. Excess serum was blotted off and the 
sections incubated in the primary antibody, F4/80, for 60 mins. Excess antibody 
was removed by two 10 min washes in PBS. Sections were incubated in the 
biotinylated secondary antibody for 45 mins and washed for 30 mins in PBS. An 
avidin DH/biotinylated horseradish peroxidase system was used to label the 
immunocomplexes and these were visualised by incubating in DAB. Sections were 
osmicated in 0.1% osmium tetroxide to enhance chromogen intensity and washed 
thoroughly in water. Sections were counterstained, dehydrated and mounted in 
DPX.
4.3.4.3 Immunostaining for T ceils
Sections for immunostaining for T cells were prepared from mice perfused with 
periodate-lysine-paraformaldehyde fixative and the tissues cryo-preserved (see 
above). Details of the antibodies, secondary antibodies and their sources are given 
in Table 6 (page 107).
Slides were immunostained for a small panel of T cell markers with the aim of 
identifying the presence of T cells. Due to the difficulty of producing suitable 
control CNS tissue splenic tissue was used as a control. Markers were chosen to 
identify the two broad categories of T cell - CD4 (“helper”) and CD8 (“killer”) 
cells. The panel also included CD45, a pan leukocyte marker that also identifies 
macrophage lineage cells including microglia, and CD3, a pan T cell marker.
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Slides were thawed and allowed to dry. Sections were permeabilised with 0.1% 
Triton-X in PBS for 5 mins and washed in PBS. Non-specific binding was blocked 
with 10% rabbit serum in PBS for 30 mins. Excess serum was blotted off and the 
sections incubated with the primary antibodies in 2% rabbit serum over night at 
room temperature. Excess antibody was removed by washing in PBS for 5 mins. 
Incubation with the secondary antibody was for 45 mins and followed by a 5 min 
wash in PBS. An avidin DH/biotinylated horseradish peroxidase system was used 
to label the immunocomplexes and these were visualised by incubating in DAB 
(Fast DAB, Sigma) for 60 secs. Counterstaining was with Harris’s haematoxylin for 
1 min and the excess washed off in water. Sections were dehydrated and mounted in 
Micromount (Surgipath).
4.3.5 Myelin morphometry, ultrastructure of myelin and glial cells
Quantitative measurements o f myelin thickness and density were made at P20 and 
P60 as described in 2.10 Morphometry (page 72). The data for axonal diameter and 
g  value were pooled for the three genotypes of mice. The morphology o f glial cells 
was examined at both these ages and also in aged mice.
4.3.6 Glial cell quantification
Total glial cell density was quantified as described in 2.10.1 Glial cell quantification 
(page 72).
4.3.7 Dead cell density
The density of dead cells in cervical cord white matter was quantified as described 
in 2.10.1.1.1 Dead cell density (page 73).
4.3.8 Transcript analysis
4.3.8.1 Northern analysis
These experiments were performed on total cellular RNA extracted from whole 
brain. The procedure of northern transfer is described in 2.5.4.2 Northern blotting 
(page 56). Hybridisation analysis was undertaken using labelled DNA fragments 
for the detection of message from the following genes: Pip, Mobp and Mbp (see 
Figure 13, page 108). PLP-1 is a 449bp fragment released from the plasmid PLP- 
p27 (Milner et al., 1985) which recognises the three Pip gene message isoforms, 
with the major band being ~3Kb in the mouse. MOBP is a 1.3Kb fragment released 
from the plasmid pMMSV2 (this clone contains the cDNA for the 81aa protein 
isoform) (Montague et a l, 1997) which because it contains sequence common to all
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Mobp message isoforms recognises 5 message species, with the most abundant 
species being 2.4Kb in the mouse. MBP is a 1400bp fragment released form the 
plasmid pSP64MBP (Mentaberry et al., 1986) recognising a major band of ~5Kb.
The preparation of radiolabelled probes is described in 2.7 Preparation of 
radiolabelled probes (page 61). Equivalence of transfer was undertaken by routine 
methylene blue staining of northern filters and hybridisation with probe for murine 
7S ribosomal RNA as a measure of invariant temporal expression. 7S is a 400bp 
fragment released from the plasmid pA6 (Balmain et al., 1982) (see Figure 13, page 
108).
4.3.8.2 Semi-quantitative RT-PCR for Plp:Dm20 ratio
The cDNAs for these experiments was prepared from whole brain as described in
2.5.4.1.2 cDNA preparation (page 55). The protocol of these experiments is 
described in 2.5.4.1.3 RT-PCR (page 56). Experiments were performed using the 
Pip gene exon 2—>4 primers (see Table 2, page 58). This primer pair produces 
separate products for the Pip and Dm20 message isoforms as they encompass the 3B 
portion of exon 3, which is spliced out in the Dm20 message isoform. Their use for 
semi-quantitative PCR for the assessment o f the Plp:Dm20 message isoform has 
previously established (Dickinson, 1995).
4.3.8.3 In situ hybridisation
In situ hybridisation studies of cervical spinal cord were performed at P20 and P60 
with studies o f cervical cord and brain in aged mice. Hybridisation was with the 
PLP-1 probe. The ISH technique is described in 2.8 In situ hybridisation (ISH) 
(page 62).
4.3.9 CNS protein analysis
Protein were extracted from whole brain and analysed by western blot (see 2.6 
Analysis o f proteins, page 60). Blots were immunostained for PLP/DM20 using the 
C-terminal antibody PLP226 (see Table 3, page 70).
4.4 Results
Unless otherwise stated hemizygous mice are compared to their non-transgenic litter 
mates (otherwise referred to as wild type).
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4.4.1 Phenotypic characteristics
4.4.1.1 Growth
At P60 the body weights of hemizygous #66 and #72 mice were not significantly 
different from wild type (p=0.9525). However, the weight o f hemizygous mice 
older than P300 was significantly less than that of wild type mice (p=0.0001) 
(Figure 14, page 109). Interpretation of this result must take into consideration that 
many, but not all, of the hemizygous mice were selected for sampling because they 
exhibited neurological abnormalities. There also likely to be an age related change 
in mouse body weight.
4.4.1.2 Neurological abnormalities
Hemizygous mice were phenotypically unremarkable for many months and they 
reproduced normally. Around 12-18 months o f age progressive neurological signs 
developed, principally tremor and ataxia. Both sexes were affected. Affected mice 
became weak and appeared to have reduced grip strength. Seizures were a late 
feature in the progression of signs but probably important in the terminal stages of 
the phenotype. A consistent finding at post-mortem in mice with advanced 
neurological signs was a distended, full bladder implying urinary retention. Such 
mice also commonly had urine staining of the perineal region. Subjectively many 
animals with advanced disease had impaired vision.
4.4.2 Pathology of neurodegeneration
4.4.2.1 Nature of neurodegeneration
Hemizygous mice older than P60, with or without phenotypic signs, showed 
evidence of pathology, most obviously in their optic nerves (see 4.4.2.2 Distribution 
of lesions, page 96). Brains of affected mice showed varying degrees of
hydrocephalus involving the lateral ventricles with the loss o f myelin being obvious 
to the naked eye (see Figure 15, page 110). Light microscopy demonstrated diffuse 
vacuolation of both the grey and white matter, which could reach dimensions of 
1mm or more, and was occasionally visible to the naked eye. Immunostaining and 
EM studies (data not shown) showed that these vacuoles arise from distension of the 
myelin sheath (Figure 17, page 114).
The affected regions were characterised by gliosis, demyelination and axonal 
degeneration. There was no inflammatory infiltrate or perivascular cuffing (with 
lymphocytes or neutrophils) and macrophages were not observed within the 
degenerating myelin. The dominant process varied between areas with
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demyelination being predominant in the optic nerve and axonal degeneration being 
the primary process in the spinal cord.
Demyelination was associated with the formation of large loops of redundant 
myelin. Axonal degeneration was demonstrated by axonal swellings and frank 
Wallerian-type degeneration of the axon and myelin sheath. Degenerate myelinated 
axons were characterised by whorls of myelin debris and axonal fragments. There 
was no proximal/distal selectivity of fibre degeneration within a tract; for example 
corticospinal tracts were affected at all levels of the spinal cord. Loss o f axons was 
implied from observing extensive areas of white matter consisting o f astrocytic 
processes. Numerous reactive microglia were present in the more chronic lesions 
(see .
Light microscopy of the sciatic nerve and muscles of the hindlimb of aged 
hemizygous mice was unremarkable (data not shown).
4.4.2.2 Distribution of lesions
White matter changes were observed in all phenotypically affected animals, 
however, during myelination and early adulthood the CNS of the hemizygous mice 
was indistinguishable from that of wild type littermates. As the mice aged the 
development o f lesions was notable for the tract specificity. Initially small fibre 
tracts are specifically targeted, as indicated by the early involvement o f the optic 
nerve. Subtle abnormalities of myelin, which may represent early changes, are 
detectable in the optic nerve at P60, however, similar changes can also be 
occasionally detected in wild type optic nerve at the same age. By P120 optic nerve 
changes are well established. Ventral column abnormalities are not seen without 
concomitant abnormalities of the dorsal columns and optic nerves whilst 
abnormalities of the dorsal columns are observed in the absence of ventral column 
pathology. This suggests that the changes observed in the dorsal columns of the 
spinal cord involving the deeper regions of the lateral columns, fasciculus gracilis 
and corticospinal tracts at around P365, represent the next stage of progression. The 
larger fibres o f the ventral funiculus and fasciculus cuneatus in the dorsal columns 
were spared, though occasional small diameter fibres were degenerating. The final 
stages of progression in the spinal cord involve the ventral columns. The 
development of neurodegeneration in the spinal cord is illustrated in Figure 16, 
pages 111-113.
The changes were progressive and associated with the eventual involvement of the 
majority of the CNS, including cerebellar and cerebral cortices, diencephalon, brain
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stem, the ventral columns of the spinal cord and also the grey matter of the spinal 
cord.
4.4.3 Glial cell density
Total glial cell densities are presented in Figure 18, page 115.
The data suggests that at P20 the total glial cell density is significantly greater in 
#72 hemizygous mice (p=0.0424), whilst this difference is no longer apparent at P60 
(p>0.05). In #66 mice the data suggests that the glial cell density is greater at P10 
(wild type values = 225 cells mm'2 and 232 cells mm"2 and median hemizygous = 
271 cells mm'2) and is similar to wild type at P20 and P60 There is no significant 
differences between wild type and either of the lines of hemizygous mice at P60 
(p>0.05).
Total white matter glial cell numbers are presented in Figure 19, page 116. Though 
white matter areas appear similar for hemizygous and wild type mice (see below) 
the increase in total glial cell numbers suggested by the increase total glial cell 
density is not as apparent.
A striking feature o f aged hemizygous #66 and #72 mice is the gliosis affecting the 
degenerating white matter tracts. Morphologically, the predominant cells types 
appear to be microglia (Figure 20, page 117) and astrocytes. At P120 examination 
of degenerating tracts suggested an increased glial cell density but this is not 
strongly supported by the total glial cell density. However, at this time point the 
ventral columns are not affected by neurodegeneration.
4.4.4 Dead cell density
At P20 the dead cells density in cervical cord white matter in #66 and #72 
hemizygous mice were not significantly different to wild type (p>0.05) (see Figure 
21, page 118) with medians of: wild type 0.72mm"2, #66 0 .48m m “2 ? #72 0.79mm_2.
4.4.5 Myelin morphometry
At P20 and P60 the area of the white matter, myelin volume and g  ratio appear 
indistinguishable from wild type (see Figure 22, pages 114-119) and no statistically 
significant differences were detected. Myelin sheath thickness did not appear to 
differ between wild type and hemizygous mice at either P20 and P60 and there 
appears to be some accumulation of myelin between these two time points in 
hemizygous #72 mice.
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4.4.6 Oligodendrocyte and axon ultrastructure
No abnormalities were observed in the oligodendrocytes of developing or young 
adult mice hemizygous for either #66 or #72 transgenes. The early changes of 
redundant myelin loops and distension of the inner tongue of oligodendrocytes in 
the optic nerve and spinal cord are shown in Figure 23 (page 121). In chronic 
lesions these was more extensive demyelination (principally in the optic nerve) and 
loss of axons, inferred from the increasing proportion of astrocytic processes, in the 
spinal cord (see Figure 24 pages 122-123). In aged animals with neurodegeneration 
the oligodendrocyte cell bodies and major processes remained morphologically 
unaffected, however, the adaxonal region of oligodendrocyte processes associated 
with non-degenerate fibres was often abnormal. Abnormalities ranged from 
distension with a granular amorphous material to vesicular degeneration. The 
abnormal features of oligodendrocytes from aged hemizygous oligodendrocytes are 
illustrated in Figure 25 (page 124).
4.4.7 Gene expression
4.4.7.1 Immunocytochemistry
Studies at P20 and P60 for PLP and MBP demonstrated the distribution and staining 
intensity of myelin proteins was indistinguishable from wild type (data not shown). 
In affected animals there was an obvious loss o f myelin-associated proteins in areas 
of neurodegeneration (e.g. MBP Figure 26, page 125).
Immunostaining for phosphorylated neurofilaments (NF) showed the presence of 
axonal swellings in many regions particularly the ventral medulla, Purkinje cell 
axons (torpedoes) and in the white matter of the spinal cord (Figure 26, page 125). 
Smaller spheroids were also observed in some regions of the basal nuclei (caudate 
nucleus and putamen) and in the cerebral cortex. Subjectively the occurrence of 
axonal swellings increased with the severity of phenotypic signs. Occasional 
neuronal perikarya, particularly in the deep cerebellar and reticular formation nuclei, 
contained phosphorylated NF. Areas of demyelination showed a reduction in 
immunostaining inferring a loss of axons from the loss of phosphorylated epitopes. 
These axonal changes are illustrated in Figure 26 (page 125).
Staining for microglia demonstrated an increase in microglia in white matter tracts 
of the brain (Figure 27 page 127). The microglia in these tracts exhibited changes in 
morphology, including hypertrophy of the soma and a reduction in the length of 
processes, consistent with a change to an activated status (Gehrmann and 
Kreutzberg, 1995).
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Immunostaining for CD45 showed a general increase in immunoreactivity in white 
matter tracts in the aged hemizygous #66 and #72 mice, whilst T cell specific 
immunostaining (CD3, CD4, CD8) was sparse, with occasional positive cells in the 
white matter. CD45 positive cells with the morphology of lymphocytes were also 
sparse suggesting that the hypercellularity was not due to B cell lymphocytes. The 
CD45 immunoreactivity is likely to represent immunostaining of the microglial 
processes. The features of immunostaining for T cells is presented in Figure 28, 
pages 129-130
The integrity o f the periaxonal space is indicated by the presence of 
immunoreactivity for MAG. Immunostaining for MAG was deficient in regions 
containing degenerate or demyelinated fibres but present where fibres remained 
intact (Figure 26, page 125).
Immunostaining for GFAP indicates are consistent with an increase in astrocyte 
processes and probable reactive astrocytosis (Figure 26, page 125).
4.4.7.2 Transcript analysis
4.4.7.2.1 Northern hybridisation
Transcription of the myelin genes Pip, Mobp and Mbp was examined (Figure 29, 
page 131). Hybridisation to S7 ribosomal RNA was used as a control for invariant 
temporal expression. All bands conformed to the predicted sizes based on the 
positions relative to the 28 and 18S ribosomal markers (which are shown for the 
Mbp hybridisation, panel d). At all ages the steady state levels of Pip gene mRNA 
(panel a) and the other selected myelin genes (panels c and e) were greater than wild 
type, though at P20 in hemizygous #72 this increase is equivocal. This persisted 
even in animals that were in the terminal stages of the disease (panels a and c, lane 
7). In #72 hemizygous mice at P20 and P60 (data not shown) Pip (panel a, lane 2) 
and Mobp (panel c, lane 3) transcript levels were only slightly greater than wild type 
whilst in aged animals they were equivalent to #66 mice (panels a and c, lane 4 wild 
type, lanes 5 and 6 #66, lane 7 #72).
4.4.7.2.2 Plp\Dm20 ratio
The Plp\ Dm20 ratio were examined by RT-PCR using cyclophilin as a control for 
invariant temporal expression, the levels of which are reasonably constant across the 
spectrum of ages and genotypes (panel b (i) and (ii) Figure 29, page 131). The 
Plp\Dm20 ratio was unaltered from that in wild type (lane 1 P20 and lane 4 aged) in 
myelinating and aged hemizygous mice (lane 2 #72 P20, lane 3 #66 P20, lane 5 #66
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aged, lane 6 #72 aged). The amount of Plp:Dm20 message was markedly increased 
in #66 hemizygous mice (lanes 3 and 5) at all ages whilst the increase in #72 
hemizygous mice was at P20 is equivocal. These findings were consistent with the 
northern hybridisation data.
4.4.7.2.3 In-situ studies
At P20 (data not shown) and P60 hemizygous mice adequate numbers o f Pip gene 
expressing cells are present. In aged mice the oligodendrocyte population of the of 
the brain and spinal cord (data not shown) were qualitatively equivalent to, if  not 
greater than wild type, with the signal per cell also being equivalent or possibly 
increased (Figure 30, page 133). The distribution of positive cells was 
indistinguishable from wild type and was predominantly in the white matter regions.
4.4.7.3 Myelin proteins
In aged hemizygous mice there was a variable increase in both protein isoforms 
(Figure 29, page 131). These changes perhaps reflect the variable nature of the 
phenotype. However, the PLP:DM20 protein isoform ratio appears to be unaltered 
from wild type.
4.4.8 Summary
The morphological development of the myelin sheath in hemizygous #66 and #72 
mice was essentially indistinguishable from their wild type litter mates. The only 
observed difference was an increase in total glial cell density during myelination in 
hemizygous mice.
The late onset neurological phenotype was related to progressive demyelination and 
axonal degeneration. The distribution of pathology showed a marked predilection 
for small diameter fibres with larger diameter fibres becoming involved only in the 
later stages.
At all ages examined, including mice in the terminal stages, the expression of 
myelin genes was greater than in wild type (P20 hemizygous #72 requires further 
characterisation to confirm an increase in Pip gene transcription). Subjectively 
oligodendrocyte numbers were maintained in animals with neurodegeneration (and 
possibly increased) and likewise the production of Plp/Dm20 message by individual 
oligodendrocytes was maintained.
Oligodendrocyte cell bodies and major processes were morphologically normal at 
all ages. However, in aged hemizygous mice there were abnormalities of the
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adaxonal region in which there was accumulation of abnormal cytoplasm in the 
inner tongue.
There was no evidence of the neurodegeneration being due to a primary 
inflammatory event though there was a microglial and astrocytic response to the 
neurodegenerative process. Though lesions were hypercellular, cells with the 
morphology of lymphocytes represented a very small proportion o f the total 
population and there was a very sparse T cell infiltrate. There was no perivascular 
cuffing, a common finding with acute inflammation where cells are attracted from 
the circulation. Macrophages were not observed within the myelin sheath, another 
common feature of inflammatory demyelination.
4.5 Discussion
The data presented in this chapter demonstrates that normal myelin development 
and myelin maintenance can be achieved in the face o f the upregulated myelin gene 
transcription found in the #66 and #72 hemizygous mice. However, in the long term 
this is associated with perturbations of not only the myelin sheath but also o f axons. 
The phenotype is different to that in mice homozygous for these transgenes, which 
is characterised by dysmyelination (see 5.6 Discussion, page 144). However, 
demyelination and axonal degeneration also develop in homozygous #66 and #72 
mice superimposed on their dysmyelinated background, and with an accelerated 
time course (see 5.6 Discussion, page 144).
Late onset demyelination has now been described in other examples o f Pip gene or 
minigene transgenic mice (see 1.4.2.4Evidence that increased Pip gene dosage 
affects myelination, page 38). The relationship between gene dosage, transcription 
and protein levels is complex and increased copies of a gene do not necessarily 
result in a predictable increase in gene transcription. In my studies the hemizygous 
#66 mice have a greater level of steady state mRNA than their homozygous 
littermates (see Figure 53, page 194). In hemizygous #66 mice the increased gene 
dosage is reflected in an raised steady state levels of Pip message which persists 
throughout life. In hemizygous #72 mice myelin gene transcription increases with 
age implying a change in myelin gene regulation or mRNA stability. In situ 
hybridisation studies suggest some increase in oligodendrocyte numbers in aged 
hemizygous animals but this not of the same magnitude of the increase in message 
levels, suggesting that the increase observed in bulk brain RNA is due to an increase 
in transcription or mRNA stability. This is supported by an apparent increase in 
signal intensity per cell on in-situ studies. Quantification of in-situ studies in
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relation to both cell numbers and transcript level is complex due to the profound 
effects o f many aspects of the procedure on the final autoradiograph. Increased 
levels o f Pip transcripts are associated with an elevation in the steady state levels of 
message for other myelin genes {Mbp and Mobp) suggesting a change in the co­
ordinate expression of myelin genes. The effect o f Pip gene copy number on other 
myelin genes has not been well described though in hemizygous Ae mice Mbp 
mRNA is reported to be reduced at P I9, though this may be related to the reduced 
number o f oligodendrocytes (Kagawa et a l, 1994). Increased myelin production, 
due to increased oligodendrocyte activity, is seen in mice with increased copies of 
IGF-1 and is not associated with a neurological phenotype (Carson et al., 1993). 
The data presented here flags the possibility that other genes involved in myelin 
elaboration and maintenance, not examined here, may also have had their pattern of 
expression altered. The significance of the apparent upregulation o f other myelin 
genes in the development of neurodegeneration in the hemizygous #66 and #72 
mice is uncertain.
A predominant feature of the phenotype is a gliosis due to increased numbers of 
astrocytes and microglia. The significance o f the these cell types in the 
development o f the lesions is uncertain. Astrocytosis is a common feature of many 
o f the myelin mutants (see 1.3.2.1 Animal models page 26) and is thought to be a 
secondary phenomenon (Bignami and Dahl, 1995). Astrocytes are known to have 
many functions including the secretion of cytokines and involvement in antigen 
presentation. Microgliosis, in the absence of lymphocyte infiltration, is now thought 
to be evidence o f chronic inflammation within the CNS (Perry, 1994). Little is 
known about the state of microglia in aged mice, however, in aged rats they exist in 
a comparatively upregulated state and it has been postulated this may exacerbate the 
response to inflammatory stimuli (Perry et al., 1993). A demyelinating phenotype 
was observed in transgenic mice over-expressing interlukin-3 (IL-3) in which there 
was a marked microgliosis, but the pathological features described were distinct 
from those observed in hemizygous #66 and #72 mice and involved 
microglia/macrophages invading myelin with the axons remaining largely 
unaffected (Chiang et al., 1996).
The significance of the apparent increase in total glial cell density in developing 
hemizygous #66 and #72 mice is uncertain. Sampling at other earlier time points 
would help confirm its presence and determine its magnitude. Quantification of the 
nature of the cell types involved is complicated by the difficulty o f confidently 
assessing cell type at younger ages (Skoff, 1990), one approach would be the 
quantification of ISH to identify Pip gene transcribing cells, though accurate 
quantification can be difficult to achieve. Another is the use of oligodendrocyte
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specific immunostaining (Carson et a l, 1993). The dead cell density in both types 
of mice at P20 was indistinguishable from wild type, though potentially it may be 
elevated at younger ages. An increase in total glial cell density is also seen in 
developing homozygous #66 and #72 mice, which is associated with a probable 
increase in dead cell density (see 5.6 Discussion, page 144).
Demyelination affected primarily tracts composed of small diameter axons. The 
loss of myelin occurs in the presence of a apparently adequate numbers of 
oligodendrocytes, which even in the most extreme manifestation of the phenotype 
continue to transcribe myelin genes. The cell bodies and major process were 
morphologically unaffected though there were abnormalities o f the adaxonal 
cytoplasm, not present in younger animals. It is uncertain whether this age-related 
change represents a primary perturbation of the oligodendrocyte/axon interface or is 
a result of the demyelinating process. Accumulations of cytoplasmic elements in 
the adaxonal region is a non-specific phenomenon occurring in the “dying-back 
oligodendrogliopathy” which can occur following the administration o f exogenous 
toxins (Blakemore, 1972), is seen as a late sequel to MAG deficiency (Lassmann et 
al, 1997) and has also been described in inflammatory demyelinating lesions 
(Ludwin, 1997), however, a dying-back oligodendrogliopathy does not necessarily 
result in axon degeneration. The dying-back oligodendropathy may indicate 
primary oligodendrocyte dysfunction though changes in the soma are minimal and 
indicates how cells with extensive transport and cytoskeletal functions are 
vulnerable to injury (Ludwin, 1997). Vacuolation of myelin is also a non-specific 
finding associated with a number of aetiologies and may be associated with minimal 
oligodendrocyte abnormalities (Blakemore, 1972). Myelin vacuolation and 
redundant loops of myelin is a feature of mice with extra copies o f the Cnp gene 
(Gravel et a l, 1996) and in HIV-1 transgenic mouse a vacuolar myelopathy is seen 
in spinal cord (Goudreau et a l, 1996). Demyelination primarily affected small 
diameter axons.
In tracts affected by demyelination many myelin sheaths exhibit focal myelin 
thickening and loops of redundant myelin. The aetiopathogenesis o f these aberrant 
myelin structures is uncertain. They could potentially reflect a number of 
derangements of myelin and/or the axon including: perturbations o f myelin 
turnover; unravelling of the myelin sheath and axonal atrophy. O f these 
possibilities investigations into myelin turnover would be the most straight forward 
to pursue. Axonal atrophy as an event proceeding myelin loss does not seem likely 
from the initial morphometric analysis of the ventral columns. Investigations would 
require following the distribution of axon diameters as the phenotype progressed 
and as discussed below this would be complicated by its very variable nature.
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The axonal degeneration also affects small diameter axons. The axonal pathology 
in the hemizygous #66 and #72 mice includes Wallerian-type degeneration and the 
development of axonal swellings (or spheroids). It is also possible that previously 
demyelinated axons also degenerate although their detection is problematical. 
Axonal degeneration and swelling is not generally a significant feature of the 
dysmyelinating Pip gene mutants though it is described in PlpJP and md-rat, and 
also in qk and Mbps^  mice, though in these later mutants it involves the 
accumulation of different organelles (Rosenfeld & Friedrich, Jr. 1983; Hirano et a l, 
1969). Immunocytochemistry shows the axonal swellings contain phosphorylated 
NFs and the accumulation of NFs was confirmed by electronmicroscopy. The 
development o f axonal swellings is a non-specific finding and probably implies 
perturbations in axonal transport of NF proteins. It has been suggested that in 
myelin mutants axonal swellings are a result of myelin deficiency (Rosenfeld & 
Friedrich, Jr. 1983) but this would not appear to be the case in the hemizygous 
transgenic mice (they are also not a feature of the dysmyelinating homozygous #66 
mice, which are lacking in myelin). The accumulation of NFs may result in axonal 
dysfunction as suggested for motor neurone disease (Lee et a l, 1994) and could 
contribute to the neurological phenotype.
The relationship between demyelination and axonal degeneration in the hemizygous 
#66 and #72 mice is not clear. It is well recognised that the development and 
integrity of the axon and its myelinating glial cell are interdependent (De Waegh et 
al, 1992; Kirkpatrick & Brady, 1994; Sanchez et a l, 1996; Aguayo et a l, 1979). 
Axons do not necessarily degenerate following acute loss of myelin although in 
chronic demyelination associated with MS plaques axonal loss may be significant 
(Ferguson et a l, 1997; McDonald, 1994). Affected hemizygous #66 and #72 mice 
contain profiles of degenerating myelin typical of those found in Wallerian-type 
degeneration. This suggests degeneration of an axon with a previously intact 
myelin sheath, indicating that prior demyelination is not necessary for axonal 
degeneration. However, it is less easy to recognise degeneration of a demyelinated 
axon which will be phagocytosed rapidly, leaving little evidence o f its previous 
existence. The presence of marked astrocytic scars and reduced axon numbers in 
tracts where demyelination is known to occur suggests that demyelinated axons 
have degenerated. It is therefore probable that axonal degeneration occurs in the 
hemizygous mice both with and without prior demyelination.
The very specific nature of the pathology is intriguing. It not only affects fibres o f a 
specific diameter but also exhibits a temporally related, tract specific nature 
implying heterogeneity within the white matter of the CNS. The heterogeneity of 
CNS myelin has been described with differences between regions o f brain and also
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between brain and spinal cord (Norton and Cammer, 1984) and 
immunocytochemistry suggests there is a difference in the amounts of the 
PLP/DM20 protein isoforms present in myelin of large and small fibres (Hartman et 
a l, 1982)- Morphological heterogeneity of the oligodendrocyte population is well 
recognised, with different subtypes being typical of different regions o f the CNS 
(Wood and Bunge, 1984), although the relative contributions o f axon and 
oligodendrocyte to the morphology of the mature cell remains unresolved (Szuchet, 
1995). Butt et al (1995) have demonstrated both biochemical and morphological 
differences between oligodendrocytes myelinating small and large diameter axons. 
It is therefore possible that the distribution of pathology in hemizygous #66 and #72 
mice reflects differences between sub-groups of the oligodendrocyte population. 
Interestingly, the pattern of demyelination/degeneration is similar to that of 
dysmyelination seen in homozygous #66 mice with the later myelinating tracts 
being the most susceptible (Readhead et a l, 1994).
Abnormalities of the levels of myelin proteins have been described in Dm20 
minigene mice and our data shows that they are perturbed in aged #66 and #72 
hemizygous mice. In the Dm20 minigene transgenic mice abnormalities of the 
myelin proteins developed before the onset of a recognisable phenotype (Johnson et 
al., 1995). The PLP/DM20 protein isoforms in #66 and #72 mice are 
indistinguishable from wild type during myelination (data not shown) but show a 
variable increase in aged mice. Currently there are no data on how these changes 
are related to the progression of the phenotype. Interestingly, changes occur in 
MBP cationicity in the Dm20 minigene mice, a finding also observed in MS 
(Johnson et al., 1995), showing that the abnormalities of myelin composition extend 
to other myelin proteins. However, these changes may reflect a consequence of 
demyelination.
Further characterisation of the neurodegenerative process in hemizygous #66 and 
#72 mice would be complicated by the apparently large variation in the progression 
of the phenotype rendering the interpretation of information gathered at specific 
time points difficult. The investigation o f these mice using more sensitive 
parameters to gauge the development of neurodegeneration may be helpful in 
discerning the sequence of events.
In conclusion the data presented in this chapter confirms that mice hemizygous for 
the #66 and #72 transgenes develop a late onset neurodegenerative disorder. The 
observation that apparently normal myelination is achieved in mice with high levels 
o f Pip and other myelin gene transcripts suggest that the relationship between Pip 
gene dosage, levels of expression and perturbations of myelination is more complex
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than purely an increase in transcriptional output. The reasons for the crisis in 
phenotypic signs in affected mice, which develop relatively rapidly in relation to the 
prolonged period during which degeneration is known to be occurring, is unknown, 
but a potential factor is the microgliosis. The mechanism of neurodegeneration is 
unknown but it is likely that that the demyelination and axonal degeneration are the 
result of related but different processes.
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Figure 13. Schematic diagram of digests for the liberation of DNA fragments 
used for northern hybridisation, a) PLP-1; b) MOBP; c) MBP; d) 7S
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Figure 14. Body weight of mice hemizygous for #66 and #72 transgenes at P60 
and affected aged mice greater than P300 compared to wild type.
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c)
Figure 15. T ra n sv erse  sections o f  brain from  aged wild  type and h em izy g o u s  #66 and  
#72 mice, a) w ild  type  (P578); b) #66  (P 448) ataxia  and apathetic; c) #72 (P663)  
apathetic .  T hese  gross  sections illustrate loss o f  w h ite  m atter  (b) and (c) and  
h y d ro cep h a lu s  (c) in aged hem izygous  mice.
1 in
Late onset neurodegeneration in hemizygous mice
(i) (ii)
b)
Figure 16. T ract specific distribution of lesions in the development of 
deniyelination in #66 and #72 hemizygous mice, a) P60 optic nerve (i) wild 
type (x990) (ii) hemizygous (#66) (x990); b) P I20 optic nerve (i) wild type (750) 
(ii) hemizygous (#72) (x990). At P60 occasional abnorm al myelin sheaths are 
observed in hemizygous mice (—) whilst at P I20 there is obvious deniyelination 
in the optic nerves of hemizygous mice, with loops of redundant myelin being a 
common feature (—).
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(i)
c)
(i) (ii)
d)
Figure 16 (continued). T ract specific distribution of lesions in the development 
of demyelination in #66 and #72 hemizygous mice, c) P I20 dorsal columns 
spinal cord (i) wild type (\150) (ii) hemizygous (#72) (x99). d) dorsal columns 
(i) wild type (P365) (x75) (ii) hemizygous (P578, #72) (x99). At P120 the dorsal 
columns are unaffected. In older animals there is degeneration affecting the 
dorsal columns with abnormalities prim arily affecting the fasciculus gracilis 
(fg) and the corticospinal tracts (cst).
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Figure 16 (continued). Tract specific distribution of lesions in the development 
of deniyelination in #66 and #72 hemizygous mice, (e) demyelination of optic 
nerve in mouse with degeneration affecting optic nerve and dorsal and ventral 
columns of the spinal cord (i) wild type (P365) (\990) (ii) hemizygous (#66, 
P489) (x990); (f) ventral column demyelination (i) wild type (P365) (x75) (ii) 
hemizygous (#66, P489) (x75). Eventually all white m atter tracts examined 
showed evidence of neurodegeneration, with the ventral columns being 
amongst the last to be involved in the spinal cord.
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(a)
(b)
Figurel7. Vacuolation of the grey and white m atter in a hemizygous #72 
mouse stained for PLP/DM20. a) transverse brain section including 
corpus callosum and optic nerve (PLP226) (x9.9); b) PLP226
immunostaining (*) of vacuolation showing that the wall of the vacuole 
contains PLP (xl50).
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Figure 19. Corrected white m atter total glial cell count in cervical cord white 
m atter (segment C2) in hemizygous #66 and #72 mice with wild type, a) #66; b) 
#72.
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Figure 20. Microglia in area of neurodegeneration in aged hemizygous mouse 
(#72, P578) (x990). Corticospinal tracts of the cerv ical cord (C2). (-►) cells with 
microglial morphology.
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Figure 21. Dead cell densities in the white m atter of cervical cord in 20 day 
hemizygous #66 and #72 mice and their wild type litter mates.
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Figure 22. M orphometric analysis of myelin in the cervical cord of hemizygous 
#66 and #72 mice at P20 and P60. a) white m atter area; b) myelin volume.
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Figure 22 (continued). M orphometric analysis of myelin in the cervical 
cord of hemizygous #66 and #72 mice at P20 and P60. c) myelin sheath 
thickness; d) mean g  ratio.
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Figure 23. Electronm icrograph of the early changes associated with 
hemizygosity for the #66 and #72 transgenes, a) optic nerve (#72, P120) 
showing redundant myelin loops (scale bar lfim); b) ventral columns of 
spinal cord (#72, P583) showing redundant myelin loops, a demyelinated axon 
(^4) and a degenerating axon (da) (scale bar 2|um). In both tracts many sheaths 
are unaffected and there is little apparent loss of myelin.
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•v:
Figure 24. Electronmicrograph of the late changes associated with 
hemizygosity for the #66 and #72 transgenes, a) optic nerve (#66 P372). Many 
axons are demyelinated (—) and there is an increase in astrocytic processes (as). 
A demyelinated swollen axon is present, which contains many dense bodies ( ) 
(scale bar 1pm).
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Figure 24 (continued). Electronmicrograph of the late changes associated with 
hemizygosity for the #66 and #72 transgenes, b) area from the fasciculus 
gracilis of a chronic lesion in a hemizygous #72 (P583) mouse showing increase 
in astrocyte processes (as), activated microglia (m) and a loss of axons. 
Degenerating fibres are present (-►) (scale bar 2|um).
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Figure 25. Electronm icrograph of the abnormalities of the inner tongue of an 
oligodendrocyte from a mouse hemizygous for the #66 transgene (P372). There 
is distension with a granular material (g). The periaxonal space appears intact 
(scale bar lp.m).
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Figure 26. Inimunostaining for myelin proteins and phosphorylated NF-H 
(SMI-31) in areas of neurodegeneration in aged hemizygous #66 and #72 mice, 
a) reduction in PLP/DM20 (PLP226) in the optic nerve (#66, P448); b) 
cerebellar cortex showing molecular layer (m) and granule cell layer (g) with 
intervening Purkinje cells inimunostained for SMI-31, the Purkinje cell axons 
exhibit numerous torpedo swellings (—).
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Figure 26 (continued). Changes in the im m unostaining for myelin proteins and  
ph osphorylated NF-II (SM I-31) in areas o f  neurodegeneration in aged hemizygous #66 and  
#72 mice, c) thoracic cord showing loss o f  im m unostaining in the degenerating corticospinal  
tracts (-►); d) dorsal columns at the junction o f  fasciculus gracilis (fg) and fasciculus cuneatus  
(fc) imm unostained for MAG dem onstrating the integrity o f  the periaxonal space; e) ventral 
colum ns o f  sam e mouse immunostained for M AG . Im m unostaining for M AG is lost in areas  
with axonal degeneration (fg) but retained in areas where myelinated Fibres are intact. In the 
ventral colum ns, which are unaffected, all fibres have a normal M AG positive periaxonal  
space.
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Figure 14. Microgliosis and astrocytosis in aged mice hemizygous for #66 
and #72 transgenes, a) F4/80 staining for microglia i) corpus callosum in 
wild type (P770) (x75); ii) microgliosis in corpus callosum of aged 
hemizygous mouse (#72, P572) (x75).
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Figure 27 (continued), b) sagittal section of brain immunostained with GFAP 
for astrocytic processes, (i) wild type (P546) (xlO); (ii) aged hemizygous (P365) 
(xlO).
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(c)
Figure 28. T cells in the brain o f  mice hemizygous for the #72 transgene, a) CD45  
imm unostaining showing general increase in immunoreactivity in the corpus callosum of  
aged hemizygous #72 mouse (P572) (i) compared to wild type (P770) (ii); b) CD8  
im m unostaining of  corpus colossi with no im m unoreactive cells; c) CD3 im m unostaining of  
corpus callosum with occasional positive cells ( -*►) (all \50).
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(iii) (iv)
Figure 28 (continued), d) immunostaining of the “T” cell region of the spleen 
as positive control for T cell antibodies (i) CD45, (ii) CD3, (iii) CD4 and (iv) 
CD8 (all x50).
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Figure 29. Expression of myelin genes in 20 day and aged mice and their wild 
type litterm ates showing autoradiographs of northern hybridisation, RT-PCR 
and western analysis, a) northern hybridisation with PLP-1 (i) and 7S (ii) at 
P20 (lane 1 wild type , lane 2 #66 and lane 3 #72) and in aged hemizygous mice 
(lane 4 aged wild type (P735), lane 5 #66 (P514, no overt phenotypic signs), lane 
6 #66 (P546, neurological abnormalities) and lane 7 #72 (P753, m oribund, 
terminal seizure); b) RT-PCR showing Plp:Dnt20 ratios at P20 (lane 1 wild 
type, lane 2 #72 and lane 3 #66) and in aged mice (lane 4 aged wild type (P546), 
lane 5 #66 (P514) and lane 6 (P546) Pip (P), Dm20 (D) and cyclophilin.
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e)
Figure 29 (continued). Expression of myelin genes in 20 day and aged mice and 
their wild type littermates showing autoradiographs of northern hybridisation, 
RT-PCR and western analysis, c) northern hybridisation for IMOBP at P20 
(lane 1 wild type, lane 2 #66 and lane 3 #72) and in aged mice (lane 4 wild type 
(P546), lane 5 #66 (P514, no overt phenotypic signs), lane 6 #66 (P546, 
neurological abnormalities) and lane 7 #72 (P753, neurological abnormalities); 
d) western analysis of protein extracted from whole brain immunostained for 
PLP/DM20 (PLP226) lane 1 #66 (P513, no phenotypic abnormalities), lane 2 #66 
(P538, mild neurological signs), lane 3 #72 (P546, no phenotypic abnormalities), 
lane 5 wild type (P546), lane 6 wild type (P546); e) northern hybridisation aged 
mice for MBP lane 1 wild type (P753), lane 2 #66 (P514) and lane 3 (P644);
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Figure 30. In-situ hybridisation (PLP-1) of transverse sections of brains from 
hemizygous mice at a) P60 (#66) (xlO) and b) aged (P754) (xlO). At both P60 
and in the aged brain there are apparently adequate num bers of cells 
expressing PlplDm20 message isoforms, with a possible increase in the num ber 
of expressing cells and message per cell in the aged animal.
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5. Dysmyelination and demyelination  
in mice hom ozygous for #66 and #72 
transgene ca sse ttes
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5.1 Background
In the first offspring generated from the #66 foundation animals it was observed 
unexpectedly that a proportion of the mice exhibited a neurological phenotype 
(Readhead et al., 1994). Affected mice had a tremor from the time of ambulation, 
quickly developed seizures, had stunted growth and died prematurely. 
Histopathological examination showed severe dysmyelination. The frequency of 
affected individuals within litters, in conjunction with Southern hybridisation 
analysis for Pip gene copy number, demonstrated that affected mice were 
homozygous for the transgene. It is this dysmyelinating phenotype, related to 
increased Pip gene dosage, that was the basis for this project.
It was subsequently shown that #72 homozygous mice also exhibited 
dysmyelination but more subtle in nature and that they also eventually developed 
seizures and died prematurely (compared to their non-transgenic littermates), but at 
a greater age than homozygous #66 mice.
5.2 Aims
The mechanism underlying the abnormalities in myelination observed in these lines 
of transgenic mice was unknown but their contrasting phenotypes suggested 
differences in the underlying cellular pathology. This study describes mice 
homozygous for #66 or #72 transgenes, with particular reference to the CNS glial 
cell population and the expression of myelin proteins. Unless otherwise stated 
homozygous animals are compared to their non-transgenic litter mates (also referred 
to as wild type).
Two time points were selected for more detailed study: P20 representing the period 
o f peak myelination; P60 representing the adult state which is also around the point 
o f death in homozygous #66 mice. #72 mice were also studied at P I20, at which 
point neurological abnormalities were established in some, but not all, mice.
5.3 Methods
The methods used are summarised in 4.3 Methods (page 90). References to the 
location of detailed descriptions of particular techniques are also given there.
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5.4 Results for homozygous #72 transgenic mice
5.4.1 Phenotypic characteristics
5.4.1.1 Growth
Male and female mice varied noticeably in body weight and as sample sizes were 
small the values for body weight are presented for each sex. Subjectively, #72 
homozygous mice were indistinguishable from their wild type and hemizygous litter 
mates and at P60 body weight of homozygotes was equivalent to wild type (Figure 
31, page 148).
5.4.1.2 Neurological abnormalities
Homozygous #72 mice lived free from gross neurological abnormalities until well 
into adulthood. Onset of disease was usually indicated by seizures, which were 
progressive in frequency and duration; ataxia and weight loss were also noted. 
Death was also usually as a result o f seizure activity. The onset of disease was very 
variable with neurological abnormalities becoming apparent between P60 to P140.
5.4.2 Neuropathology
Dysmyelination and the development of demyelination in homozygous #72 mice is 
illustrated in Figure 32, pages 149-152. Dysmyelination was evident in all white 
matter tracts examined at P20, with generalised thinning of myelin sheaths. Though 
the great majority axons in the optic nerve and corticospinal tracts were ensheathed 
there were occasional naked fibres. At P20 infrequent myelin sheaths in the optic 
nerve exhibited focal myelin thickening; by P60 demyelination and axonal swellings 
were apparent and by P I20 the optic nerve was largely demyelinated. The dorsal 
columns of the spinal cord had a heterogeneous appearance at all ages studied, with 
the most affected areas being the corticospinal tracts. At P20 the these tracts 
contained a number of naked axons with occasional focal thickenings o f myelin 
sheaths. At P60 these abnormalities were more extensive and by P I20 there was 
extensive demyelination of the corticospinal tracts with occasional axonal swellings. 
The ventral columns appeared virtually unaffected until P I20 by which time there 
were abundant abnormalities of myelin sheaths with focal myelin thickenings and 
the formation of redundant loops of myelin.
The development of pathology in the brain was not examined.
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5.4.3 Glial cell density
The data for corrected total glial cell density is presented in Figure 33, page 153. 
There is a trend is for an increase in glial cell density during myelination which 
appears to decrease with time, until at P60 values are similar to wild type. At P20 
there is a significant difference between homozygous and wild type (p=0.0286) 
which is not present at P60 (p>0.05). In homozygous #72 mice at P I20 the cell 
densities, which were performed in the ventral columns, are similar to wild type. 
However, in the dorsal column tracts affected by neurodegeneration there is a 
subjective increase in cells with the morphology of microglia.
5.4.4 Dead cell density
The dead cell density in cervical cord at P20 was estimated to be approximately 4x 
greater than wild type (Figure 35, page 155). (median wild type = 0.72cells mm'2 
and #72 = 2.6 cells mm~2. Though this is not significant (p=0.0571) the p value 
suggests that further data points might confirm this difference.
5.4.5 Myelin morphometry
The data for myelin morphometry in homozygous #72 mice is presented in Figure 
36, pages 156-158. The white matter area appears to be reduced compared to wild 
type at both P20 (wild type median =1.13mm“2 and #72 = 0.99m m "2) and P60 
(median wild type =1.57mm~2 and #72 = 1.37mm-2) but does, however, appears to 
increase with age. Myelin sheaths are thin, being approximately 70%  the thickness 
o f wild type at P20 and 80% at P60. The apparent increase in myelin sheath 
thickness with age is reflected in an apparent increase in the myelin volume, 
however, by P60 they have not apparently attained an equivalent thickness to that in 
the wild type at P20. The apparent reduction in myelin thickness is associated with 
an apparent increase in the mean g  ratio. None of these differences are statistically 
significant.
5.4.6 Ultrastructure of oligodendrocytes and myelin
The myelin in homozygous #72 mice was compacted normally with a recognisable 
MDL and double IPL (see Figure 37, page 159).
At P20 (Figure 38, page 160) and P60 (Figure 39, page 161) apparently normal and 
abnormal oligodendrocytes were observed within the ventral columns. The primary 
abnormality was the presence of vacuolar structures, which had an appearance 
similar to those observed in homozygous #66 mice (see 5.5.6 Ultrastructure of 
oligodendrocytes and myelin, page 142 and Figure 40, page 163). In areas of
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demyelination abnormalities of the oligodendrocyte inner tongue were observed, 
similar to those seen in aged hemizygous #66 and #72 mice (see 4.4.6 
Oligodendrocyte and axon ultrastructure (page 98) and Figure 25, page 124).
5.4.7 Gene expression
5.4.7.1 Immunocytochemistry
Immunostaining for myelin proteins (PLP/DM20 and MBP) demonstrated a 
reduction in immunostaining, particularly in the more dramatically affected small 
fibre tracts, commensurate with the reduction in myelin observed on methylene 
blue/azur II sections. An example of immunostaining for MBP in a homozygous 
#72 mouse at P60 is given in Figure 43 (page 168). Immunostaining with SMI-31 
demonstrated axonal swellings in affected tracts (Figure 43, page 168).
5.4.7.2 Transcript analysis
5.4.7.2.1 Northern hybridisation
Transcription of the myelin genes Pip and Mobp were examined at P20 (Figure 44, 
page 169). Pip mRNA steady state levels were approximately equivalent to wild 
type(panel a) whilst the message levels for Mobp (panel b) were marginally 
elevated.
5.4.7.2.2 RT-PCR for Plp:Dm20 ratio
The Plp\ Dm20 ratio was examined by RT-PCR using cyclophilin as a control for 
invariant temporal expression, the levels of which are reasonably constant across the 
spectrum of ages and genotypes (panel c (i) and (ii) Figure 44, page 169). The 
Plp:Dm20 ratio was equivalent to wild type (lane 1) at P20 (lane 3) and P60 (lane
6). The total PCR product was, however, elevated compared to wild type at both 
P20 and P60. This supports the finding for the Pip northern hybridisation 
experiment that Pip gene transcription is not reduced at P20 (lane 3 ) and suggests 
that the same is likely to be true for P60. However, it emphasises that further 
experiments are required to clarify the relative levels of Pip gene transcription in 
wild type and homozygous #72 mice. This may represent a difference in sensitivity 
between the two experimental approaches. The findings in hemizygous mice where 
Mobp and Mbp gene transcription were elevated in conjunction with increased Pip 
gene transcription (4.4.7.2.1 Northern analysis, page 99) suggests that this may be 
the case in homozygous #72 mice (as it is for homozygous #66 mice - see 5.5.7.2.1 
Northern hybridisation, page 142).
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5.4.7.3 In  situ hybridisation studies
In-situ studies using the PLP-1 probe demonstrated a similar number of 
oligodendrocytes in white matter regions at P20 (data not shown). However, at P60 
there was an apparent reduction in positive cells, seen in the region of the 
corticospinal tracts, suggesting a possible loss o f oligodendrocytes (Figure 45, page 
170).
5.4.8 Summary of the phenotype of homozygous #72 mice
Homozygous #72 mice are dysmyelinated but the degree of perturbation is 
insufficient to induce the gross neurological abnormalities observed in homozygous 
#66 mice and other dysmyelinating mutants. However, older mice exhibit 
progressive neurological disease and premature death (as compared to their 
hemizygous and wild type litter mates).
Myelination appears to commence at a similar time to wild type, myelin sheaths are 
thinner but have a normal periodicity, and myelin continues to accumulate into 
adulthood. Pip gene transcription is not reduced at P20 or P60 and may possibly be 
increased. The ratio of the Plp:Dm20 message isoforms appears to be similar to 
wild type. Myelin is lost in older animals with the pattern of demyelination being a 
feature o f tracts containing small diameter axons. Demyelination is progressive, 
initially affecting the optic nerve, followed by small fibre tracts of the dorsal 
columns (e.g. corticospinal tracts), lateral columns and the smaller diameter axons 
of the ventral columns. Myelin loss is associated with the development of focal 
thickening and redundant loops of myelin. There is no evidence of remyelination in 
affected tracts. In areas of myelin loss there is an axonopathy. Demyelinated 
swollen axons are also occasionally observed with the axoplasm containing dense 
bodies. Abnormal oligodendrocytes contain vacuolar structures, some of which 
may represent autophagic vacuoles although not all oligodendrocytes have obvious 
abnormalities.
Myelination is associated with a gliosis and subjectively the onset of disease is also 
associated with a gliosis in affected tracts related to an increase in microglia. In-situ 
hybridisation studies indicate that the abnormalities observed are not due to a lack 
of oligodendrocytes.
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5.5 Results for homozygous #66 transgenic mice
5.5.1 Phenotypic characteristics
5.5.1.1 Growth
On examination of litters of #66 mice those with the phenotypic characteristics of 
homozygosity for the transgene appeared subjectively to be smaller than their wild 
type litter mates. However, the pooling of data from multiple litters and the 
corresponding differences related to litter size etc. (see 2.13 Growth o f mice, page 
75) obscures this. This trend is apparent at P60, as male and female mice vary 
noticeably in body weight and as sample sizes were small the values for body 
weight are presented for each sex (Figure 31, page 148).
5.5.1.2 Neurological abnormalities
Homozygous mice were identifiable from the time of ambulation as they had a 
tremor associated with movement. The time of onset of seizure activity was 
variable. Observation of the mice suggested the frequency and duration of seizures 
increased with age and eventually animals became moribund. Older animals were 
less active. Death occurred between approximately P40 and P70.
5.5.2 Neuropathology
Dysmyelination and demyelination in homozygous #66 mice is illustrated in Figure 
32, pages 149-152. Dysmyelination was evident in all tracts at P10 with a reduction 
in the number o f myelinated axons and the thickness of the myelin sheaths. At P10 
there were very few myelinated fibres in the optic nerve and though this had 
increased subjectively by P20 the number of myelinated sheaths was still reduced 
compared to wild type. However, at P60 there was virtually no myelin present and 
any remaining myelin sheaths showed evidence of focal thickening and formation of 
myelin loops. At P10 the dorsal columns, particularly the corticospinal tracts had 
very few myelinated fibres, though the proportion appeared to have increased by 
P20. At P60 the proportion of myelinated fibres appeared to have decreased 
compared to P20, the corticospinal tracts were largely demyelinated and abnormal 
myelin sheaths were common. Subjectively, a higher proportion of axons were 
myelinated in the ventral columns as compared to the dorsal columns at all ages 
examined. The proportion of myelinated fibres in the ventral columns increased 
subjectively between P10 and P60, though by P60 there were fibres exhibiting focal 
thickenings and loops of redundant myelin.
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Subjectively there was an increase in cells with the morphology of astrocytes and 
microglia compared to wild type in the white matter. The proportion of both types 
of cell appeared to increase with age.
The development of pathology in the brain was not studied.
5.5.3 Total glial cell density
The data for total glial cell density is presented in Figure 33, page 153. The trend at 
all ages is for a greater glial cell density in homozygous #66 mice. Though the 
differences at P20 and P60 are not significantly different from wild type the p values 
(p=0.1 and p=0.1333 respectively) suggest that further data points are likely to 
confirm this increase in total glial cell density in homozygous mice as being 
significant. This apparent increase in total glial cell density became less marked 
with age. However, the total glial cell numbers in white matter were reduced 
(Figure 34, page 154), probably reflecting the reduction in white matter area (see 
below).
5.5.4 Dead cell density
Dead cell densities in the white matter of the cord were apparently elevated in 
homozygous #66 mice to approximately 6x wild type at P20 (Figure 35, page 155). 
(median wild type = 0.72 cells mm"2 and the two data points for #66 homozygous =
4.1 and 5.7 cells mm'2). This difference is not statistically significant
5.5.5 Myelin morphometry
The data for myelin morphometry for homozygous #66 mice is presented in Figure 
36 (pages 156-158). The white matter area was apparently reduced at both P20 
(median wild type = 1.13mm“2 and #66 = 0.86mnr2) and P60 (median wild type = 
1.57mm“2 and the two data points for #66 = 0.95mm“2 and 1.04mm“2). There is 
little evidence of the increase in myelin sheath thickness that appears to occur in #72 
mice and myelin sheaths are approximately 60% the thickness of wild type at P20. 
The apparent increase in mean myelin volume suggest an increase in the amount o f 
myelin between P20 and P60, though more data points would be required to 
establish this.. Two possible events would lead to an increase in myelin volume, an 
increase in myelin thickness which seems unlikely, or an increase in the proportion 
of myelinated axons. The mean g  ratio appears to be increased at both P20 and P60 
in comparison to wild type, consistent with the thin myelin sheaths.
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5.5.6 Ultrastructure of oligodendrocytes and myelin
The earliest time point examined by EM was P3, an age before the major 
upregulation of the production of myelin proteins. The most striking abnormalities 
of the oligodendrocytes were abundant vacuolar structures in most areas of the 
cytoplasm, o f which there were two groups distinguished by the thickness of their 
walls (Figure 40, page 163 cf. P3 wild type Figure 41, page 165). The thicker 
walled structures probably represent autophagic vacuoles, whilst the nature of the 
thinner walled structures is uncertain. The presence of autophagic vacuoles implies 
abnormal protein turnover. Similar changes were present in the oligodendrocytes of 
P10 mice (Figure 42, page 166-167) and older mice (Figure 38, page 160).
5.5.7 Gene expression
5.5.7.1 Immunocytochemistry
Immunostaining for myelin proteins (PLP/DM20 and MBP) demonstrated a 
reduction in immunostaining, particularly in the more dramatically affected small 
fibre tracts, commensurate with the reduction in myelin observed on methylene 
blue/azur II sections. Examples of immunostaining for MBP in a homozygous #66 
mice at P60 and #72 at P70 is given in Figure 43 (page 168). GFAP 
immunostaining demonstrated an increase in immunoreactivity consistent with the 
apparent increase in astrocytes as described by Readhead et al (1994) (data not 
shown).
5.5.7.2 Transcript analysis
5.5.7.2.1 Northern hybridisation
Transcription of the myelin genes Pip and Mobp was examined at P20 and P60 for 
Pip and P60 for Mobp (see Figure 44, page 169). At P20 Pip mRNA steady state 
levels were marginally increased compared to wild type (panel a lanes 1 and 2) 
whilst at P60 they were equivalent to wild type (panel a lanes 5 and 6). At P60 
Mobp mRNA levels were equivalent to wild type (panel b lanes 3 and 4).
5 .5 .122  RT-PCR for Plp:Dm20 ratio
The Pip: Dm20 ratio was examined by RT-PCR using cyclophilin as a control for 
invariant temporal expression, the levels of which are reasonably constant across the 
spectrum of ages and genotypes (panel c (i) and (ii) Figure 44, page 169). The 
Plp:Dm20 ratio was equivalent to wild type at P60. However, at P20 there is a 
reduction in the intensity in the band representing the Pip message isoform relative 
to wild type whilst the Dm20 band is of similar intensity (panel c (i) lanes 1 and 2).
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Total product appears to be reduced compared to wild type, primarily because of the 
reduction in the Pip isoform band. Though this does support the increase in Pip 
gene transcription suggested by the Pip northern hybridisation other such 
hybridisation experiments (not shown) do support an increase in Pip gene 
transcription in #66 P20 homozygous mice. This conflict in levels as assessed by 
these different approaches may reflect a difference in sensitivity (see 5.6 
Discussion, page 144).
5.5.7.3 In-situ  studies
In-situ studies using the PLP-1 probe demonstrated a similar number of 
oligodendrocytes in white matter regions at P20 (data not shown). However, at P60 
there was an apparent reduction in positive cells, seen in the region of the 
corticospinal tracts, suggesting a possible loss of oligodendrocytes (Figure 45, page 
170).
5.5.8 Summary of the phenotype of homozygous #66 mice
Homozygous #66 mice are severely dysmyelinated with many naked axons and any 
myelin sheaths formed are abnormally thin. The neurological phenotype is 
progressive and the mice die prematurely compared to their hemizygous and wild 
type littermates.
The onset of myelination is possibly delayed with the proportion of myelinated 
fibres increasing between P10 and P20. The perturbation in the formation of myelin 
sheaths appears to be more profound in small fibre tracts. Between P20 and P60 the 
proportion of myelinated fibres appears to decrease in tracts with a proportion of 
small diameter axons e.g. the optic nerve. At P20 Pip gene transcription appears to 
be elevated although there is a change in ratio of the transcripts with a reduction in 
the Pip message isoform. There is an apparent increase in total glial cell density in 
the developing CNS white matter, the nature of which has yet to be confirmed but 
many of these cells have the morphological appearance of oligodendrocytes. In P60 
mice the glial cell population subjectively contains an increased proportion of 
microglia.
Demyelination occurs in older mice and is most predominant in tracts composed of 
small fibres e.g. the optic nerve and corticospinal tracts.
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5.6 Discussion
The data presented in this chapter confirms that mice homozygous for the #66 or 
#72 transgenes are dysmyelinated. The evidence for this is the development of 
abnormally thin myelin sheaths and the apparent increase in the incidence of 
amyelinated axons. There is a marked difference in the degree to which they are 
affected which presumably contributes to the difference in the severity o f their 
phenotypes, with #66 mice having a more severe perturbation in myelin 
development. Though not formally documented in this chapter, subjectively there is 
a difference in the degree of dysmyelination between tracts with late myelinating, 
predominantly small fibre tracts being the most affected.
Homozygosity for both the #66 and #72 transgenes is associated with an increase in 
total glial cell density during myelination. The data indicate that this is probably 
greatest early in myelination with cell numbers declining to around wild type levels 
at P20, the peak of myelination in wild type mice, though further data points would 
be required to be confident of this. An increase in glial cell density during 
myelination is a feature of many, but not all, Pip gene mutants but is not prominent 
in mutations affecting other myelin genes. In PlpJP mice this has been demonstrated 
to include increased oligodendrocyte precursor proliferation (Hernandez et al., 
1997). Immaturity of the glial cell population results in an altered Plp\Dm20 
message isoform ratio, with a decrease in Pip dominance (Nadon & Duncan, 1996; 
Tosic et al, 1994). Similarly an increase in the proportion of immature cells within 
the oligodendroglial population might be expected to alter the Plp:Dm20 ratio. This 
was observed in homozygous #66 but not #72 mice, suggesting differences in the 
dynamics of oligodendrocyte population differentiation. The factors driving this 
increase in total glial cell density is unknown but amyelinated axons per se are 
unlikely to be responsible, as there are many amyelinated axons in non-Pip gene 
mutants.
The increase in total glial cell density seen in affected Pip gene mutants is 
associated with increased oligodendroglial cell death, with the incidence broadly 
correlating with the severity of the hypomyelination (Skoff, 1995). Increased cell 
death in affected Pip gene mutants appears to be due to apoptosis, with cells 
exhibiting classic morphological changes, however Skoff (1995) has suggested that 
there may be subtle differences in the mechanism o f apoptosis in the immature 
oligodendrocytes of the PlpJP mouse. Increased cell death is a feature of both 
homozygous #66 and #72 mice at P20, however, in-situ studies indicate that an 
adequate number of oligodendrocytes is present. Interestingly a relationship of 
increased cell death and increased severity of dysmyelination is present in the #66
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and #72 mice. This is in contrast to homozygous 4e mice, which in common with 
PlpJP mice have a reduction in mature oligodendrocytes but apparently adequate 
numbers of precursors (Kagawa et al, 1994). Homozygous #66 mice may loose 
some oligodendrocytes as they age. The nature of the glial cell population during 
the development of transgenic mice expressing the Dm20 minigene is not described 
but would be interesting as the DM20 protein isoform is speculated to play a role in 
oligodendrocyte development and there is evidence that it might be elevated in Pip 
gene transgenic mice (see below).
Dysmyelination in homozygous #66 and #72 occurs despite an apparently adequate 
numbers o f oligodendrocytes (as identified by PLP-1 ISH). The oligodendrocyte 
populations of homozygous #66 and #72 mice are, however, compromised in their 
ability to elaborate and maintain myelin (see below). Though not formally 
investigated in this project there is a probably a delay in myelination in homozygous 
#66 mice. Delayed myelination has been described in the less severely affected Pip 
gene mutants Plp/T7"1-^  mice and Pt rabbit (Tosic et a l, 1993; 221). Possible 
explanations for a delay is a failure to generate sufficient oligodendrocytes 
competent to myelinate axons or a reduction in the rate of myelin production by 
individual oligodendrocytes.
Oligodendroglial cells of homozygous #66 and #72 mice have ultrastructural 
abnormalities during development, that become less apparent with age. These are 
observed during the pre-myelination differentiation phase and during the major 
elaboration of myelin. They are much less striking in adults. The changes seen 
(e.g. autophagic vacuoles) are indicative of abnormal protein trafficking. This may 
indicate that the oligodendrocytes of these mice have compromised intracellular 
transport systems that show evidence of abnormalities only during high demand.
It is intriguing that at the peak of myelination the combined transcriptional output of 
the exogenous and endogenous Pip genes in homozygous #66 and #72 mice is not 
only very similar to each other but very similar to wild type, though there are major 
differences in the progress of myelination. In-situ hybridisation studies and total 
glial cell counts suggest that oligodendrocyte numbers are probably also similar 
suggesting that the transcriptional output of individual oligodendrocytes is probably 
at least equivalent to wild type, if not marginally increased. This points to a post- 
transcriptional effect on Pip gene expression. It is possible that it is the ability to 
produce myelin rather than PLP/DM20 protein isoforms that is the principle 
derangement, as it is known that reasonable amounts of myelin can be elaborated in 
the complete absence of these proteins (Klugmann et al., 1997; Boison & Stoffel,
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1994). Though there is evidence of abnormalities in ultrastructural elements 
involved in protein transport there is no conclusive evidence that it is blocked.
The finding of apparently adequate levels of Pip gene transcription in #66 and #72 
mice is superficially contradictory to the findings in homozygous Ae mice where at 
P19 there is a marked fall in mRNA levels. However, other evidence points to these 
mice having a reduced population of mature oligodendrocytes and the change in Pip 
gene transcription on an individual cell basis is less certain. This illustrates that 
levels o f steady state mRNA based on tissue samples in relation to the activity in 
individual cells must be interpreted with a degree of caution. In this project the 
steady state levels for the mRNAs of Pip and other myelin genes has been equated 
to oligodendrocyte numbers as estimated by in situ hybridisation and cell counting. 
Whether the small increases in steady state mRNA levels for the Pip gene suggested 
for homozygous #66 and #72 mice is a result o f increased cell numbers remains 
unresolved. The magnitude of this has not been fully established with variations 
occurring between the different experimental methods. In the initial description of 
the #66 and #72 mice a radioactive PCR method in conjunction with 
phosphoimaging documented a 50% increase over wild type in Pip gene 
transcription in homozygous #66 mice at P60 (Readhead et a l, 1994). This serves 
to illustrate the differences in sensitivities of experimental procedures and how this 
can be significant when examining relatively small differences. More accurate 
quantification of the various cell types, an estimation of the maturity of the 
population and further characterisation of the magnitude of any elevation in 
transcription would be required to resolve this.
The development of demyelination superimposed on dysmyelination was 
unrecognised as a feature of #66 and #72 mice before the studies presented here 
were undertaken. This is of particular interest in the light of the late-onset 
demyelination in hemizygous #66 and #72 mice. In homozygous #72 mice the late- 
onset demyelination rather than their mild dysmyelination would appear to be the 
significant factor in development of a neurological phenotype and probably 
contributes to their early death. In older homozygous #72 mice the abnormalities of 
the inner oligodendrocyte tongue are similar in nature to those in aged hemizygous 
#66 and #72 mice.
The data presented here support the concept that increased Pip gene dosage is 
associated with dysmyelination. However, the mechanism by which increased 
dosage of this gene has such devastating effects remains elusive. These studies on 
the homozygous #66 and #72 mice suggest that it is not a reduction in Pip gene 
transcription during myelination which is the underlying reason for dysmyelination,
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with both types o f mice having steady state mRNA levels around that of wild type. 
The magnitude of increase in steady state mRNA levels in the two types of 
homozygous mouse is probably fairly similar and is therefore unlikely to be 
responsible for the perturbation of myelination, indeed far greater levels were found 
in the hemizygous (particularly #66) mice (see Figure 53, page 194).
In conclusion, the reason for the dysmyelination observed in homozygous #66 and 
#72 mice remains unelucidated. However, these studies do suggest that a 
potentially fruitful area of further investigation lies in the early development of the 
oligodendrocyte population.
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Figure 31. Body weights of homozygous #66 and #72 mice and wild type at 60 
days. The trend is for homozygous #66 (a) mice to be smaller than wild type 
whilst homozygous #72 mice (b) appear to be similar to wild type.
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(iii)
a)
Figure 32. Abnormali t ies  of  myelination in homozygous #66 and  #72 mice, a) 
P20 optic nerve  (i) wild type (ii) #66 (iii) #72. Opt ic  nerves  from homozygous 
mice are  hypomyelinated,  with thin myelin sheaths,  amyel inated  fibres and  a 
gliosis. These  abnormal i t ies  a re  more  p ro found  in #66 mice (all x990).
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Figure  32 (continued).  Abnormali t ies  o f  myelination in homozygous #66 and  
#72 mice, b) dorsa l  columns at  P20 (i) wild type (ii) #66 (iii) #72. Both 
homozygous mice a re  hypomyelinated,  though the degree  varies between trac ts  
and  #66 mice a re  m ore  profoundly  affected (all \90).
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(iii)
c)
Figure  32 (continued).  Abnormali t ies  of  myelination in homozygous #66 and 
#72 mice, c) P60 optic nerve  (i) wild type (ii) #66 (iii) #72. The  optic nerves 
from both homozygous mice a re  profoundly  hypomyelinated.  Subjectively,  in 
#72 optic nerve the re  is a reduction in the p ropor t ion  of  myel inated fibres and  
some myelin sheaths  exhibit focal th ickening and  r e d u n d a n t  myelin. #66 optic 
nerve  remains  profoundly  hypomyelinated and  myelin sheaths  exhibit  s imilar 
abnorm al i t ie s  to those observed in #72 mice (all x990).
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(iii) 
d)
Figure  32 (continued).  Abnormalit ies  of myelination in homozygous  #66 and 
#72 mice, d) P I 20 homozygous #72 (i) optic nerve  (x990) (ii) dorsa l  columns 
( \ I 5 0 )  (iii) ventra l  columns (x!50).  At P I 20 optic nerve is demyel inated  and 
the dorsa l  and  ventra l  columns show demyel inat ion,  which is more  profound  in 
the dorsa l  columns.  Pathology in the dorsa l  co lumns exhibits  a t r ac t  specific 
n a tu re  (e.g. the corticospinal tracts  (cst) a re  par t icu lar ly  affected).
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Figure 33. Total  glial cell density in homozygous #66 and # 72mice. a) #72; b) 
#66. The t rend  is for an increase  in total  glial cell density dur ing  myelination.
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Figure 34. Total glial cell numbers in white m atter in homozygous #66 and # 
72mice. a) #72; b) #66.
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Figure 35. Estimates of dead cells in cervical cords of #66 and #72 homozygous 
mice at P20.
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Figure 36. Myelin morphometry in #66 and #72 homozygous mice at P20 and 
P60. a) white m atter area; b) myelin sheath thickness.
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Figure 36 (continued). Myelin morphometry in #66 and #72 homozygous mice 
at P20 and P60. c) mean g  ratio at P20 and P60.
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Figure 36 (continued). Myelin morphometry in #66 and #72 homozygous mice 
at P20 and P60. d) myelin volume.
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Figure 37. Electronm icrograph of the ultrastructure of myelin from the 
ventral columns of a homozygous #72 mouse. There is a compacted lam ellar 
structure with the MDL *n> and the double IPL (jf) (scale bar O.lfim)
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(b)
Figure 38. Electronm icrograph of spinal cord white m atter at P20: (a) 
homozygous #66 (scale bar 2p.ni) , (b) homozygous #72 (scale bar 2p.m). The 
m ajority of axons in the #66 homozygous mouse are amyeiinated with any 
myelin sheaths being thin whilst in homozygous #72 mice the m ajority of axons 
are myelinated, albeit with sheaths of reduced thickness. A microglial cell (me) 
in the homozygous #66 contains many phagosomes, contents unknown.
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(b)
Figure 39. Electronmicrographs of spinal cord white m atter at P60 in #72 
homozygous mice, a) the majority of axons are myelinated though myelin is 
thin. The degree of hypomyelination is variable between fibres (scale bar 
2pm); b) the cytoplasm of some oligodendrocytes appears normal (scale bar 
lp m ) .
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(d)
Figure 39 (continued). Electronmicrograph of spinal cord white m atter at P60 
in #72 homozygous mouse, c) other oligodendrocytes in the same area of white 
m atter have vacuolar structures in the cytoplasm (scale bar 2f.im) d) same 
oligodendrocyte at a higher magnification (scale bar ljLim).
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(a)
Figure 40. Electronm icrograph of spinal cord white m atter of a homozygous 
#66 (P3) mouse (c.f. wild type Figure 41, page 165). a) Occasional myelin 
sheaths are present. The cytoplasm of an oligodendrocyte (ol) is striking for 
the num erous vesicular bodies present. These appear to be of two types: 
relatively thick walled structures which probably represent autophagic 
vacuoles, and thinner walled structures, the nature of which is unknown 
(scale bar 1pm).
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(b)
Figure 40 (continued). Electronmicrograph of spinal cord white m atter of a 
homozygous #66 (P3) mouse, b) this higher magnification electronm icrograph 
shows an area of cytoplasm that is relatively unaffected. The RER is relatively 
normal. An oligodendrocyte process is in the early stages of w rapping an axon 
(—) (scale bar lp.ni).
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Figure 41. Electronmicrograph of spinal cord white m atter of a wild type (P3) 
mouse (scale bar lpm ). Thin myelin sheaths are present though the 
m ajority of axons are naked. Oligodendrocyte processes are wrapping axons 
( 0) ).The relatively homogeneous cytoplasm contains some structures (e.g. 
mitochondria (m)).
165
Dysmyelination and demyelination in homozygous mice
(a)
Figure 42. U ltrastructure of developing (P10) homozygous #66 oligodendrocyte 
and myelin, a) thin myelin sheaths are present but the m ajority of axons 
remain naked. The vacuolar structures in oligodendrocyte cytoplasm noted at 
P3 are still present (scale bar lprn).
166
Dysmyelination and demyelination in homozygous mice
(b)
Figure 42 (continued). U ltrastructure of developing (P10) homozygous #66 
oligodendrocyte and myelin, b) higher magnification of the cytoplasm shows 
the cisternal structure of the RER is severely disrupted with the ribsomes 
showing displacement (-*) (scale bar 0.5|im).
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Figure 43. M B P  im munosta in ing  showing reduced  im munoreac t iv i ty  at  P60 in 
thoracic  cord  reflecting the reduced am o u n t  of myelin present,  a) homozygous 
#66 (P60); b) homozygous #72 (P70). The  reduced  im m unos ta in ing  is 
pa r t icu la r ly  evident in trac ts  conta ining p redom inan t ly  small  Fibres e.g. the 
cor ticospinal  trac ts  (cst) (both \75).
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a)
b)
c)
Figure 44. Transcription of the Pip (PLP-1) and Mobp genes in homozygous 
#66 and #72 mice at P20. a) northern hybridisation with PLP-1: #66 lane 1 
wild type, lane 2 homozygote, #72 lane 3 wild type, lane 4 homozygote; b) 
northern  hybridisation with MOBP-1: #72 lane 1 wild type, lane 2 homozygote;
c) RT-PCR for Plp:Dm20 ratios (i) primers Pip gene exon 2—>4 P20 lane 1 wild
type, lane 2 #66, lane 3 #72 P60 lane 4 wild type, lane 5 #66 and lane 6 #72 (ii) 
prim ers cyclophilin lanes 1-6 as above.
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c)
Figure 45. In-situ hybridisation with PLP-1 of cervical cord from homozygous 
#66 and #72 mice and wild type at P60. a) #66; b) #72; c) wild type (all x30). 
The numbers of positive cells appear similar to wild type in both groups of 
transgenic mice, with the exception of the spinocerebellar tracts, where the 
num ber of positive cells appears to be reduced (-►), and the dorsal columns in 
general in #66 mice.
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6.1 Background
The compact myelin of the central and peripheral nervous systems share many 
features but differ in a number of respects, including their protein composition. P()? 
the major constituent protein of PNS myelin is absent from the CNS. Although PLP 
and DM20 are present in Schwann cells it is generally accepted they are not 
incorporated into PNS myelin (1.2.1.2 Comparison of CNS and PNS myelin page 
4). It is known, however, that the Pip gene is both transcribed and translated in 
NMFSC and MFSC with the Dm20 mRNA being the dominant message isoform 
(1.2.3.3 Expression of the Pip gene in the PNS page 23). Immunocytochemistry 
demonstrates the presence of protein in the paranodes and Schmidt-Lanterman 
incisures of both the MFSC and NMFSC. Differential staining with antibodies 
recognising both polypeptides or only PLP, suggest that DM20 is present in all these 
locations. PLP staining appears restricted to the perinuclear region o f the MFSCs 
and is absent from NMFSCs (Griffiths et a l, 1995). PLP and/or DM20 proteins 
have, however, been demonstrated in the peripheral myelin of other genera (see
1.2.2.1.1 Phylogenetic evolution of the Pip gene page 13) and both have been 
observed to co-localise with the Pq (PLP in amphibia and DM20 in bony fish). In 
evolutionary terms PLP/DM20 appears to have replaced Pq in the CNS but not in 
the PNS. It has been proposed that the lack of PLP/DM20 in the myelin of 
mammalian PNS is due to specific exclusion by Schwann cells (Puckett et al., 
1987). It has recently reported that the PLP/DM20 protein isoforms are present in 
normal rabbit PNS myelin (Tosic et al., 1996).
The function of the Vlp gene products in the PNS is unknown, and thus it is 
uncertain whether their transcription underlies a specific function or represents an 
evolutionary legacy. Studies on the regulation of the Pip gene in the PNS suggest 
that the gene is uncoupled from the co-ordinated expression of the PNS myelin 
genes (Dickinson, 1995; Kamholz et al., 1992; Stahl et al., 1990). The use of an 
alternative transcription start site compared to the CNS is consistent with a different 
cohort of trans factors in the Schwann cell, though the regulatory significance of 
this is uncertain (Kamholz et al., 1992). The apparent normality of the PNS in Pip 
gene mutants and Pip gene knockout mice is not suggestive of a pivotal function for 
this gene in the development and function of PNS myelin.
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The work presented in this chapter was stimulated by the unexpected observation of 
positive immunostaining for the PLP/DM20 protein isoforms in the ventral nerve 
roots of spinal cord from homozygous #72 mice.
6.2 Aims
The initial aim was to confirm that the PLP/DM20 immunostaining observed in the 
PNS of the #72 homozygous mice was due to the insertion of the PLP/DM20 
protein isoforms into the peripheral myelin and that it was a influenced by Schwann 
cells.
The availability o f a range of Pip transgenes (#72, #66, Plptg 1 and Dm20tg2) 
afforded the possibility o f examining the behaviour o f constructs encoding for the 
two proteins both in conjunction and individually in the PNS environment. To 
facilitate this a PlpjP background was used as the level o f endogenous Pip gene 
activity is low and the gene transcripts and products can be distinguished from full 
length gene products. The antibodies directed against the PLP-CT do not react with 
PlpJP proteins.
6.3 Methods
Double immunostaining was used to assess whether the PLP polypeptides co- 
localise with Pq, the major protein in PNS myelin. With the lack of an antibody 
specific to DM20 its presence or absence is inferred from the differential pattern of 
staining with the PLP-CT and PLP-specific antibodies.
Transplantation techniques were used to confirm that incorporation of the 
PLP/DM20 protein isoforms into PNS myelin is a property of #72 homozygous 
MFSC rather than a result o f axonal signalling. A graft o f sciatic nerve anastomosed 
in a transected nerve serves as a scaffold for the regrowing proximal axons which 
are myelination by the transplanted Schwann cells (Aguayo et a l, 1977). Nude 
mice are used as recipients to minimise the problems associated with tissue 
rejection.
RT-PCR technology was chosen to investigate the transcription of transgenes as it is 
possible to examine the ratios of Pip and Dm20 mRNA as well as the overall level 
of transcription. An approach that would require the breeding of smaller numbers of 
mice than would be required for the northern hybridisation approach. An alternative 
technique would have been an RNase protection assay, which as a direct assay of 
message levels (Mason et al., 1993). Experiments were designed to confirm
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transgene transcription and to investigate the relative levels of transcription in the 
#72 hemi and homozygous mice in comparison to their wild type littermates.
Electron microscopy was used to ascertain whether the incorporation of the 
PLP/DM20 protein isoforms altered the ultrastructure of the peripheral myelin.
6.3.1 Mouse breeding
The breeding and identification of animals for these experiments is described in 3 
Genotyping and breeding of transgenic mice page 76. Mice were killed at 21 days, 
as the PlpiP mutation is lethal by about 4 to 5 weeks, with the exception of nude 
mouse transplant recipients (see below).
6.3.2 Immunocytochemistry
Tissues were harvested and fixed as described in 2.1 Tissue fixation and processing 
(page 43). Tissues for extraction o f RNA were removed immediately into liquid 
nitrogen.
Both frozen and paraffin wax sections of cervical cord, sciatic nerve and cauda 
equina were used for immunocytochemistry. Immunostaining for myelin is better 
visualised using paraffin wax sections although cytoplasmic staining around myelin 
is lost using such preparations. Cytoplasmic immunoreactivity is retained in frozen 
tissue sometimes making it difficult to distinguish from staining of the myelin. For 
this reason both methods were used to determine the localisation of PLP/DM20.
Sciatic nerve preparations were teased in PBS to separate fibres and facilitate 
visualisation of the distribution of immunoreactivity along fibres (Griffiths et a l, 
1995).
Tissues were immunostained for PLP-CT, PLP-specific, Pq and SMI-31 antibodies 
using indirect Immunofluorescence. Techniques are described in 2.9.1.2 
Immunofluorescence (page 69) and the details of individual antibodies are given in 
Table 4 (page 71). Double staining of tissues was undertaken to demonstrate 
localisation of the PLP/DM20 protein isoforms relative to axonal or Schwann cell 
components.
6.3.3 Transplant studies
Donor homozygous #72 mice were killed and the sciatic nerves removed into sterile 
PBS. Recipient nude mice were anaesthetised with halothane, the sciatic nerve 
transected, and a 5mm portion of #72 sciatic was anastomosed into the gap. Ethilon
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(14/0) sutures were used to maintain the graft’s position and for later orientation. 
Mice were killed 60 days following transplantation and perfused with 
paraformaldehyde (2.1 Tissue fixation and processing page 43). Both sciatic nerves 
were removed and embedded in paraffin wax. A control experiment was performed 
using a non-transgenic littermate as the donor of sciatic nerve.
6.3.4 Ultrastructure of myelin
Sciatic nerve and lumbar nerve root were removed from 60 day old homozygous 
#72 mice perfused with Kamovsky's modified fixative and the tissue prepared for 
EM (2.1 Tissue fixation and processing page 43) to examine the morphology of 
myelin and Schwann cells.
6.3.5 Transcript analysis by RT-PCR
The ambitions of the RT-PCR experiments were two-fold: a) to confirm the 
transcription of the transgenes in PlpJP sciatic nerves; b) to examine the 
transcriptional output from the combined endogenous and exogenous Pip genes in 
wild type mice complemented with genomic transgenes.
The low yields of RNA from murine sciatic nerves necessitated the pooling of 
tissue, usually 2-8 pairs of nerves. The preparation o f RNA is described in 2.5.1.2 
The isolation and storage of RNA page 49. The preparation of cDNA is described 
in 2.5.4.1.2 cDNA preparation, page 55.
6.3.5.1 Identifying transgene activity on a PlpJP background
To highlight transgene expression on the PlpJP background required development of 
a primer pair that would produce a product exclusively from transgene-derived 
message. In experiments described in previous chapters the Plp:Dm20 ratios were 
examined using a primer pair spanning exons 2—>4. which also produce product 
from a PlpJP cDNA. As exon 5 is not transcribed in PlpiP (see page 26) a primer 
pair was designed with one primer upstream of exon 3 (in exon 2) with the reverse 
primer within exon 5 (2.5.4.1.1 Design of novel PCR primers, page 55).
6.3.5.2 Semi-quantitative RT-PCR of #72 mice
These experiments were undertaken on the wild type background at 21 days. The 
exon 2—>4- primers were used for this experiment (2.5.4.1.3 RT-PCR page 56).
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6.4.1 Immunocytochemistry
The myelin of wild type peripheral nerves immunostains strongly for Pq but not 
with PLP-CT or PLP-specific antibodies. In teased sciatic nerve preparations there 
is staining of the SLIs and paranodes of MFSC and the cytoplasm of NMFSC with 
the PLP-CT antibody. This distribution of PLP/DM20 and Po immunostaining in 
wild type mice is illustrated in Figure 46 (pages 181-182). It has been shown 
previously that staining of the cytoplasmic components with PLP-specific antibody 
is weak, and limited to the perinuclear region, and that the predominant protein 
isoform in Schwann cells is DM20 (Griffiths et a l., 1995). In marked contrast to 
wild type, the peripheral myelin of homozygous #72 mice stains strongly with PLP- 
CT and PLP-specific antibodies and co-localises with Pq staining (Figure 47, page 
183). Additionally, the cytoplasmic staining with the PLP-CT antibody is retained in 
the transgenic mice
When expressed on a PlpJP background the genomic transgenes (#66 and #72) 
produce an appearance similar to that in homozygous #72 animals with PLP/DM20 
immunostaining co-localising with Pq and strong immunoreactivity in the 
cytoplasmic regions o f the MFSC and NMFSC (Figure 48, pages 184-186). In 
contrast, expression of the Plptgl in the PlpJP background results in a more uniform 
staining of the myelinated fibres making the cytoplasmic domains less prominent. 
Paraffin wax sections immunostained with PLP-CT and PLP-specific antibodies 
indicate that it is the PLP protein isoform that is present in the myelin sheath (Figure 
49, page 187). Complementation with the Dm20tg2 transgene results in 
immunostaining of the cytoplasmic domains of myelinated fibres only (Figure 48, 
pages 184-186), with no reactivity for the DM20 protein isoform in myelin (Figure 
49, page 187).
6.4.2 Nerve transplantation study
Grafts from transgenic or wild type mice anastomosed into the sciatic nerves of 
nude mice were readily reinnervated by host axons resulting in myelination of the 
graft and distal stump. When the donor Schwann cells are derived from a #72 
homozygous transgenic mouse the myelin in the graft immunostains with the PLP- 
CT antibody, whereas the distal stump remains negative. This confirms that the 
incorporation of the PLP/DM20 protein isoforms into myelin is a function of the 
transgenic Schwann cells (Figure 50, page 188).
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6.4.3 Morphology
The ultrastructure of peripheral myelin containing PLP, from #72 mice shows no 
differences from wild type at 60 days (Figure 51 page 189). The IPL and MDL are 
normally compacted and subjectively the periodicity of the IPL and MDL appeared 
unaltered. The relationship between myelin thickness and axon diameter appeared to 
be unaltered. No evidence of abnormality was detected in the Golgi apparatus or 
RER of the Schwann cells from transgenic animals.
6.4.4 RT-PCR
The RT-PCR data is presented in Figure 52, page 190.
The dominance of the Dm20 message, in wild type sciatic nerve, is maintained in 
sciatic tissue from #72 transgenic mice and when this transgene is expressed on the 
PlpiP background. Semi-quantitative RT-PCR demonstrates that the incorporation 
of the PLP protein into peripheral myelin of #72 homozygous and hemizygous mice 
is associated with increased levels of Pip gene transcript, though the Plp:Dm20 ratio 
is probably unaltered. The levels of transcription appear similar for the hemizygous 
and homozygous states. The level of transcription of the P q gene appears unaltered 
in the #72 transgenic mice. The Plptgl and Dm20tg2 transgenes were transcribed in 
the sciatic nerves o f PlpJPTY mice producing the single expected message isoform.
6.5 Discussion
The consensus that the PLP/DM20 protein isoforms are not present in PNS myelin 
stems from the inability to detect it immunocytochemically, both in tissue sections 
and by western blots. It is possible, however, that this methodology is insufficiently 
sensitive, as suggested by the work of Agrawal and Agrawal (1991) where a 
radioactive labelling technique identified PLP/DM20 in rat PNS myelin. However, 
this work has not been corroborated. It is also possible that different species may 
incorporate the polypeptides to different levels, thus producing further variation in 
results.
These studies confirm the original supposition that mice transgenic for the #72 
transgene incorporate PLP and/or DM20 in the myelin o f their PNS. The 
implication from the experiments using transgenes expressing only a single isoform 
on the PlpJP background, is that PLP is incorporated into myelin. This challenges 
the current consensus that products of the Pip gene are found only in the 
cytoplasmic domains of Schwann cells.
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The assertion that the PLP protein isoform is incorporated into the peripheral myelin 
is based on co-localisation of immunoreactivity with P q, known to be present in 
PNS myelin. The orientation of PLP within the myelin membrane is unknown but 
the preservation of immunoreactivity suggests that certain epitopes are preserved. 
Exact localisation of PLP within the myelin structure would require more detailed 
analysis, a potential technique being immunogold staining and examination by 
electronmicroscopy (Mastronardi et al., 1993). It is known that both the PLP and 
DM20 protein isoforms can coexist with P q in PNS myelin in other genera, without 
disrupting the lamellar structure. My observations show that this is also possible in 
the mammalian PNS. P q is thought to be largely responsible for the periodicity of 
PNS myelin (Martini et a l, 1995; Giese et a l, 1992; Lemke et a l, 1988) and is 
proposed to have a larger extracellular domain than the PLP/DM20 protein 
isoforms. It is probable therefore that PLP is thus prevented from forming its 
normal structural associations by the increased distance between extracellular 
surfaces in PNS myelin.
The incorporation of the PLP protein isoform into PNS myelin appears to be a dose 
related phenomenon. The level of endogenous Pip gene transcription in the 
Schwann cells of #72 transgenic mice is augmented by the presence o f transgenes 
resulting in increased total level of Pip transcripts. Thus the lack of the PLP protein 
isoform in normal PNS myelin appears to be as a result of low levels o f production 
rather than specific exclusion. It may be that this is related to the use o f a different 
transcription start site in the PNS, which is not part of the co-ordinated programme 
of myelination and is transcribed at a low level. Different trans-factors are 
operating in the Schwann cell compared to the oligodendrocyte. The incorporation 
of the PLP/DM20 protein isoforms into the myelin-like figures in P q knockout mice 
is interesting as it implies that the entry of these proteins into PNS myelin may also 
depend on the relative quantities of other myelin proteins. The disruption of the IPL 
in these Po deficient mice not only confirms the role of Po in the IPL of the PNS but 
suggests that the incorporated PLP/DM20 protein isoforms are either not present in 
sufficient quantities to replace the absent P q or are incapable of its functional 
replacement.
One of the potential problems with the expression of transgenes is activity outwith 
the normal tissue range leading to aberrant effects. The expression of these 
transgenes in the PNS would not be considered ectopic as this tissue normally 
expresses the Pip gene. In the CNS of hemizygous #72 mice, increased steady state 
levels of Pip message are associated with increases in the transcriptional levels of 
other myelin genes (see 4.3.8.1 Northern analysis, page 93). Interestingly, the levels 
of P q gene transcription are unaltered in the transgenic PNS, which concurs with the
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idea that in the PNS Pip gene transcription is uncoupled from the regulation of the 
other myelin genes (Griffiths et a l, 1995).
The expression of the genomic transgenes on the PlpJP/Y background with the 
consequent production of PLP/DM20 protein confirms that these transgenes are 
capable of altering the mutant phenotype. In the CNS the activity o f the mutant 
PlpiP gene interferes with transgene activity (Schneider et a l, 1995)and it was a 
concern that a similar effect might be observed in the PNS. At the time these 
experiments were performed the preferred background o f a true null Pip gene 
background was unavailable. The lack of apparent effect o f the PlpJP allele on 
transgene activity in Schwann cells is interesting but perhaps unsurprising, in that 
endogenous gene activity might be expected to be low and that the any potential 
negative effects would be swamped by transgene activity. The results o f the 
experiments with the genomic transgenes confirmed that the PlpiP/Y background 
was a reasonable environment to study the separate Pip and Dm20 cDNA 
transgenes.
The two protein isoforms were targeted differently, with only the Plptgl transgene 
producing incorporation of protein into the myelin. However, both protein isoforms 
were found in the cytoplasmic domains. The implication of these findings is that 
the PLP protein isoform can be transported within the cell and be inserted into PNS 
myelin in the absence of DM20. As discussed in 7 General discussion (page 191) 
the evidence from transfection studies on intracellular trafficking of the two protein 
isoforms have produced conflicting results. However, none of these studies have 
been on myelinating cells and these in vivo studies suggest that the myelinating 
environment may influence trafficking. My studies also corroborate the 
observations in some transfection studies that PLP can be transported to cell 
membranes in the absence of DM20 (Schedl et a l, 1996; Gow et a l, 1994) (Dr P. 
Montague personal communication). However, my studies conflict with cell 
transfection experiments in which DM20 has also been transported to the 
membrane. It may well be that DM20 is handled differently in myelinating cells and 
cell lines. Evidence from a Plp-LacZ mouse suggests that the first 13 amino acid 
residues are sufficient for targeting of PLP protein to myelin (Wight et a l, 1993), 
but the results presented here suggest that this general response may be modified by 
other signals within the PLP and DM20 protein isoforms, possibly residing in the 35 
amino acid PLP-specific region. The properties conferred on PLP by this segment 
result in differences in inositol hexakisiphosphate binding, a protein possibly 
involved in vesicular transport (Yamaguchi et a l, 1996). A further possibility is 
that the tertiary structure adopted by PLP is beneficial to transport and incorporation 
in myelin. These studies support the hypothesis o f differential targeting o f the two
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Pip gene products and suggest the possibility of this occurring in oligodendrocytes, 
though any extrapolation from Schwann cell to oligodendrocyte should be made 
with great caution.
The present study shows that the two Pip gene products, particularly DM20, are 
enriched in uncompacted cytoplasmic domains o f the MFSC. This is a region where 
a number o f adhesion or adhesion related molecules, not all specific to Schwann 
cells, accumulate, such as certain integrins, ankyrin, spectrin and connexin 32 
(Colman et al., 1996; Scherer, 1996). It is also a region rich in MAG, which is 
excluded from compact myelin, and is thought to act as a heterophilic adhesion 
molecule between axon and Schwann cell (Montague and Griffiths, 1997). The 
intense staining of these regions probably reflects the presence of protein, probably 
DM20, in the plasma membranes and transport vesicles. The functional 
significance o f this cytoplasmic localisation of DM20 in myelinated fibres is 
unknown. DM20 per se does not appear to be essential for the development and 
maintenance o f the peripheral nerves, as indicated by their apparent normality in 
mice with missense and null mutations of the Pip gene.
In conclusion these studies have addressed the expression of the Pip gene in the 
other myelinating cell type, the Schwann cell, and indicate that the lack of the PLP 
and DM20 protein isoforms in peripheral myelin is not due to exclusion but rather to 
the low level o f gene expression in this cell type. The use of specific minigenes 
containing specific cDNAs that generate the individual protein isoforms allows 
investigation o f the targeting of these individual isoforms in this myelinating 
environment. The results demonstrate that PLP can be incorporated into myelin 
whilst DM20 appears to be targeted to cytoplasmic domains, regions that are 
populated with proteins having cell adhesion and pore formation properties. The 
differential targeting of the PLP and DM20 protein isoforms also implies that 
myelinating cells may handle these two protein isoforms differently, which is 
pertinent to the heterogeneity of disease seen with Pip gene mutations (see 7 
General discussion page, 191).
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(a)
(i) (ii)
Figure 46. PLP/DM20 and P0 immunostaining in wild type CNS and PNS. a) a 
merged confocai image of paraffin section of spinal cord with a ventral root 
showing PLP/DM20 (green) staining in the CNS and P0 (red) in the PNS; b) (i) 
bright field of teased sciatic nerve preparation (x56) (ii) immunofluorescence 
showing immunoreactivity for PLP/DM20 in the MFSC localised at the 
Schm idt-Lanterm an incisures ( ^ )  and paranodes ( ^ f )  whilst the NMFSC 
appear as bright green bands (—) (x56).
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Figure 46 (continued). PLP/DM20 and P0 immunostaining in wild type CNS 
and PNS. c) merged confocal image of a teased sciatic nerve preparation 
double stained for PLP/DM20 (green) and P0 (red) emphasising that in wild 
type sciatic nerve the two proteins localise to different domains. The 
paranodes (open arrow) and Schm idt-Lanterm an incisures (closed arrow) 
immunostain for PLP-CT, which is also present in the thin outer layer of 
Schwann cell cytoplasm surrounding the myelin sheath.
182
Expression of PLP transgenes in the PNS
c)
Figure 47. Immunostaining of PNS myelin in a homozygous #72 mouse, a) 
unmerged confocal images of a paraffin section of spinal cord (sc) and ventral 
nerve root (vr) double stained for P0 (red) (i) and PLP/DM20 (green) (ii); b) 
merged confocal image of (a) with the co-localisation of PLP/DM20 and P0 
showing as yellow; c) merged confocal image of a paraffin section double 
stained for PLP/DM20 (green) and SIM I (red) showing the PLP/DIM20 in the 
myelin. The slight gap separating axon and myelin is probably a fixation 
artefact.
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(ii)
a)
Figure 48. The distribution of Pip transgene-derived PLP/DM20 (green) 
proteins in the Plp'r/ \  PNS. a) (i) teased Plpin sciatic preparation (x56) (ii) 
same field immunostained for PLP/DM20.
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(ii)
b)
Figure 48 (continued). The distribution of Pip transgene-derived PLP/DM20 
(green) proteins in the PljjplY PNS. b) (i) #66 with immunoreactivity of the 
cytoplasmic domains of 1MFSC and NMFSC, giving a similar pattern to wild 
type (x56) (ii) #72 exhibiting a similar pattern to #66 (x56).
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(iv)
b)
Figure 48 (continued). The distribution of Pip transgene-derived PLP/DM20 
(green) proteins in the Pip/'1!Y PNS. (iii) complemented with a Pip Tagl 
transgene shows a more uniform immunoreactivity of nerve fibres though still 
with immunostaining of the cytoplasmic regions (x 112) (iv) complemented with 
a Dm20T<\°2 transgene exhibits cytoplasmic immunostaining in myelinated 
fibres only (x56).
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Figure 49. The P//?Tagl transgene facilitates the incorporation of PLP into 
PNS myelin whilst the Dm20Jdg2 transgene does not appear to facilitate the 
incorporation of DM20 into myelin. IJnnierged confocal images of paraffin 
sections of sciatic nerve double stained for PLP/DM20 (green) and P0 (red), a) 
P I/^/Y  mouse complemented with the P//;Tagl transgene showing PLP/DM20 
immunoreactivity of myelin; b) Plpfp! \  mouse complemented with the 
D//f20Tag2 transgene showing the lack of PLP/DM20 immunoreactivity in 
myelin.
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(b)
Figure 50. Unmerged confocal images of paraffin sections of sciatic nerve 
from a nude mouse that received a graft of sciatic nerve from a 
homozygous #72 mouse, double stained for PLP/DM20 (green) and P0 
(red), a) region distal to the graft where reniyelination has been achieved 
by host Schwann cells. The myelin is P0 positive and PLP/DIM20 negative; 
b) region of the graft, showing remyelination where the myelin contains 
both P0 and PLP/DM20.
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Figure 51. Electronmicrographs of PNS myelin sheaths from the ventral nerve 
roots of a wild type mouse and a homozygous #72 litter mate at 60 days. Both 
sheaths show normal major dense lines and double intraperiod lines, a) wild 
type; b) homozygous #72. (scale bar = 0.1f.im).
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Figure 52. RT-PCR data illustrating the behaviour of Pip transgenes on a wild 
type and Plplp backgrounds. All samples represent P20. a)Plp gene exon 2-»4
prim ers have been used to assess Plp:Dm20 ratios (p and d), P0 prim ers (po) 
and cyclophilin (c). Lane 1 sciatic nerve from wild type; lane 2 sciatic nerve 
from hemizygous #72; lane 3 sciatic nerve from homozygous #72; brain from 
wild type. Sciatic nerves from the transgenic mice show increased intensity of 
both bands relative to wild type but maintain the Dm20 dominance, b) RT- 
PCR products from Plp/P mice expressing various transgenes. Pip gene exon 
2—>5 primers were used to demonstrate the presence of transgene derived
transcripts. Lane 1 brain from wild type; lane 2 brain from Plpfp\ lane 3 sciatic 
nerve from wild type; lane 4 sciatic nerve from Plp!p harbouring #72 transgene; 
lane 5 sciatic nerve from Plplp mouse harbouring Pip minigene; lane 6 sciatic 
nerve from Plplp mouse harbouring Dm20 minigene.
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The material presented in this thesis concerns the effects of extra copies o f the wild 
type Pip gene on the development and maintenance of the axon/oligodendrocyte 
unit. The data presented support the concept that increased Pip gene dosage can 
influence both these processes. The picture that emerges is o f a complex relationship 
between gene dosage and the phenotype with extra copies o f the wild type Pip gene 
being associated with both dysmyelination (see 5 Dysmyelination and 
demyelination in mice homozygous for #66 and #72 transgene cassettes, page 134) 
and demyelination and with axonal abnormalities (see 4 Late onset 
neurodegeneration in mice hemizygous for the #66 and #72 transgenes, page 89). 
Further, the data show that demyelination occurs in the already dysmyelinated 
homozygous #66 and #72 mice, suggesting that though both processes are a result of 
increased gene dosage they are due to perturbations of separate aspects of the 
oligodendrocyte\axon relationship. The purpose of this general discussion is to 
examine the relationship between gene dosage and the effects on myelination and 
myelin maintenance in the light of the data presented and how these relate to the 
phenotypes observed with other Pip gene mutations.
However, before examining the aspects o f gene dosage which may be related to 
dysmyelination it is worth considering whether there is any concern that the 
products o f the transgenes differ from those of the wild type Pip gene. The 
constructs used carry all the known coding sequence and have been demonstrated to 
produce a protein that immunostains with a PLP-C-terminal antibody, thus 
demonstrating a full length polypeptide. It is present in CNS myelin suggesting that 
it can adopt a suitable conformation to be incorporated. For both transgenic 
cassettes the authors recloned the transgenes from their transgenic mice and 
demonstrated that the sequence was unaltered. As discussed in 1.2.1.3.2.1 The 
myelin proteolipid protein (page 5) there is no functional assay for the PLP and 
DM20 protein isoforms which would be useful in confirming the status of the 
transgene products. However, the transgenes are capable of preventing the 
axonopathy that develops in Pip knockout mice (Griffiths, personal 
communication), thus suggesting the products are functionally active. Considering 
these observations there is no reason to believe that the nature of transgene derived 
PLP and DM20 protein isoforms is different from wild type or is in itself 
detrimental.
The relationship between gene copy, transgene zygosity and phenotype for 
transgenic mice with extra copies of the Pip gene is complex. As discussed in 1.4.1 
Expression of cloned genes (page 34) the relationship between copy number and 
transgene activity cannot be assumed to be a direct function of the number of copies 
in transgenic cassettes, though position-independent/copy dependent activity can be
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achieved by the inclusion of the appropriate regulatory regions. Thus, though the 
relationship between gene copy number and phenotype observed with the 
homozygous #66 and #72 mice is suggestive of increasing gene dosage being 
deleterious it must be seen in the light of known problems associated with transgene 
regulation and it is possible that the different site o f integration contributes to the 
more extreme nature of the #66 transgene. Interestingly, in the hemizygous state the 
#66 transgene is not demonstrably different in its effects to the #72 cassette. In #66 
and #72 mice dysmyelination is related to zygosity rather than gene copy number. 
This relationship between zygosity and dysmyelination is also observed in the 4e 
mice (Kagawa et al., 1994). The increase in copy number required to produce 
abnormalities of myelination in man is a single extra copy.
The dysmyelination observed in conjunction with increased gene copy number is 
often loosely referred to as “gene over expression”, however, this term is rather 
imprecise and does not address at which stage in the multistep process o f eukaryotic 
gene transcription, translation and product transport the abnormalities are thought to 
be occurring. It is more fruitful to examine the available evidence for the different 
stages of gene expression. Dysmyelination in #66 and #72 mice occurs in the 
presence of apparently adequate numbers of oligodendrocytes. Though 4e mice and 
some human cases are reported to be deficient in oligodendrocytes the observations 
in #66 and #72 mice implies that though lack of sufficient mature oligodendrocytes 
may impair myelination, probably in the number of intemodes formed, it is not the 
primary reason for the thin myelin sheath.
Estimation of the steady state mRNA levels for the Pip and other myelin genes 
suggest a post-transcriptional pathway affecting myelination. There is no evidence 
that dysmyelination is due to increased transcriptional levels in myelinating cells. At 
20 days hemizygous #66 and #72 mice are myelinating normally yet the levels of 
Pip message are elevated compared to the dysmyelinated homozygous mice and 
wild type mice (Figure 53, page 194). In homozygous 4e mice dysmyelination is 
associated with decreased levels of Pip mRNA; however, there is also a decreased 
mature oligodendrocyte population.
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Figure 53. Northern hybridisation analysis of Pip gene transcription in #66 and 
#72 mice at P20. A comparison of wild type, hemizygous and homozygous 
mice. Panel a) #66: lane 1 wild type, lane 2 hemizygous, lane 3 homozygous; 
panel b) #72: lane 1 wild type, lane 2 hemizygous, lane 3 homozygous.
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These studies have only addressed Pip gene transcription at two time points and do 
not directly consider the circumstances during development. It is postulated that the 
DM20 protein isoform may play a role in glial cell development (see 1.2.2.2 
Developmental expression of the Pip gene in the CNS, page 15). Studies in Ae mice 
show that transgene activity in the embryonic mouse reflects gene dosage more 
directly, implying high levels of Dm20 message isoform during this possibly 
sensitive stage may result in a compromised oligodendrocyte population. 
Ultrastructural studies o f developing oligodendrocytes from homozygous #66 mice 
show abnormalities present from an early stage. Further, more detailed studies with 
serial electronmicrographs, would be required to determine whether these changes 
were restricted to myelinating oligodendrocytes. The presence of autophagic 
vacuoles indicates abnormal protein turnover and could represent the elimination of 
proteins from the periphery of the cell. Studies o f glial cell densities and the likely 
increase in the incidence of cell death suggest that in homozygous mice the 
dynamics o f the developing glial cell population are altered. Labelling experiments 
with 3 h  thymidine would be required to establish the nature of the cell types 
involved, though subjectively this would appear to involve the oligodendrocyte 
population. Whilst an increased ratio of Dm20 relative to Pip message isoforms has 
been described in one human pedigree (Carango et al., 1995) a number o f studies 
involving Dm20 minigenes have failed to create a dysmyelinating model (see
1.4.2.4 Evidence that increased Pip gene dosage affects myelination, page 38). It 
has been suggested that a stoichiometric relationship between the PLP and DM20 
protein isoforms may be disrupted by imbalance of the two proteins leading to 
instability of the myelin formed (Hodes & Dlouhy, 1996). Tissue culture 
experiments show that PLP and DM20 protein isoforms can be transported and 
inserted into myelin independently, suggesting that the proposed precise 
stoichiometric relationship may not exist.
Examination of the steady state mRNA data for the #66 and #72 mice shows that 
extra copies of the Pip gene in these mice influence the co-ordinate control of the 
CNS myelin genes Figure 53 (page 194) but not the PNS myelin genes (see 6.4.4 
RT-PCR, page 177). This raises the question of contribution of other genes to the 
observed phenotype. The development of oligodendrocytes and the formation of 
myelin represent the contributions of a myriad of closely co-ordinated genes coding 
for myelin proteins and many other products associated with cell contact, protein 
transport, etc. It is entirely possible that changes in the developmental profile of 
related genes contributes to the phenotype. The point of development at which this 
may be significant may also be very specific. For instance transgenic mice carrying 
extra copies o f the Cnp gene are abnormally myelinated and there is evidence that
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over-expression of the Cnp gene interferes with the development of 
oligodendrocyte/axonal contact early in myelin formation (Gravel et al., 1996). 
Interestingly increased gene dosage of the Cnpase gene also influences the 
transcription of other myelin genes, including the Pip gene.
As described in 1.2.2.1.1 Phylogenetic evolution of the Pip gene (page 13) the Pip 
gene is a member of the larger DM family of genes, which generally have yet to be 
ascribed functions. The relationship of their products to those of the Pip gene have 
not been elucidated, however, there are minimal changes in the profile o f M6a in the 
Pip gene knockout mouse (Klugmann et al., 1997). Membership o f a gene family 
does not imply that products of family members can necessarily substitute for one 
another. However, the possibility arises that if these genes are involved in the co­
ordinated programme of myelin gene transcription that their function may be 
disrupted in Pip mutants.
The extra copies of the Pip gene associated with PMD and the #66,#72 and Ae mice 
all contain non-coding sequences, varying in length, that are o f significance in Pip 
gene transcription and other myelin genes (1.4.2.3.1 Pip transgenic mice with extra 
copies of the wild type Pip gene (page 37) and 1.2.3 Regulation of Pip gene 
expression and co-ordinate expression of the myelin genes (page 16)). The 
increased population of c/s-elements potentially offers increased competition for 
trans factors within a cell. It is known that disease can be related to trans factor 
deficiency and that the levels of trans factors can be critical at certain times of 
development as the associated diseases tend to represent abnormalities of 
development (Engelkamp & van Heyningen, 1996). Model systems for assessing 
the toxic effects of regulatory genes have been developed in yeast (Daniel, 1996). 
The lengths of 5’ non-coding sequence varies between #66/72 mice and Ae mice but 
whether the extra 5’ sequence in Ae mice includes significant extra sequences that 
contribute to the severity o f the phenotype as argued by Ikenaka and Kakawa (1995) 
is debatable, considering the other factors influencing transgene activity. Extra 
copies of 5’ sequence are also present in the Lac-z fusion transgenic mice (Wight et 
al, 1993) and the Pip and Dm20 minigene mice (1.4.2.4 Evidence that increased Pip 
gene dosage affects myelination, page 38) none of which show evidence of 
dysmyelination, suggesting that homozygosity for these 5’ regulatory sequences 
alone is not sufficient to induce dysmyelination.
Do Pip gene duplications and the other mutations of Pip share a common 
pathogenesis? The investigation of naturally occurring and engineered models of 
Pip gene mutation have demonstrated that a dysmyelinating phenotype is associated 
with mutation events of quite different natures. A number o f authors have
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attempted to identify whether there is a relationship between mutation and 
phenotype in PMD (e.g. Hodes & Dlouhy, 1996). This task is complicated by the 
relatively small number of cases, (there is only one example of the same mutation 
occurring in separate human pedigrees), and the influence of varying genetic 
background resulting in noticeable heterogeneity within and between families. The 
effects o f other loci on phenotype present problems in linking specific mutations to 
phenotypic changes (Erickson, 1996), however, some patterns do emerge in such a 
study o f PMD. Complete deletions, o f which at least two are recorded, and 
mutations affecting only the 3B portion of PLP are related to relatively mild clinical 
abnormalities. Also the only mutation shared by a human pedigree and a animal 
model (Plp/jP"18^ ) exhibits relatively mild phenotypic signs in both species 
(Kobayashi et al., 1994). Whether there is a “duplication phenotype” as seen with 
PMP22 in peripheral neuropathies (see 1.3.2.4 Hereditary motor and sensory 
neuropathies (HMSN) of the PNS, page 34) is uncertain (Hodes & Dlouhy, 1996). 
The outbred human population shows that modifying loci can have a significant 
impact on the development of phenotype. The animal models o f Pip mutation are 
usually studied on stable in-bred populations and thus variation in phenotype is less 
apparent (interestingly Pt rabbit is described as having a noticeably variable 
phenotype, with the worst affected animals selected for the description o f the 
pathology (Tosic et a l, 1993)). However, both the PlpiP and Plp//7-^ !1 alleles 
exhibit variation in phenotype when bred onto different genetic backgrounds 
(Griffiths, unpublished observations).
However, this variation in phenotype with mutation does suggest that there are 
potentially a number of mechanisms leading to a similar endpoint. Investigation of 
the relationship between mutation and phenotype in relation to the Pip gene is 
further complicated as the two protein isoforms exhibit different developmental 
profiles and probably have different functions. This is underlined by mutations in 
exon 3B showing that a normal DM20 protein can positively influence development 
o f myelination even in the face of a mutated PLP protein.
Mutations inducing a change in the protein structure and disrupting postulated 
protein-protein interactions (see 1.2.2.1.1 Phylogenetic evolution o f the Pip gene, 
page 13) might well be expected to influence the properties of the PLP and DM20 
protein isoforms. Studies of some animal models indicate that protein transport is 
perturbed with abnormalities primarily affecting the RER, probably due to abnormal 
protein folding (Gow et a l, 1994). It has been suggested that in PlpiP the abnormal 
proteins are in some way toxic to the oligodendrocyte (Schneider et a l, 1995). 
However, this is questioned by observations that oligodendrocyte death appears to 
occur before major production of the PLP/DM20 protein isoforms (Vermeesch et
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a l, 1990). Additionally, transplant (Lachapelle, 1995) and cell culture studies 
(Knapp et a l, 1996) show that myelinating abilities of PlpiP oligodendrocytes are 
influenced by their environment. Transfection studies have shown that mutant PLP 
and DM20 proteins are abnormally distributed suggesting perturbations of 
trafficking and membrane insertion. Interestingly, positive correlations can be made 
between phenotypic severity and the ability of mutant proteins to reach the cell 
surface and enter the endocytic pathway (Thomson et a l, 1997; Gow & Lazzarini, 
1996; Gow et a l, 1994). In these studies mutations associated with the most severe 
phenotypes resulted in both PLP and DM20 being retained in the RER whilst with 
mutations associated with milder phenotypes DM20, but not PLP, passed to the cell 
membrane. These studies demonstrate clearly that the changes in protein structure 
associated with mutation affects protein transport and can induce the RER changes 
that are observed in some mutants. The observations are used to argue quite 
strongly for protein trafficking perturbations being a major contributor to the 
phenotypic findings in PMD and animals models (Gow & Lazzarini, 1996; Gow et 
al, 1994). However, it is not surprising that altered proteins are abnormally 
translocated and the significance of these effects in relation to dysmyelination 
(Schedl et al, 1996) remains to be determined.
The severe disruption of myelin and myelination seen with mutations affecting the 
strongly conserved putative transmembrane regions highlights the sensitivity o f this 
structure to change. However, mutants such as Plp/7,-rsh and the knockout mice in 
which there is relatively mild disease and no abnormal phenotype respectively, 
suggest that disruption of the IPL alone is not the reason for the severe phenotypes 
associated with some Pip gene mutations. The developmental profile o f Pip gene 
expression implies that PLP and DM20 have different roles during development and 
myelin formation (1.2.2.2 Developmental expression of the Pip gene in the CNS, 
page 15). Dm20 transcripts are maximal during the pre-myelination phase of 
oligodendrocyte development and have also been detected in PNS glia (where the 
Pip gene does not appear to be part of the co-ordinated transcription programme of 
myelin genes (Griffiths et a l, 1995)), embryonic neural cells (Ikenaka et a l, 1992) 
and cardiac myocytes at about 0.1-0.2% of the levels in the brain (Campagnoni et 
a l, 1992). In cardiac myocytes there is evidence of developmental regulation. 
Recently, both message and product have been demonstrated in the human foetal 
thymus, spleen and testis (message only) confirming expression in non-glial tissue 
(Pribyl et a l, 1996). Mutant animals such as Pip//7-1*8!1 and Pt rabbit in which glial 
cell death and hypomyelination are uncoupled (usually both features o f Pip gene 
mutant animals) illustrate that mutations can selectively affect these two features of 
oligodendrocyte biology (see 1.3.2.1 Animal models, page 26).
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General discussion
Molecular studies of the human Pip gene and relevant animal models indicate the 
range of phenotypes associated with mutation is considerably greater then 
previously recognised. This illustrates the potential value of animal models in 
furthering the understanding of disease in conditions where rarity contributes to 
difficulties of collating information and provides pointers to features that should be 
examined carefully. For example, though SPG2 is probably a demyelinating disease 
(Hodes & Dlouhy, 1996) nothing is known about the development of myelin in 
these cases; however, the transgenic model suggests that it may be relatively normal 
and that the disease may be more complicated than demyelination alone, as the 
transgenic mice exhibit an axonopathy. PMD, essentially a dysmyelinating 
disorder, is described as progressive in some cases. Although some of this clinical 
deterioration may be due to dysmyelination (myelination in man continues into the 
second decade) there is indication from the #66 and #72 transgenic mice that 
demyelination may also be occurring, contributing to the progression of the disease.
Another aspect of this project has expanded the understanding of the Pip gene in the 
PNS. The work described in 6 Expression of Pip transgenes in the peripheral 
nervous system(page 171) shows that myelinating Schwann cells handle PLP and 
DM20 protein isoforms differently. Though caution should be exercised in 
extrapolating from Schwann cell to oligodendrocyte it implies that there is a signal 
within the PLP-specific region that can be used for differentiating between the two 
protein isoforms. As described above tissue culture experiments and in vivo 
observations (Schedl et al., 1996) have shown that for several mutations o f the Pip 
gene, protein trafficking and membrane insertion of the DM20 isoform are less 
affected than that of the cognate PLP isoform. This observation of successful 
DM20 transport is more noticeable for the mutations associated with the less severe 
phenotypes and may be a contributing factor to the less severe nature of disease in 
these mutants.
In conclusion the work presented in this thesis has illustrated that increased dosage 
of the Pip gene affects myelin during both development and maintenance and shows 
a parallel between the experimental models and the spectrum of disease associated 
with PLP gene duplications in man. The mechanisms underlying the deleterious 
effects of Pip gene duplication remain unelucidated and this work suggests they are 
likely to be complex and may involve perturbations in the expression of other genes.
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8.1 Fixatives
8.1.1 Buffered neutral formaldehyde, 4%  (BNF)
For 1L of fixative:
40% formaldehyde
(Merck)
tap water
sodium di-hydrogen 
phosphate
di-potassium hydrogen 
phosphate
100ml
900ml
4g
8g
8.1.2 Karnovsky's modified fixative 
(paraformaldehyde/glutaraldehyde 4%/5%)
For 500ml “strong fix”:
8% formaldehyde 
25% glutaraldehyde 
0.0 8M cacodylate buffer 
pH7.2
calcium chloride
250ml 
100ml
mix formaldehyde and 
glutaraldehyde and 
make up to 500ml 
250mg
Filter and store at 4^C for a maximum o f -14  days.
8% formaldehyde: 20g paraformaldehyde + 250ml distilled water; heat to 65^C; 
addlM  NaOH to clear the solution; cool to 4^C.
0.08M cacodylate buffer: add 17.12g sodium cacodylate buffer to 11 and adjust pH 
to 7.2.
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8.1.3 Periodate-lysine-paraformaldehyde
For 1L of fixative:
lysine monohydrochloride 13.7g in 375ml distilled
water
sodium hydrogen 
phosphate water
mix to give 475ml at 
pH7.4
20g in 200ml distilled
1.8g in 100ml distilled
paraformaldehyde
water
store at 4^C until required, overnight if  required
Mix buffered lysine and paraformaldehyde and make up volume to 1L with 0.1M 
phosphate buffer. Add 2.14g sodium periodate and allow to dissolve. Use 
immediately.
8.2 Tissue processing protocols
8.2.1 Paraffin wax processing
Solutions used for preparation of tissue for paraffin blocks:
1) 70% methylated spirit / 5% phenol 2 hrs
2) 90% methylated spirit / 5% phenol 2 hrs
3) methylated spirit 2 hrs
4) ethanol / 5% phenol x3 2 hrs
1 hr 
1 hr
5) 1% celloidin in methyl benzoate* 4 hrs
6) xylene 1 hr (x3)
7) paraffin wax x2 7 hrs
* celloidin was obtained as Necoloidine (Merk) and considered as a 100% solution 
(lm l in 100ml benzyl benzoate).
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8.2.2 Resin processing
Processing involved the following solutions:
1) isotonic cacodylate 
buffer
4<>C 50 mins
2) 1% osmium tetroxide in 
cacodylate buffer
room temperature 2 hrs
3) isotonic cacodylate 
buffer
room temperature 30 mins
4) 50% ethanol 40c 5 mins
5) 50% ethanol 40c 10 mins
6) 70% ethanol 40c 5 mins
7) 70% ethanol 40c 10 mins
8) 80% ethanol 40c 5 mins
9) 80% ethanol 40c 10 mins
10) 90% ethanol 40c 5 mins
11) 90% ethanol 40c 10 mins
12) ethanol 40c 20 mins
13) ethanol 40c 20 mins
14) propylene oxide room temperature 15 mins
15) propylene oxide room temperature 15 mins
16) 1:3 resin* :propylene 
oxide
room temperature 13 hrs
17) 1:2 resinrpropylene 
oxide
room temperature 6 hrs
18) 1:2 resin :propylene 
oxide
room temperature 18 hrs
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19) resin 30^C 4 hrs
* resin composition page 204.
isotonic sodium cacodylate buffer: 16.05g sodium cacodylate, 3.8g sodium
chloride, 0.055g calcium chloride, 0.102g magnesium chloride + distilled water to 
1000ml; adjust topH7.2 - 7.3
Processed samples were embedded in resin filled silicone moulds and left to 
polymerise overnight at 60^C.
8.3 Mounting media
8.3.1 Araldite resin
30g araldite CY212 resin
25.2g dodecanyl succinic hardener
anhydride (DDSA)
1.2ml 2,4,6-tri- accelerator
dimethylaminomethyl 
-phenol (DMP 30)
1.0ml di-butyl phthalate plasticiser
8.4 Staining protocols and stains
8.4.1 Haematoxylin and eosin
Sections were passed through the following solutions:
1) xylene 2 min
2) absolute alcohol 2 min
3) methylated spirit 2 min
4) water 2 min
5) Lugols iodine 1 min
6) water 1 min
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7) 5% sodium thiosulphate
8) water
9) Mayer's haematoxylin*
10) 1% acid alcohol
11) water
12) Scot's tap water substitute*
13) water
14) methylated spirit
15 saturated alcoholic eosin
16) methylated spirit
17) absolute alcohol
18) histoclear
19) xylene
* details page 205.
8.4.2 haematoxylin
1) water
2) Mayer's haematoxylin
3) water
4) Scot's tap water substitute
1 min 
10
mins 
3 dips
2 mins
1 min
2 mins 
10 secs 
2 mins 
2 mins 
2 mins 
2 mins 
5 mins
2 mins 
50 secs
wash off excess 
haematoxylin
30 secs
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8.4.3 Staining of tissues for electronmicroscopy
1) saturated uranyl acetate in 5-15
50% ethanol mins
2) 50% ethanol rinse
3) 50% ethanol rinse
4) distilled water rinse x 2
5) air dry
6) Reynold's lead citrate* 5-10 
(Sodium hydroxide mins
moistened chamber)
7) 1M sodium hydroxide rinse x 3
8) distilled water rinse x 5
* details page 207.
8.4.3.1.1 Mayer's haematoxylin:
1.0g haematoxylin
10.Og potassium alum
0.2g sodium iodate
made up in 11 distilled water. Bring to boiling point and allow to cool over night 
and add:
1.0g citric acid
50g chloral hydrate
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8.4.3.1.2 Scot's tap water:
3.5 g sodium bicarbonate
20.Og magnesium sulphate
in 11 distilled water.
8.4.3.1.3 Methylene blue / azur II:
1% methylene blue
1% azur II
1% borax
in distilled water.
8.4.3.1.4 Reynold's lead citrate:
1.33g lead nitrate
1.76g sodium citrate
each dissolved in 15 ml distilled water for lmin vigorous shaking followed by 
occasional shaking for the next 30 mins. Clear with 8.0ml 1M sodium hydroxide 
and make up to final volume of 50ml with distilled water (final pH 12).
8.4.3.2 methylene blue
0.15g methylene blue
50ml 3M sodium acetate
made up to 500ml in DW to give 0.03% (w/v) methylene blue. Check pH5.2.
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8.5 Buffers
8.5.1 Tris buffered saline
3g Tris base
8g sodium chloride
0.2g potassium chloride
Dissolve in 800ml DW, adjust pH to7.4 with hydrochloric acid and make up to 11
with DW. This give final concentrations of 25mM Tris pH7.4, 136mM sodium
chloride, 2.6mM potassium chloride.
8.5.1.1 Phosphate buffered saline
8g sodium chloride
0.2g potassium chloride
1.44g di-sodium hydrogen phosphate
0.2g potassium hydrogen phosphate
Dissolve in 800ml DW, adjust pH to 7.4 with hydrochloric acid and make up to 11 
with DW.
8.5.2 Gel running buffer
8.5.2.1 Tris acetate EDTA buffer xlO
0.04M Tris acetate, 0.001M EDTA.
48.4g Tris base
11.4ml glacial acetic acid 
20ml 0.5 MEDTA 
made up to 1L in DW.
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8.S.2.2 M OPSxlO
Sodium MOPS 0.2M, sodium acetate 50mM and lOmM EDTA pH7.0
23.lg sodium MOPS
3.4g sodium acetate
10ml 0.5MEDTA
3.55ml acetic acid
made up to 500ml with DW. Autoclaved, which results in light green colouration, 
and stored at 4^C.
8.5.2.3 Northern denaturing buffer
formamide 20.3 pi
MOPSxlO 4.16pl
40% formaldehyde 6.66pl
Total volume 31.12 pi
This buffer was made up as a master mix to ensure accurate pipetting. Added to 
lOpl o f RNA sample.
8.5.3 SSC (Sodium chloride / sodium citrate) x20
3M sodium chloride / 0.3M sodium citrate
1753g sodium chloride 
882g sodium citrate
made up to 101 with DW.
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8 .5 .4  TE
lOmM Tris ph8.0, ImM EDTA 
500 j l x 1 1M Tris pH8.0 
lOOpl 0.5M EDTA
8.6 Loading dyes
8.6.1.1 6x buffer for TAE conditions
30% glycerol (Sigma); 0.25% bromophenol blue; 0.25% xylene cyanol FF (Sigma).
8.6.1.2 Northern loading dye
50% glycerol (Sigma); ImM EDTA; 0.25% bromophenol blue; 0.25% 0.25% 
xylene cyanol FF (Sigma).
8.7 Bacteriological media
8.7.1 Luria-Bertani medium
10g tryptone (Oxid)
5g yeast extract (Oxid)
lOg sodium chloride
Make up to 11 in DW and adjust to pH7.0 using ~0.2ml 5N sodium hydroxide. 
Sterilise by autoclaving for 20 mins at 151b in^. Store at4^C.
8.7.2 SOC medium
20g tryptone (Oxid)
5g yeast extract (Oxid)
0.5g sodium chloride
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Make up to 970ml in DW, add 10ml 250mM potassium chloride and adjust to pH7.0 
using ~0.2ml 5N sodium hydroxide. Autoclave for 20 mins at 151b in^. Cool to 
<60^C and add 20ml filter sterilised 1M glucose solution.
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9. Abbreviations
Abbreviation Full name
aa amino acid
APES 3-aminopropyltriethoxy-silane
BAER brain stem evoked response
CMT1A Charcot-Marie-Tooth disease 1A
CGT UDP-galactose:ceramide galactosyl-
transferase
CNP 2',3'-cyclic nucleotide 3'-
phosphodiesterase 
CNS central nervous system
CST cranial sympathetic trunk
DAB 3,4,4',4',-tetraminobiphenyl
hydrochloride
DEPC di-ethyl pyrocarbonate
DM20 the small isoform of the PLP gene
DMD Duchenne muscular dystropy
DNA de-oxyribo nucleic acid
dNTP deoxynucleotides
DSD Dejerine-Stottas disease
DTT dithiothreitol
DW distilled, deionised water
EDTA Ethylene-di-amine-tetra-acetate
EM electronmicroscopy
EMG electromyography
ES embryonic stem
FITC fluoroscein isothiocyanate
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gDNA genomic DNA
GFAP glial fibrillary acidic protein
H and E haematoxylin and eosin
HNPP hereditary neuropathy with liability to
pressure palsies
HMSN hereditary motor and sensory neuopathy
HSP hereditary spastic paraplegias
IGF-1 insulin-like growth factor 1
IL-3 interleukin-3
IP intraperiod line
ISH in-situ hybridisation
Leant 1 neural cell adhesion molecule LI
L-MAG large isoform of myelin associated
glycoprotein
MAG myelin associated glycoprotein
MASA mental retardation, Apasia, shuffling
gait, adducted thumb
MBP myelin basic protein
MDL major dense line
min(s) minute(s)
MFSC myelin forming Scwann cell
MHV murine hepatitis virus
NMFSC non-myelin forming Scwann cell
MOBP myelin-oligodendrocyte basic protein
MOSP myelin/oligodendrocyte specific protein
MOPS 3-(N-morpholno) propanesulphonic acid
MS multiple sclerosis
MyTl Myelin transcription factor 1
NF neurofilament
NGS normal goat serum
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NO nitric oxide
NSE neurone-specific enolase
P post natal age (days)
PAP peroxidase anti-peroxidase
PCR polymerase chain reaction
PLP proteolipid protein
PMD Pelizaeus-Merzbacher disease
PMP22 peripheral myelin protein gene 22
Pol II RNA polymerase II
RER rough endoplasmic reticulum
RNA ribonucleic acid
RNAaseA RibonucleaseA
rpm revolutions per minute
ROS reactive oxygen species
RS rabbit serum
SLI Scmidt-Lanterman incisure
snRNP small nucleur ribnonucleoprotein
S-MAG small isoform of myelin associated
glycoprotein
SPG1 spastic paraplegia gene locus 1
SPG2 spastic paraplegia gene locus 2
SSC standard sodium citrate buffer
STAR protein signal transduction and activator of RNA
STW sterile distilled, deionised water
TAE buffer Tris acetate EDTA buffer
TBS Tris buffered saline
THR thyroid hormone receptor
TLCK Na-p- tosyl-l-lysine chloro-methyl
ketone
TMEV Theiler's murine encephaloyelitis virus
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TXR Texas red
UV ultra violet
Abbreviations
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